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Abstract
Members of the C-type lectin domain (CTLD) superfamily are metazoan proteins 
functionally important in glycoprotein metabolism, mechanisms of multicellular
integration and immunity. This thesis presents the results of several computational and 
experimental studies of the CTLD structure, function and evolution. 
Core structural properties of the CTLD fold were explored in a comparative analysis
of the 37 distinct CTLD structures available publicly, which demonstrate significant 
structural conservation despite low or undetectable sequence similarity. Pairwise
structural alignments of all CTLD structures were created with three different methods
(DALI, CE and LOCK) and analysed manually and using a computational algorithm
developed for this purpose. The analysis revealed a set of conserved positions and 
interactions, which were classified based on their role in CTLD structure maintenance.
The CTLD family is large and diverse. To organize and annotate the several 
thousand of known CTLD-containing protein sequences and integrate the information
on their evolution, structure and function a local database and a web-based interface to 
it were developed. The software is written in Perl, is based on bioperl, bioperl-db and 
Apache::ASP modules, and can be used for collaborative annotation of any collection of 
phylogenetically related sequences. 
Several studies of CTLD genomics were performed. In one such study, carried out 
in collaboration with the RIKEN structural genomics centre, CTLD sequences from the 
Caenorhabditis elegans genome were identified and clustered into groups based on 
similarity. The most representative members of the groups were then selected, which if
characterized structurally would tell most about the C. elegans CTLDs and provide 
templates for homology modelling of all C. elegans CTLD structures.
In the other whole-genome study, the CTLD family in the puffer fish Fugu rubripes
was analysed using the draft genome sequence. This work extended and complemented
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three genome-level surveys on human, C. elegans and D. melanogaster reported 
previously. The study showed that the CTLD repertoire of Fugu rubripes is very similar
to that of mammals, although several interesting differences exist, and that Fugu CTLD-
encoding genes are selectively duplicated in a manner suggesting an ancient large-scale 
duplication event. Another important finding was the identification of several new 
CTLDcps, which had mammalian orthologues not recognized previously.
CBCP, a novel CTLD-containing protein highly conserved between fish and 
mammals with previously unknown domain architecture, was predicted in the Fugu 
study based solely on ab initio gene models from the Fugu locus and cross-species 
genomic DNA alignments. To test if the prediction was correct, a full-length cDNA of
the mouse CBCP was cloned, its tissue distribution characterized and untranslated
regions determined by RACE. The full-length mCBCP transcript is 10 kb long, encodes 
a protein of 2172 amino acids and confirms the original prediction. The presence of a 
large N-terminal NG2 domain makes CBCP a member of a small but very interesting 
family of Metazoan proteins. 
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Chapter 1.
Introduction
The superfamily of proteins containing C-type lectin-like domains (CTLDs) is a 
large group of extracellular Metazoan proteins with diverse functions. In this 
introduction I will briefly overview the literature on the superfamily, focusing on those
aspects, which were directly related to the computational and experimental studies I 
undertook as part of my project. The amount of information on the superfamily is 
immense, and some of its properties have been studied in great detail. The literature is, 
however, strongly biased towards several groups of vertebrate proteins. As the general 
goal of my project was to systematically analyze the family as a whole using different 
in silico techniques, I will not attempt to provide a description of the known members
proportional to the amount of published data, but will try to capture the family in all its 
variety.
1.1 The CTLD superfamily 
1.1.1 A brief history of discovery
C-type lectins were among the first animal lectins discovered. Bovine conglutinin, 
which belongs to the collectin group of C-type lectins, has been known since 1906, and 
agglutinating activity of the snake venom lectins was first described much earlier, in 
1860 (Kilpatrick 2002). In 1988 Drickamer suggested to organize animal lectins into 
several categories, and classified Ca2+-dependent lectins structurally similar to the
asialoglycoprotein receptor as the C-type lectin group (Drickamer 1988). Since then, the 
known family has grown significantly, and now includes more than a thousand 
identified members, most of which lack lectin activity, from different animal species. 
1
Chapter 1 Introduction
1.1.2 Term definitions: CTLD, CRD, C-type lectin 
The terms “C-type lectin”, “carbohydrate recognition domain” (CRD), “C-type 
lectin domain” (CTLD), “C-type lectin-like domain” (also abbreviated as CTLD), are 
often used interchangeably in the literature, which may be a source of confusion. The 
history of introduction and the common meanings of the terms are outlined below 
followed by the definitions that I will use in this thesis. 
The term “C-type lectin” was introduced to distinguish a group of Ca2+-dependent
(C-type) carbohydrate-binding (lectin) animal proteins from the other (Ca2+-
independent) types of animal lectins. When the structures of C-type lectins were 
established biochemically and functions of different domains was defined, it was found 
that carbohydrate-binding activity was mediated by a compact module – the 
“carbohydrate-recognition domain” (CRD) – which was present in all Ca2+-dependent
lectins but not other types of animal lectins (Drickamer et al. 1986; Drickamer 1988, 
1989). Comparison of CRD sequences from different C-type lectins revealed conserved 
residue motifs characteristic of the domain (Drickamer 1988, 1989, 1993), which 
allowed discovery of many more proteins that contained it. At the same time,
crystallographic studies confirmed that the CRD of the C-type lectins has a compact
globular structure, which was not similar to any known protein fold (Weis et al. 1991b). 
This domain has been called “C-type CRD” or “C-type lectin domain”. As the number
of determined sequences grew, it became clear that not all proteins containing C-type 
CRDs can actually bind carbohydrates or even Ca2+. To resolve the contradiction, a 
more general term “C-type lectin-like domains” was introduced to refer to such domains
(Weis et al. 1998; Drickamer 1999). The usage of this term is however, somewhat
ambiguous, as it is used both as a general name for the group of domains homologous to 
C-type lectin CRDs (regardless of the carbohydrate-binding properties) and as a name 
of the subset of such domains that do not bind carbohydrates, while the subset that does 
bind carbohydrates is called C-type CRDs (Drickamer and Fadden 2002; Dodd and 
Drickamer 2001). In addition both “C-type CRD” and “C-type lectin domain” terms are 
still used in relation to the C-type lectin homologues that do not bind carbohydrate (e.g. 
Plougastel et al. 2001; Kikuno et al. 2004; Hurtado et al. 2004), and the group of 
proteins containing the domain is often called the “C-type lectin family” or “C-type 
2
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lectins”, although most of them are not in fact lectins. The abbreviation CRD is used 
both in the meaning of “C-type carbohydrate-recognition domain” and in a more
general meaning of “carbohydrate-recognition domain”, which encompasses domains
from different lectin groups (Dodd and Drickamer 2001). Occasionally CRD is also 
used to designate the short amino acid motifs (i.e. amino acid domain) within CTLDs 
that directly interacts with Ca2+ and carbohydrate (e.g. Rivkin et al. 2000). 
Structure comparisons adds one more meaning to the definition of the C-type lectin 
domain, as structural similarities were discovered between C-type lectin CRDs and 
protein domains that did not show significant sequence homology to any of the known 
C-type lectins but adopted similar fold (Brissett and Perkins 1996; Kohda et al. 1996; 
Luo et al. 2000; Parker et al. 1994; Stein et al. 1994a). As the fold is very unusual, 
these domains have been separated into a common group in structure classification 
databases. For example, in the SCOP database (Murzin et al. 1995) C-type lectins and 
structurally related domains are grouped at the fold level (“C-type lectin-like fold”),
which is the second level from the top of the classification hierarchy. However, 
although the structural similarity is often acknowledged in the literature, the common 
meaning of the C-type lectin-like domain does not include these domains (Drickamer
1999; Drickamer and Fadden 2002). 
I will be using the term “C-type lectin-like domain” (CTLD) in its broadest 
definition to refer to protein domains that are homologous to the CRDs of the C-type 
lectins, or which have structure resembling the structure of the prototypic C-type lectin 
CRD. Proteins harboring this domain will be called CTLD-containing proteins 
(CTLDcps) instead of the more common “C-type lectins” as the latter implies
carbohydrate-binding ability, which most of the CTLDcps are not known to possess. 
1.1.3 Phylogenetic distribution, groups
With a few exceptions, which will be discussed below, CTLDs are only found, 
extracellularly, in Metazoa. The domain has been a very popular framework for 
generating new functions and is found in various structural and functional contexts. 
CTLDcps are ubiquitous in multicellular animals, and are found in a broad range of
species, from sponges to human (Gundacker et al. 2001; Drickamer and Fadden 2002). 
3
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CTLDcp-encoding genes have been found in all fully sequenced metazoan genomes,
and, in general, in large numbers. For example, the CTLD is the 7th most abundant 
domain family in C. elegans (Consortium 1998). The family shows both evolutionary 
flexibility and conservation. Whole-genome studies have shown that although there are 
virtually no similarities between CTLDcps from worm, fruit fly and vertebrates (Dodd 
and Drickamer 2001), relatively few modifications occurred within the vertebrate 
lineage during evolution from fish to mammals (Chapter 5), with some members
showing sequence conservation approaching the conservation of histones. 
Non-Metazoan CTLDs
There are several interesting examples of non-metazoan CTLDcps, which can be 
divided into two groups. Members of the first group come from parasitic bacteria and 
viruses; these are involved in interactions with the animal host and are either hijacked 
host proteins or their imitations. This group includes bacterial toxins (pertussis toxin: 
Stein et al. 1994a;  proaerolysin: Parker et al. 1994) and outer membrane adhesion 
proteins (intimin from enteropathogenic E. coli: Luo et al. 2000;  and invasin from
Yersinia pseudotuberculosis: Hamburger et al. 1999) and viral proteins. Viral CTLDcps 
are either transmembrane proteins or structural envelope proteins, and include, for 
example, eight ORFs in the fowlpox virus genome (Afonso et al. 2000), proteins from 
vaccinia virus (Wilcock et al. 1999; Goebel et al. 1990), African swine fever virus 
(Galindo et al. 2000), cowpox virus (Shchelkunov et al. 1998), Avian adenovirus gal1 
(Davison et al. 2003), myxoma virus (Cameron et al. 1999), molluscum contagiosum 
(Senkevich et al. 1997), Epstein-Barr virus (Mullen et al. 2002), alcelaphine 
herpesvirus (Ensser et al. 1997). Unlike bacterial CTLDs, which were assigned to the 
CTLD superfamily only on the basis of structural similarity, viral proteins contain a 
canonical CTLD with significant similarity to mammalian CTLDcps. 
While the presence of CTLDcps in parasites has an obvious explanation, the origins 
of the other group of non-metazoan CTLDcps is unclear. During my studies I found 
three proteins that can be attributed to this group: two proteins from plants, and a 
putative protein encoded by an ORF from a marine planctomycete Pirellula sp.
(GenBank ID:32443381). The latter sequence, which is 7716 amino acids long and is 
encoded by the biggest ORF in the genome of that bacterium (Glockner et al. 2003), 
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contains several C-type lectin-like, laminin G and cadherin domains, all of which are 
almost exclusively found in Metazoa. The most parsimonious explanation of the 
presence of all these domains in the Pirellula genome is horizontal gene transfer, but 
what might be the function of the protein harboring them is a mystery, as Pirellula are
free-living species. The plant CTLDcp sequences originate from the Arabidopsis
thaliana genome annotation (transcript IDs At4g22160 and At1g52310) and are not 
characterized functionally. At1g52310 is a transmembrane protein with a typical CTLD
in the extracellular domain and protein kinase domain in the cytoplasmic part, and has a 
well-conserved orthologue in the rice genome sequence. 
It is not absolutely clear whether the CTLD superfamily is monophyletic, as 
homology between the canonical and some of the compact CTLDs (see p.6) cannot be 
confidently established. There is little doubt that the Link domain group of CTLDs has 
emerged as a result of a deletion of the LLR from an ancestral canonical CTLD, 
because the Link domains have a much narrower phylogenetic distribution (only found 
in vertebrates), is less diverse, and shows detectable sequence similarity to the canonical
CTLDs (Brissett and Perkins 1996). However, the evolutionary relationship of the 
compact CTLDs from the bacterial toxins to the animal CTLDs is uncertain (Rossjohn
et al. 1997). These domains could either have been acquired by horizontal transfer or 
could have arisen by convergent evolution, as mimicry of host proteins. 
1.2 The CTLD fold 
The CTLD fold has a double loop structure (Figure 1-1). The overall domain is a 
loop, its N- and C-terminal E strands (E1, E5) come close together forming an 
antiparallel E-sheet. The second loop, which is called the long loop region (LLR), lies 
within the domain; it enters and exits the core domain at the same location. Four 
cysteines (C1-C4), which are the most conserved CTLD residues, form disulfide
bridges at the bases of the loops: C1 and C4 link E5 and D1 (the whole domain loop) 
and C2 and C3 link E3 and E5 (the LLR). The rest of the chain forms two flanking D
helices (D1 and D2) and the second (“top”) E-sheet, formed by strands E2, E3 and E4.
The LLR is involved in Ca2+-dependent carbohydrate binding, and in domain-swapping
dimerization of some CTLDs (Figure 1-2), which occurs via a unique mechanism
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(Mizuno et al. 1997; Feinberg et al. 2000a; Mizuno et al. 2001; Hirotsu et al. 2001; Liu 
and Eisenberg 2002).
Figure 1-1 CTLD structure
A cartoon representation of a typical CTLD structure (1k9i). The long loop region is shown in blue.
Cystine bridges are shown as orange sticks. The cystine bridge specific for long form CTLDs (C0-C0’) is
also shown.
The conserved positions involved in CTLD fold maintenance and their structural 
roles will be discussed in detail in Chapter 4. In addition to the four conserved 
cysteines, one other sequence feature needs to be mentioned here, the highly conserved 
“WIGL” motif. It is located on the E2 strand, is highly conserved and serves a useful 
landmark for sequence analysis. 
1.2.1 Variations of the fold: canonical, compact, long, short 
Structurally, CTLDs can be divided into two groups: canonical CTLDs having a 
long loop region, and compact CTLDs that lack it (Figure 1-2). The second group 
includes Link or protein tandem repeat (PTR) domains (Kohda et al. 1996; Brissett and 
Perkins 1996) and bacterial CTLDs (Rossjohn et al. 1997; Kelly et al. 1999; Hamburger
et al. 1999). Another family usually included in the CTLD superfamily is that of 
endostatin (Murzin et al. 1995; Hohenester et al. 1998; Drickamer 1999). However, in 
the comparative structure analysis described in the Chapter 4, I did not find substantial 
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similarity between the CTLD and endostatin folds, apart from the general topology. 
Sequence similarity between endostatin and CTLDs is also absent. Therefore, in my
work I did not consider the endostatin fold as an example of a CTLD and did not 
include it in the analyses.
Another subdivision of CTLDs is based on the presence of a short N-terminal
extension, which forms a E-hairpin at the base of the domain (Figure 1-1). The CTLDs 
containing such an extension are called “long form”. The hairpin is stabilized by an 
additional cystine bridge, and the presence of these two additional cysteines at the 
beginning of the CTLD sequence is used to distinguish between long and short form
CTLDs in sequence analysis. No systematic study of the N-terminal extension, or of its 
possible roles, has been published. 
Figure 1-2 Variation of the long loop region structure
Three common forms of the CTLD LLR are shown. Panels (a) and (c) show canonical CTLDs in which
the LLR is tightly packed (a) or flipped out to form a domain-swapping dimer (c). A compact CTLD from
human CD44 Link domain is shown in panel (b). The core domain and LLR are colored green and blue,
respectively.
7
Chapter 1 Introduction
1.2.2 Secondary structure element numbering
Although the CTLD fold is very well conserved among its known representatives, 
there is no general agreement on the numbering of CTLD secondary structure elements
(SSE) in the literature. The SSE numbering scheme in the first solved CTLD structure
(rat MBP-A, Weis et al. 1991b) included 5 strands, 2 helices and 4 loops. However, this 
description turned out to be insufficient, as MBP lacks some SSE that are present in 
long-form CTLD structures, while other small strands were not defined. Other studies 
describing the structures of CTLDs that have a different number of SSEs than MBP-A 
either introduced their own SSE numbering (E strands 1-6 in asialoglycoprotein receptor 
(ASGPR, Meier et al. 2000); 6 E strands in link module, with labeling not consistent 
with ASGR or MBP-A (Kohda et al. 1996); E1- E7 in NKG2D (Wolan et al. 2001); E1-
E8 in EMBP (Swaminathan et al. 2001)), or extended the SSE naming scheme used for 
MBP-A (Ly49A SSE numbering is consistent with that in MBP-A (Tormo et al. 1999)). 
For consistency I will use a universal SSE numbering scheme in my thesis (Figure 1-3), 
taking the same approach as was used in the Ly-49A structure, as it both allows direct 
reference to the most studied CTLD structures (MBP-A and -C) and assigns individual 
numbers to the SSE that are present throughout the family. The others will have derived 
names and numbers: the E strand specific for the long-form CTLD is labeled E0, the 
short E strand between D1 and D2 is labeled E1’, and the two E strands forming a 
hairpin C-terminal to E2 are labeled E2’ and E2’’.
Figure 1-3 CTLD secondary structure element numbering
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1.2.3 Ca-binding sites
Four Ca2+-binding sites are found in CTLDs 
There are four Ca2+-binding sites in the CTLD domain that recur in CTLD structures
from different groups (Figure 1-4). The site occupancy depends on the particular CTLD 
sequence and on the crystallization conditions (Weis et al. 1992; Weis et al. 1991b), 
and in different known structures zero, one, two or three sites are occupied. Sites 1, 2 
and 3 are located in the upper lobe of the structure, while site 4 is involved in salt bridge 
formation between D2 and the E1/E5 sheet. 
Figure 1-4 Ca-binding sites in CTLDs
Sites 1 and 2 were observed in the structure of rat MBP-A complexed with 
holmium, which was the first CTLD structure determined (Weis et al. 1991b). Site 3 
was first observed in the MBP-A complex with Ca2+ and oligomannose asparaginyl-
oligosaccharide (Weis et al. 1992). It is located very close to site 1 and all the side 
chains coordinating Ca2+ in site 3 are involved in site 1 formation. As biochemical data 
indicate that MBP-A binds only two calcium atoms (Loeb and Drickamer 1988), Ca2+-
binding site 3 is considered a crystallographic artifact (Weis et al. 1992). However, in 
many CTLD structures where site 1 is occupied, a metal ion is also found in site 3 and 
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molecular dynamics simulations of the MBP-A/mannose complex suggested that Ca2+-3
is involved in the binding interaction (Harte and Bajorath 1994). 
Ca-binding site 2 is involved in carbohydrate binding 
Residues with carbonyl sidechains involved in Ca2+ coordination in site 2 form two 
characteristic motifs in the CTLD sequence, and together with the calcium atom itself
are directly involved in monosaccharide binding. The first group of residues, the “EPN
motif” in MBP-A (E185, P186, N187), is contributed by the LLR and contains two 
residues with carbonyl sidechains separated by a proline in cis conformation. The 
carbonyl side chains provide two Ca-coordination bonds, form hydrogen bonds with the 
monosaccharide and determine binding specificity. The cis-proline is highly conserved 
and maintains the backbone conformation that brings the adjacent carbonyl side chains
into the positions required for Ca2+ coordination. The second group of residues, the 
“WND motif” (positions 204-206), is contributed by the E4 strand. Although only 
asparagine and aspartate are involved in Ca-coordination, tryptophan immediately 
preceding them is a highly conserved contributor to the hydrophobic core (position 
E4W, see Chapter 4) and is a useful landmark for detecting the motif in a sequence. In 
the MBP-A structure Asn205 and Asp206 provide three Ca-coordination bonds (two from 
the side chains, one from the backbone carbonyl of Asp) and also form hydrogen bonds 
with the sugar. One more carbonyl side chain is involved in the site 2 formation. It 
belongs to the residue preceding the second conserved cysteine at the end of the LLR 
(Glu193 in MBP-A), and forms one coordination bond with the Ca2+.
As no other Ca-binding site except for site 2 is known to be involved in sugar-
binding, and as the site 2 residue motifs can be confidently detected in the sequence, it 
is common in the literature to associate the predicted Ca2+/carbohydrate binding 
properties of an uncharacterized sequence with the presence of these motifs (e.g. Dodd 
and Drickamer 2001; Drickamer and Dodd 1999). Although this is a useful 
simplification, it should be noted that the absence of the motifs associated with Ca2+-
binding site 2 does not indicate that the CTLD is incapable of binding Ca2+, as there are 
two independent sites (1 and 4). Also, the presence of these motifs does not guarantee 
lectin activity for the CTLD, as there are numerous examples of CTLDs that contain the 
conserved motifs but are not known to bind monosaccharides.
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Sites 1, 2 and 4 play structural roles 
Despite their spatial proximity, from the evolutionary and structural points of view 
Ca2+-binding sites 1 and 2 should be considered as independent. Crystallographic 
studies of rat MBP-A CTLD crystallized at a low metal ion concentration (0.325 mM 
Ho3+ instead of 20 mM as used to obtain the CTLD complexed with mannose) have 
shown that site 1 has higher affinity for Ca2+ as it remains occupied and Ca2+-
coordination geometry is retained while site 2 loses its metal ion (Ng et al. 1998). On 
the other hand in the 4th CTLD of the human macrophage mannose receptor, Ca2+-
binding site 1 is less stable than site 2 (Mullin et al. 1997; Feinberg et al. 2000a). This 
is also the case for the rat pulmonary surfactant protein A (SP-A), where only some of 
the required ligands for Ca2+-1 are present and these can provide only 3 coordination 
bonds to the Ca2+. In one of the two solved SP-A structures (PDB 1r14) both site 1 and 
site 2 are occupied by metal atoms, while in the other (PDB 1r13) only site 2 is 
occupied (Head et al. 2003). The SP-A is a particularly good example supporting the 
mutual independence of sites 1 and 2, because in its close homologue – pulmonary
surfactant protein D – sites 1, 2 and 3 are occupied by Ca2+ (PDB 1pw9, 1pwb Shrive et 
al. 2003). Independence of the Ca2+-binding site 1 is also supported by the fact that in 
several CTLD structures site 1 is missing, while site 2 contains a calcium ion and is 
involved in carbohydrate binding. Examples of such structures are human E- and P- 
selectins (PDB 1esl, 1g1t, 1g1q, 1g1r, 1g1s) and tunicate lectin TC14 (PDB 1byf, 1tlg). 
Ca2+-binding site 4 was first observed in the structure of the factor IX/X-binding 
protein from the venom of Trimeresurus flavoviridis, where it was the only location of
Ca2+ ions (Mizuno et al. 1997). It is occupied by Ca2+ in several other snake venom
CTLD structures. Two observations suggest that this site is a property of the CTLD in 
general rather then the snake venom group of CTLDs. First, it is present in the human
asialoglycoprotein receptor I (Meier et al. 2000), which is a very remote homologue of 
the snake venom CTLDs. Second, as shown by comparative analysis of CTLD 
structures (see Chapter 4, p 84) Ca2+-4 is involved in a stabilizing interaction that is a 
highly conserved structural feature observed in virtually all CTLD structures. It can be 
mediated by salt bridge formation between charged groups and by metal ion 
coordination. In one structure (galactose-specific C-type lectin from rattlesnake
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Crotalus atrox (PDB 1jzn, 1muq`; Walker et al. 2004)) Na+ was found instead of Ca2+
in the site 4.
A stabilizing effect of bound Ca2+ on CTLD structure has been reported for a 
number of proteins from different CTLD groups (Loeb and Drickamer 1988; Mullin et 
al. 1994; Weis et al. 1991a). Ca2+ removal greatly increases CTLD susceptibility to 
proteolysis and changes physical properties of the domain such as circular dichroism
spectra and intrinsic tryptophan fluorescence. Structures of the apo forms of human
tetranectin (Nielbo et al. 2004) and rat MBP-C, and of the one-ion form of rat MBP-A 
(Ng et al. 1998), have demonstrated the mechanism underlying these changes. In these 
structures compactness of the LLR is disrupted leading to multiple conformational
changes including a cis-trans isomerization of the conserved proline. However, not all 
CTLDs require Ca2+ to form a stable LLR structure. NMR studies of the tunicate CTLD 
TC14 have shown that its LLR maintains its compact fold when Ca2+ is removed (Poget
et al. 2001). 
Role of Ca2+ in CTLD function
The most important functional role of the bound Ca2+ in CTLDs is monosaccharide
binding. This function is limited to site 2 and is discussed in detail in Section 1.3. 
However, in several cases, which are described below, Ca2+-binding sites participate in 
interactions that do not involve carbohydrate recognition. 
In proteins, Ca2+ is found in 7- or 8-coordinated form. Because of the metal’s ability 
to simultaneously interact with multiple ligands within the protein, its binding can 
orchestrate dramatic rearrangements in the tertiary structure of the protein. At the same
time, the reversible nature of the binding and its dependence on different parameters of 
the milieu (e.g. ion concentration, pH) provide mechanisms to control the structural
transformations induced by metal binding. 
There are several examples of CTLD functions that are mediated by the Ca2+-
induced structural changes, namely the destabilization of the LLR caused by Ca2+
removal, rather than its involvement in monosaccharide binding. It is thought that the 
destabilization of the LLR caused by pH-induced Ca2+ loss plays a physiological role in 
the function of the CTLDs in endocytic proteins such as asialoglycoprotein receptors 
12
Chapter 1 Introduction
(Loeb and Drickamer 1988; Wragg and Drickamer 1999) and macrophage mannose
receptor (Mullin et al. 1997; Feinberg et al. 2000a). Transition of the receptor-ligand 
complex from the cell surface into the acidic environment of a lysosome leads to Ca2+
loss and to the release of the bound ligand. After release, the ligand is processed by the 
lysosomal enzymes, while the receptor is recycled to the cell surface.
Another example of functional CTLD transformation induced by Ca2+ is human
tetranectin. Although in the CTLD of tetranectin Ca2+-binding sites 1 and 2 are present, 
the CTLD is not known to bind carbohydrates. The domain, however, interacts with 
several kringle domain-containing proteins, including plasminogen, and the interaction 
involves several residues from the Ca2+-binding site 2. Moreover, the interaction with 
kringle domain 4 of plasminogen is only possible when Ca2+ is lost from the binding 
site (Graversen et al. 1998), which leads to changes in the LLR conformation similar to 
those observed in the apo-MBP-C (Nielbo et al. 2004; Ng et al. 1998). The
physiological role of Ca2+ as an inhibitor of the tetranectin/plasminogen interaction is, 
however, unclear. 
The antifreeze protein (AFP) from Atlantic herring provides an interesting example
of a CTLD in which Ca2+ bound in site 2 is involved in an interaction with a non-
carbohydrate ligand (Ewart et al. 1998). Ewart et al. have shown that not only is the 
antifreeze activity of the protein Ca2+-dependent (Ewart et al. 1992), but that it is 
disrupted by minor changes in the geometry of the Ca2+-binding site 2 introduced by 
replacing the original galactose-type QPD motif by a mannose-type EPN motif (Ewart
et al. 1998). This strongly suggests that Ca2+ site 2 in the herring antifreeze protein 
interacts directly with the ice crystal altering its growth pattern. 
1.3 Ligand binding
CTLDs selectively bind a wide variety of ligands. As the superfamily name
suggests, carbohydrates (in various contexts) are primary ligands for CTLDs and the 
binding is Ca2+-dependent (Weis and Drickamer 1996). However, the fold has been 
shown to specifically bind proteins (Natarajan et al. 2002), lipids (Sano et al. 1998) and 
inorganic compounds including CaCO3 and ice (Geider et al. 1996; Ewart et al. 1998; 
Mann and Siedler 1999; Weiss et al. 2000). In several cases the domain is multivalent
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and may bind both protein and sugar (Yokoyama 1998; Matsumoto et al. 1998; 
Kijimoto-Ochiai 2002).
Carbohydrate binding is, however, a fundamental function of the superfamily and 
the best studied one. The first characterized vertebrate CTLDcps were Ca2+-dependent
lectins, and most of the functionally characterized CTLDcps from lower organisms
were isolated because of their sugar-binding activity. Although as the number of 
CTLDcp sequences grows it becomes clearer that the majority of them1 do not possess 
lectin properties, CTLDcps are still regarded a lectin family. Unlike many other 
functions of the CTLDcps, Ca2+-dependent carbohydrate binding is found across the 
whole phylogenetic distribution of the family, from sponges to human, and thus is likely 
to be the ancestral function. Also, Ca2+/carbohydrate-binding CTLDs from different 
species demonstrate amazing similarity in the mechanisms of sugar binding. Systematic
studies by Drickamer and his colleagues have provided deep understanding of many of 
aspects of this mechanism.
The results of this theoretical and experimental work established a basis for 
developing bioinformatics techniques for predicting CTLD sugar-binding properties 
with substantial reliability by sequence analysis (Drickamer and Taylor 2003). All 
previous published whole-genome studies of the CTLD family focused on the evolution 
of the carbohydrate-binding properties used these prediction methods (Drickamer and 
Fadden 2002; Drickamer and Dodd 1999; Dodd and Drickamer 2001). Although my 
approach was somewhat different, for carbohydrate-binding prediction I used the 
techniques developed by Drickamer and coworkers. An overview of the literature on the
mechanism of Ca2+-dependent monosaccharide binding by CTLDs is given below. 
Ca2+-dependent monosaccharide binding
The mechanism of Ca2+-dependent monosaccharide binding by several CTLDs has 
been studied in great detail by X-ray crystallography, site-directed mutagenesis and 
biochemical methods. The first crystallographic study of a complex between a CTLD 
and a carbohydrate was carried out on rat MBP-A and the N-glycan Man6-GalNAc2-
1 According to Drickamer, ~85% of C. elegans and 81% of Drosophila CTLDcps are predicted as
non carbohydrate binding (Drickamer and Fadden 2002).
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Asn (Weis et al. 1992). In the structure obtained, a ternary complex between the 
terminal mannose moiety of the oligosaccharide, the Ca2+ ion bound in site 2 and the 
protein was observed. The complex is stabilized by a network of coordination and 
hydrogen bonds: oxygen atoms from 4- and 3- hydroxyls of the mannose form two 
coordination bonds with the Ca2+ ion and four hydrogen bonds with the carbonyl 
sidechains that form the Ca2+-binding site 2 (Figure 1-5). This bonding pattern is 
fundamental for CTLD/Ca2+/monosaccharide complexes and is observed in all known 
structures. It is also a major contributor to the binding affinity, especially in CTLDs 
specific to the mannose group of monosaccharides. For example in MBP-A, mannose
atoms form very few interactions with the protein other than hydrogen/coordination 
bond formation by the two equatorial hydroxyls, and extensive mutagenesis screening 
has shown that the only other significant contributor to mannose binding is CE from
His189 that forms a hydrophobic interaction with the sugar (Iobst et al. 1994). 
Figure 1-5 Ca2+-dependent monosaccharide binding by CTLDs 
(a) A schematic representation of a Ca2+-hexose-CTLD complex. Two hydroxyl oxygens and the ring of
the hexose are shown. Ca2+ atom is shown as a large grey sphere, oxygens as empty circles and ovals.
Protein groups that act as hydrogen donors and acceptors are not shown. Light-grey arrows indicate the 
direction of hydrogen bonds in galactose-specific CTLDs. (b) A stereoview of the MBP-A complex with
mannose (PDB 2msb). Coordination bonds are orange. Hydrogen bonds where sugar hydroxyl acts as 
acceptor and donor are red and blue, respectively. Ca2+ atom is shown as a blue sphere.
The positioning of hydrogen donors and acceptors in the bindings sites has two 
important properties. First, it determines the overall positioning and orientation of the 
ligand in the binding site. It may seem from Figure 1-5 (a) that the sugar-binding site of 
CTLDs has a 2-fold symmetry axis relating the sugar hydroxyls, and the hypothetical 
sugar shown can be rotated by 180º without introducing any changes to the bonding 
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scheme. It is now known that this is indeed the case, although some early modeling and 
mutagenesis studies were based on the assumption that the orientation of the sugar was
fixed. However, when the structure of a complex between rat MBP-C with mannose
was determined, the orientation of the bound mannose was opposite to the orientation 
that was observed in MBP-A (Ng et al. 1996), and further studies revealed some of the 
factors that determine the preferred orientation (Ng et al. 2002). Although MBP-A is 
the only established example of a CTLD that can bind carbohydrates in both 
orientations, it is known that different CTLDs bind the same monosaccharide in 
different orientations (e.g. galactose-binding MBP-A mutant and CEL-I vs TC-14 
lectin).
The second constraint imposed by the Ca2+-coordination site on the ligand 
determines the properties of the carbohydrate hydroxyls that the site can accept, and this 
is best demonstrated by the mechanism of discrimination between the mannose group of 
monosaccharides and the galactose group of monosaccharides by CTLDs. Early in the 
history of CTLDs an important correlation between the residues flanking the conserved 
cis-proline in the long loop region, which are involved in the Ca2+-binding site 2 
formation, and the specificity for either galactose or mannose was made. In all 
mannose-binding proteins known at that time, the sequence of the motif was EPN (E185 
and N187 in MBP-A), while in the galactose-specific CTLDs it was QPD. In a series of 
elegant mutagenesis experiments Drickamer and coworkers have shown that replacing 
the EPN sequence in MBP-A with a galactose-type QPD sequence was enough to 
introduce the specificity to galactose (Drickamer 1992), and that further modifications 
around the binding site (mainly introduction of a properly positioned aromatic ring to 
form a hydrophobic interaction with the apolar face of the sugar) can increase the 
affinity and specificity of the mutant MBP-A for galactose to the level observed in 
natural galactose-binding CTLDs (Iobst and Drickamer 1994).
Crystallographic analysis of the galactose-specific MBP-A mutant showed that the 
EPN to QPD change does not cause any serious restructuring of the Ca2+-binding site 2 
geometry (Kolatkar and Weis 1996); this suggested that the key switch in the specificity 
was induced by swapping the hydrogen-bond donor and acceptor across the 
monosaccharide-binding plane and changing the hydrogen-bonding pattern from the 
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mannose-type asymmetrical (Figure 1-5 a, dark-grey arrows) to galactose-type 
symmetrical (Figure 1-5 a, light-grey arrows). The same distribution of hydrogen-
bonding partners was observed in the galactose-binding lectin TC-14 from the tunicate 
Polyandrocarpa misakiensis (Poget et al. 1999). TC-14 CTLD contains an unusual EPS
motif in the LLR, which is similar to the motifs of the mannose-binding proteins but 
contains a serine as a hydrogen-bond donor instead of the asparagine in MBP-A. The 
crystal structure revealed that due to a compensatory change on the opposite side of the 
ligand-binding site (the “WND” motif is changed to LDD), and a 180º rotation of the 
galactose residue compared with the orientation observed in the galactose-binding 
MBP-A mutant, the symmetrical pattern of the hydrogen bonding is maintained.
Although many of the determinants of the monosaccharide-binding specificity have 
been established experimentally, the mechanism underlying them is still unclear. 
Mutual spatial disposition of bonded hydroxyls, which was initially suggested to be the 
main contributor to the specificity, is no longer considered so important; a growing 
number of crystal structures of CTLDs with the MBP-A-like (“asymmetrical”)
distribution of hydrogen-bond donors and acceptors have shown that the core binding
site is compatible not only with any two equatorial hydroxyl (3- and 4-OH of mannose
and glucose, 2- and 3-OH of fucose), but also with a combination of an axial and an 
equatorial hydroxyls (3- and 4-OH of fucose, as in E- and P-selectin structures). A 
comparative study of different lectin-carbohydrate complexes published by Elgavish 
and Shaanan (1997) suggests that additional stereochemical factors need to be taken 
into consideration. Elgavish and Shaanan noted the unique clustering of hydrogen-bond 
donors and acceptors around the 4-OH hydroxyl in all compared structures, which was 
not observed for other hydroxyls: in a Newman projection along the O4-C4 bond, 
hydrogen bond acceptors are never gauche to both vicinal ring carbons (C3 and C5), 
and thus the 4-OH proton is always pointing outside the ring. Poget et al. (1999) 
confirmed this observation and also noted that in CTLDs the same rule is also true for
the 3-OH. However, no explanation of the unique stereochemistry of the 4-OH has been 
offered.
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Other contributions to monosaccharide binding affinity and specificity 
Although the networks of interactions between the Ca2+ ion, the carbonyl residues 
that coordinate it and the sugar hydroxyls determines basic binding affinity and 
specificity to either mannose-type or galactose-type monosaccharides, other structural 
elements in the binding sites increase the affinity to the level required for efficient
binding, impose sterical limitations on the orientation of the ligand and introduce 
selectivity to the particular members within the mannose or galactose groups. 
Structural determinants of specificity for particular monosaccharides from both 
mannose and galactose groups were studied by protein engineering on the MBP 
framework (Kolatkar et al. 1998; Feinberg et al. 2000b) and by mutagenesis of several 
wild-type proteins (mechanisms of discrimination between Glc and GlcNAc by chicken 
hepatic lectin: Burrows et al. 1997;  contribution of His189 to the mannose-binding
affinity in MBP-A: Iobst et al. 1994;  mutations affecting MBP-A binding of mannose:
Quesenberry and Drickamer 1992;  discrimination between GalNAc and Gal by 
ASGPR: Iobst and Drickamer 1996;  increasing the mutant MBP-A affinity towards 
galactose: Iobst and Drickamer 1994;  residues affecting pH-dependent ligand release 
by ASGPR: Wragg and Drickamer 1999). These additional contributors to binding, 
however, are variable even between close homologues, which combined with the 
inherent plasticity of the core binding site makes any predictive modeling questionable. 
Reliability of Ca2+/carbohydrate-binding prediction 
As noted above the molecular mechanism of Ca2+-dependent carbohydrate binding 
is conserved in all family members studied; the amino acids that form the core of the 
binding sites form characteristic motifs (“EPN” and “WND”) that can be identified by 
sequence similarity and are indicative of the binding specificity (mannose vs galactose). 
These observations provide a simple and very popular approach to predicting whether a 
CTLD of unknown function is likely to bind sugar (“EPN” and “WND” present) and 
whether it would preferentially bind mannose- or galactose-type ligands (“EPN” vs 
“QPD”). This simple prediction technique is widely used and has proven to be reliable 
in many cases. However, its development was based on comparison of a limited set of 
well-characterized domains, whereas the number of uncharacterized sequences to which 
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it is applied is quickly growing, as does also the evolutionary distance between the 
characterized and new sequences. It is, therefore, important, especially for studies 
involving large-scale CTLD sequence analysis, to take into account the assumptions on 
which this approach is based, and its possible limitations.
The three main assumptions are:
1. The presence of Ca2+-binding site 2 strongly suggests sugar-binding activity. 
2. Ca2+-dependent sugar binding involving Ca2+-binding site 2 is the only (major) 
mechanism of monosaccharide binding by CTLDs. 
3. Positioning of hydrogen-bond donors and acceptors flanking the conserved 
proline in the LLR determines specificity to either mannose- or galactose-type 
monosaccharides.
As described above, the presence of the residue motifs associated with Ca2+-binding
site 2 does not guarantee that the CTLD will bind carbohydrates. Several examples exist 
in the literature where sugar-binding activity and specificity predicted from the 
sequence were not confirmed by experiment. The CTLD of human tetranectin contains
a galactose-type QPD motif and binds two Ca2+ ions, but the only demonstrated
carbohydrate-binding activity of this protein (Clemmensen 1989) is not associated with 
the CTLD (Lorentsen et al. 2000). Antifreeze protein from Atlantic herring also 
contains a galactose-type QPD motif and binds Ca2+, but does not bind carbohydrate 
(Ewart and Fletcher 1993, unpublished data mentioned in the discussion). Although 
human macrophage mannose receptor CTLDs 4 and 5 both contain mannose-type EPN
motifs and other positions typically involved in Ca2+-binding are occupied by identical 
or similar residues (Taylor et al. 1990), monosaccharide-binding activity could only be 
demonstrated for CTLD 4 (Taylor et al. 1992). On the other hand, lung surfactant 
protein A has an EPK motif in the LLR, but binds Ca2+ at site 2 and also 
monosaccharides from the mannose  group (Haurum et al. 1993; Haagsman et al. 1987) 
As to the second assumption, there is no firm evidence that would indicate that an 
alternative mechanism of monosaccharide binding by CTLDs exist, but I found several 
examples in the literature that may suggest this possibility: 
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- Existence of a secondary site was proposed for rabbit and rat hepatic lectins 
based on binding data (Lee and Lee 1988). 
- In a study using photo-activatable galactose derivative to map the binding site of 
a galactose-specific lectin from acorn barnacle (BRA-3) the labeled regions were 
not adjacent to the Ca2+-site 2 (Muramoto and Kamiya 1992). 
- A secondary binding site was observed in one of the MBP-C crystals soaked 
with a high concentration (1.3 M) of D-Methyl-Mannose (Ng et al. 1996). 
Although the second binding site was not observed at lower monosaccharide 
concentration (0.2 M) and electron density for the sugar could only be assigned 
for one of the two copies in the asymmetric unit, it has been suggested that the 
secondary binding site may be a part of an extended site that has significant 
affinity only for larger ligands (Ng et al. 1996). Interestingly, the 
monosaccharide bound at the alternative site is in contact with the regions
corresponding to the regions labeled in the acorn barnacle lectin study. 
- Although the CTLD of human thrombomodulin does not contain the typical Ca-
binding sequence signature, aggregation of melanoma cells mediated by it is 
abolished by Ca2+ removal or by addition of mannose, chondroitin sulfate A or 
chondroitin sulfate C (Huang et al. 2003), which suggests a Ca2+-dependent
carbohydrate-binding activity. 
The evidence for an alternative mechanism of sugar binding by CTLDs is scarce and 
does not show any common trend. On the other hand, a surprisingly large (>80%) 
number of CTLDs from invertebrates are predicted as not sugar binding. It is possible 
that some of these proteins use an alternative mechanism for sugar binding. In this 
regard the example of the Link group of proteins is pertinent. These proteins do not 
contain a LLR but nevertheless bind carbohydrates via a different mechanism.
As to the last assumption, there is no compelling explanation of the correlation 
between donor-acceptor positioning in site 2 and the discrimination between galactose
and mannose, although it is supported by the majority of the CTLDs discovered since 
the observation was made. However, the example of the Polyandrocarpa lectin shows 
that the correlation is not absolute (Poget et al. 1999). 
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1.4 Groups of vertebrate CTLDcps 
In a review of the C-type lectin family published in 1993 Drickamer separated the 
CTLDcps known at that time into 7 groups (I-VII) based on their domain architecture 
and showed that such grouping correlates well with the results of phylogenetic analysis 
of the CTLD sequences and captures functional similarities between the proteins 
(Drickamer 1993). The classification was revised in 2002 (Drickamer and Fadden 2002) 
with the addition of 7 new groups (VIII-XIV). Whereas the first seven groups of 
CTLDcps have substantial history and are widely referenced in the literature, the new
groups were only briefly outlined in the work introducing them. Along with the updated 
classification, a link to the “World-wide web-based resource for animal lectins”
(http://ctld.glycob.ox.ac.uk) was published, where some additional information on the 
new groups can be found, including the lists of database identifiers for the sequences 
that were used to define them. However, no functional description of the CTLDcps 
from the new groups similar to the description of the groups I-VII has been published. 
The domain architecture of the CTLDcps in different groups is shown in Figure 1-6. In 
addition to the 14 groups present in the updated classification, three new groups (XV-
XVII) are shown, which I have added to accommodate the novel vertebrate proteins
identified by me in the study of Fugu CTLDcps (Chapter 5). A brief description of the 
CTLDcp groups focusing on the structural and functional features of the CTLDs 
follows. The new groups will be discussed in Chapter 5. 
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Figure 1-6 Domain architecture of CTLDcps from different groups
Group numbers are indicated next to the domain charts. Numbers of the groups created by me are 
highlighted. I –lecticans, II – the ASGR group, III – collectins, IV – selectins, V – NK receptors, VI – the
macrophage mannose receptor group, VII – REG proteins, VIII – the chondrolectin group, IX – the
tetranectin group, X – polycystin 1, XI – attractin, XII – EMBP, XIII – DGCR2, XIV – the
thrombomodulin group.
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1.4.1 Group I – Lecticans
Lecticans (hyalectans) are large extracellular proteoglycans that carry mainly
chondroitin sulfate side chains. Mammalian genomes encodes 4 lecticans: aggrecan, 
brevican, versican and neurocan. Historically lecticans are divided into three globular 
domains (N-terminal G1 and G2 and a C-terminal G3) and a central extended region to 
which glycosaminoglycan chains are attached. G1 and G2 contain 2-4 Link type 
CTLDs, while G3 contains a canonical CTLD. Monosaccharide-binding activity has 
been demonstrated for the aggrecan C-terminal CTLD, which has a galactose/fucose 
specificity (Halberg et al. 1988; Saleque et al. 1993). This domain also interacts with 
protein ligands: fibrillin-1 microfibrils (Isogai et al. 2002), fibulin-1 (Aspberg et al.
1999), fibulin-2 (Olin et al. 2001) and tenascin-R (Aspberg et al. 1997). A complex of 
tenascin-R and the aggrecan G3 CTLD has been studied by X-ray crystallography 
(Lundell et al. 2004).
CTLDs of group I molecules regulate their intracellular processing and trafficking. 
The G3 region, which has been shown to promote glycosaminoglycan chain attachment
and aggrecan secretion (Domowicz et al. 2000; Zheng et al. 1998). The structure of G3 
varies due to alternative splicing, but the CTLD is always present (Baldwin et al. 1989).
1.4.2 Group II – Asialoglycoprotein receptor and DC receptors
The second group of vertebrate CTLDcps is large and heterogeneous. It can be 
divided into four subgroups based on the gene linkage in mammals: asialoglycoprotein 
receptor (ASGR or ASGPR) gene cluster (ASGR1, ASGR2, HML, MMGL), dendritic 
cell (DC) receptor gene cluster (DC-SIGN paralogues and CD23), macrophage receptor 
gene cluster (Dectin-2, Mincle, DCIR, DLEC/BDCA-2) and several lone members. A 
more conventional approach to discussion of most of the group II members found in the 
literature is based on grouping by expression profile and function (macrophage
receptors, dendritic cell receptors etc.`; Figdor et al. 2002; Geijtenbeek et al. 2004), but 
this is often not consistent with phylogeny, and brings members of different groups into 
one set. 
As for the group V CTLDcps, members of group II are type II transmembrane
proteins, which contain a short cytoplasmic tail, a transmembrane domain, a stalk 
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region and an extracellular domain. The length of the stalk region, which is involved in 
oligomerization, varies between different members of the group. Most of the group 
members have an established carbohydrate-binding activity, although the functional 
importance of carbohydrate binding varies. 
I will describe the group in detail, as it has significantly expanded recently, and 
because to the best of my knowledge it has not been reviewed from the point of view of 
CTLD evolution. 
Asialoglycoprotein receptor subgroup 
The asialoglycoprotein receptors subgroup includes two members (ASGR1 and 
ASGR2) found in different mammals, and one and two more members identified in 
human and rodents, respectively. In sequenced mammalian genomes the genes encoding 
proteins from this subgroup are clustered. Asialoglycoprotein receptor (ASGR or 
ASGPR`; reviewed in Schwartz 1984; Stockert 1995), also known as hepatic lectin, was 
one of the first C-type lectins discovered (Stockert et al. 1974; Kilpatrick 2002). The 
receptor functions as a heterotrimer made of two distinct subunits (ASGR1 and ASGR2 
- major and minor, respectively). In rat and mouse ASGR2 is found in two differently 
glycosylated forms, which were initially considered as separate proteins (rat hepatic 
lectin (RHL) 2 and 3 or RHL2/3`; Hong et al. 1988). Heterooligomeric structure is 
essential for high-affinity binding and internalization (McPhaul and Berg 1986; Braun
et al. 1996). Interestingly, rat spermatogenic cells express an unusual oligomer of 
ASGR2 called rat sperm galactosyl receptor, that consists of a full-length form and a 
truncated form that lacks the C-terminal part of the CTLD (Abdullah and Kierszenbaum 
1989; Rivkin et al. 2000).
ASGR binds and internalizes galactose-terminated oligosaccharides of desialylated 
glycoproteins. After the ligand dissociates in the acidic environment of lysosomes,
ASGR is recycled to the cell surface. The mechanism of the galactose binding has many
interesting aspects, as the subunits have different monosaccharide specificity (Ruiz and 
Drickamer 1996), and bind the same complex carbohydrate molecule simultaneously,
which is unusual for CTLDcps.
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A protein called “chicken hepatic lectin” was isolated and sequenced shortly after 
the mammalian ASGRs (Drickamer 1981). However, sequence analysis now shows that 
it is more similar to proteins from the DC-SIGN subgroup, which is consistent with its 
specificity for mannose-type ligands (N-acetyl-D-glucosamine, Kawasaki and Ashwell 
1977; Loeb and Drickamer 1987). 
Unlike ASGRs, which are found exclusively on liver parenchyma, other members of 
the ASGR gene cluster are expressed by macrophages. The macrophage galactose-
binding lectins1 (MGL) are present in two copies in mouse (mMGL1, Ii et al. 1990;  and 
mMGL2, Tsuiji et al. 2002), but only one copy is found in human (hMGL, also called 
human macrophage lectin, HML`; Suzuki et al. 1996). Recombinant mMGL1 and 
mMGL2 CTLDs have shown differences in carbohydrate-binding specificities (Tsuiji et 
al. 2002). 
DC-SIGNs and CD23 
Dendritic cell-specific ICAM-grabbing non-integrin (DC-SIGN, CD209) and its 
close homologue DC-SIGNR (DC-SIGN receptor) have recently become the most
topical of the C-type lectins, because of their binding of the GP120 protein from the 
human immunodeficiency virus (HIV) envelope. Internalization of HIV by DC-SIGN 
(Engering et al. 2002) is responsible for viral particle transfer and in-trans infection of 
susceptible T-cells. Apart from HIV, DC-SIGN is a receptor for a number of other 
pathogens: Mycobacterium tuberculosis (Geijtenbeek et al. 2003), hepatitis C virus 
(Wang et al. 2004), Ebola virus (Alvarez et al. 2002), and human cytomegalovirus
(Halary et al. 2002).
The DC-SIGN subgroup is an actively evolving gene family, and significant 
differences are observed between mammals. Two genes (DC-SIGN and DC-SIGNR) 
were identified in human, a group of paralogues was found in nonhuman primates
(Bashirova et al. 2003), and five DC-SIGN homologues were found in mouse (Park et
al. 2001), which were named DC-SIGN2, SIGNR1, SIGNR2, SIGNR3 and SIGNR4. 
1 Not to be confused with the macrophage C-type lectin (MCL).
2 mDC-SIGN was identified as the hDC-SIGN orthologue based on the proximity of its gene to the
mCD23 gene. In the human genome hCD23 and hDC-SIGN are closely linked.
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Interestingly, in the fish genome the DC-SIGN group is also expanded (Chapter 5). Two
works describing structural studies of DC-SIGN(R) complexed with oligosaccharides
have been published recently (Feinberg et al. 2001; Guo et al. 2004). Carbohydrate 
recognition plays a central role in the DC-SIGN binding of pathogens.
CD23 (reviewed by Bonnefoy et al. 1997; Mossalayi et al. 1997; Kijimoto-Ochiai
2002), also known as the low affinity IgE  receptor (FcIgE2R) is a key molecule of B-
cell activation and growth (regulation of IgE synthesis). It is a glycoprotein expressed 
on a number of cell types including lymphocytes, eosinophils, platelets, and 
macrophages, and is also found in a soluble form, which is produced by proteolysis. 
The stalk region of CD23 has D-helical structure and is involved in oligomerization (tri-
or tetra-) of the receptor, by coiled-coil formation (Beavil et al. 1992), which 
significantly increases its affinity for IgE (Dierks et al. 1993). The CTLD of CD23 is 
involved in both protein-protein and protein-carbohydrate interactions. Although human 
CD23 binds IgE in a carbohydrate-independent manner (Vercelli et al. 1989), 
recognition of another ligand (CD21) and CD23-induced cell aggregation require Gal-
terminated glycan chains (Kijimoto-Ochiai and Uede 1995; Kijimoto-Ochiai et al.
1994; Aubry et al. 1994). The predicted Ca2+-binding site 2 motifs of human CD23 
CTLD are EPT and WND (EPN in mouse, rat and horse), which are typical for 
mannose-binding CTLDs, so galactose specificity of CD23 is unexpected. 
Recently a new CTLDcp encoded by the DC-SIGN gene cluster has been 
characterized (Liu et al. 2004). The protein (LSECtin) was found in sinusoidal 
endothelial cells of human liver and lymph node, which is similar to the expression 
profile of DC-SIGNR. The CTLD contains an EPN motif and, as expected, 
preferentially binds mannose-type ligands. 
Macrophage receptors
The macrophage receptor cluster (Flornes et al. 2004; Balch et al. 2002) is located 
on chromosome 12p13 in human (Ch 6F2 in mouse) and is closely linked to the NK cell 
receptor complex (group V, see p. 29). The cluster encodes several CTLDcps expressed
by macrophages and dendritic cells: macrophage C-type lectin (MCL`; Balch et al.
1998), macrophage-inducible C-type lectin (Mincle`; Matsumoto et al. 1999), dendritic 
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cell immunoreceptor (DCIR`; Bates et al. 1999), dendritic cell lectin (DLEC or BDCA-
2`; Arce et al. 2001; Dzionek et al. 2001) and dendritic cell-associated lectin-2 (Dectin-
2`; Ariizumi et al. 2000a; Kanazawa et al. 2004). The rodent gene cluster contains 
several members that are not present in human, such as DCIR paralogues (DCIR2-
DCIR4, Flornes et al. 2004), and a dendritic cell immunoactivating receptor (DCAR`; 
Kanazawa et al. 2003). The members of this subgroup were discovered relatively 
recently, and their function is poorly understood (Ariizumi et al. 2000a). To my
knowledge, the only information about carbohydrate-binding properties of these 
proteins comes from two studies on Dectin-2, which gave conflicting results: in one 
case Ca2+-dependent binding to mannose was observed (Fernandes et al. 1999), while in 
the other the protein did not bind carbohydrate (Ariizumi et al. 2000a). In all group 
members, a Ca2+-binding site 2 motif is present, although in some cases this has an 
unusual sequence (e.g. EPK, ESN, EPD in rat, mouse and human MCL, respectively). 
Langerin and Kupffer Cell Receptor 
A cluster of two genes on human chromosome 2p13 (mouse Ch 6D1) encodes 
CTLDcps Langerin (CD207) and Kupffer cell receptor (KuCR). Langerin is an 
endocytic receptor uniquely expressed by Langerhans cells and associated with Birbeck 
granules (human, Valladeau et al. 2000;  mouse, Takahara et al. 2002). It has a long 
stalk region that is involved in trimerization of the receptor by coiled-coil formation.
The CTLD of Langerin has typical motifs associated with mannose binding, and it has 
been shown that the protein indeed binds mannose-group monosaccharides (Stambach
and Taylor 2003). Kupffer cell receptor from rat has a structure similar to Langerin, but
is expressed in liver and functions as an endocytic receptor for fucose-terminated 
glycoproteins  (Hoyle and Hill 1988; Lehrman and Hill 1986).  The KuCR locus in the 
human genome lacks the 3’-terminal exon, which truncates the CTLD at the beginning 
of the LLR; this led Fadden and coworkers to suggest that the human receptor is a 
pseudogene, which was also supported by their failure to identify hKuCR cDNA 
expression by PCR or by EST database search (Fadden et al. 2003). However, full-
length cDNA (AK096429) for hKuCR is now available in GenBank. Also, an alignment
between human and rat proteins shows a high level (63% identity) of conservation. Rat
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KuCR, which contains a galactose-type QPD motif is also interesting as it binds fucose 
with a relatively high affinity (Fadden et al. 2003). 
Other group II members 
Scavenger receptor with a C-type lectin domain (SRCL, human Ch 18.p11`; 
Nakamura et al. 2001a; Nakamura et al. 2001b) has an unusual structure for group II 
proteins. Its long stalk region contains a collagen domain between the juxtamembrane
coiled-coil region and the CTLD: this is why it is also described as a placental collectin
(CL-P1`; Ohtani et al. 2001) and its HUGO-approved name is COLEC12. However, 
despite the presence of the collagen region, the domain structure of the protein is 
analogous to other group II CTLDcps, and phylogenetic analysis of the CTLD 
alignments confidently places SRCL into the group II branch. The CTLD of SRCL is 
similar to the ASGR CTLDs and includes all the elements which were shown to 
contribute to high-affinity galactose binding by ASGR (QPD motif, a tryptophan and 
glycine-rich loop`; Kolatkar and Weis 1996). As expected, SRCL binds galactose-type 
ligands (Yoshida et al. 2003). 
1.4.3 Group III – Collectins 
Collectins are soluble CTLDcps that contain a collagen domain and function at the 
first line of the innate immune defense (Hakansson and Reid 2000). Unique binding 
specificity and spatial organization of the CTLDs in the oligomeric complexes allows 
collectins to recognize ordered arrays of carbohydrates specific to the surfaces of 
microorganisms (pathogen associated molecular patterns, PAMPs). This leads to 
complement activation by a special lectin pathway involving MBP-associated serine 
proteases (MASP-1 and MASP-2), which promotes phagocytosis.
Because of their involvement in immunity, the family has been the subject of 
extensive studies, and many reviews of its structure and function are available (e.g. van 
de Wetering et al. 2004; Wright 2004; Nakagawa et al. 2003). Collectins (MBP-A, 
MBP-C, PSP-A and PSP-D) were also used in the classical studies of the mechanism of 
carbohydrate recognition by CTLDs carried out by Drickamer and his colleagues, as 
already discussed. 
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In addition to the well studied MBPs and PSPs, the collectin group includes several 
members that are much less studied: human liver collectin CL-L1 (Ohtani et al. 1999), 
which was found only in cytoplasm, and three collectins that are found only in Bovidae, 
conglutinin, CL-43 and CL-46 and whose genes are linked with the bovine MBP and 
PSP orthologues (Gjerstorff et al. 2004). I found a database sequence of another 
collectin highly conserved between vertebrates during the Fugu study (Chapter 5), this 
is discussed on p. 102. 
1.4.4 Group IV – Selectins (CD62) 
Selectins are important cell adhesion molecules and are well described in any 
immunology or glycobiology textbook (e.g. Varki 1999). Three selectin L- (leukocyte), 
P- (platelet) and E- (endothelial), are encoded by a cluster of genes on human
chromosome 1; this organization is conserved among vertebrates. Selectins are involved 
in the first step of leukocyte recruitment from the blood stream into sites of 
inflammation and lymphatic tissues. As part of a multistage process, selectins promote
initial attachment (tethering) and subsequent movement (rolling) of leucocytes to the 
vessel walls where they become activated as consequence of exposure to locally 
produced chemokines. The CTLDs of all three selectins bind to the carbohydrate sialyl 
LewisX (SLeX) with low affinity; different high-affinity glycoprotein ligands have been 
also identified (reviewed by Varki 1997; Patel et al. 2002; Rosen 2004). Crystal 
structures of E- and P-selectin complexes with SLeX revealed that binding occurs via an 
extended site on the CTLD, and that in addition to the fucose binding at the primary site 
(Ca2+-binding site 2), electrostatic and hydrogen-bond interactions are formed with the 
other monosaccharide moieties of the SLeX (Somers et al. 2000). 
1.4.5 Group V – “NK cell receptors”
Group V includes non-Ca2+-binding type II transmembrane CTLDcps and is also 
known as natural killer (NK) receptors. This group is evolutionarily young, has been 
unambiguously identified so far only in higher vertebrates, and is mostly encoded by a 
single large gene cluster (human Ch 12p13, mouse Ch 6F3). The number of group 
members varies substantially between rodents and human. In particular, whereas in 
mouse, a set of receptors (Ly49-A – Ly49-x, official symbols KLRA1-KLRA28; some
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of these are alleles) has been identified, in human this set is represented by a single gene 
(Ly49L/KLRA1) encoding a truncated protein, which lacks the distal part of the CTLD 
(Westgaard et al. 1998). A recent work has shown that the group is expanded even 
further in rat and includes at least 36 genes (Wilhelm and Mager 2004).
Most of the group V members belong to the killer cell lectin-like receptor [KLR; 
unofficial names NKG2 (NK cell group 2) and Ly49 in rodents] group and are variously 
associated with inhibition or activation of NK cell function, although exact function of 
many is unknown. The KLRs are known to form homo- (KLRK1/NKG2D) or 
heterodimers (CD94 and KLRC1/NKG2A). Structures of several KLRs (uncomplexed
and with their protein ligands) were solved (Appendix A). 
Although the common definition of the group is “type II NK cell receptors”, many
of  its members are not (exclusively) expressed by NK cells: CD72 is expressed on B-
cells; CD69 is expressed by various hematopoietic cells (Testi et al. 1994); 
KLRG1/MAFA is expressed on basophils and NK cells (Butcher et al. 1998); LOX-1 is 
expressed by vascular endothelial cells (Kume et al. 1998; Yoshida et al. 1998); 
DCAL1, CLEC-1, KLRL1 and Dectin-1 are expressed by dendritic cells (Ryan et al.
2002; Ariizumi et al. 2000b; Colonna et al. 2000); MDL-1 is expressed exclusively in 
monocytes and macrophages (Bakker et al. 1999); and CLEC-2 expression was 
observed in liver (Colonna et al. 2000). Some of these genes form a sub-cluster in the 
NK gene cluster (Sobanov et al. 2001). CD72 and MDL-1 are unique among the group 
V proteins as their genes are located outside of the “NK cluster”: CD72 on 
chromosomes 9 and 4 in human and mouse, respectively (von Hoegen et al. 1991), and 
MDL-1 on chromosome 7p33 in human (Bakker et al. 1999). 
1.4.6 Group VI – Multi-CTLD endocytic receptors 
Group VI CTLDs are type I transmembrane proteins with an N-terminal ricin-like 
domain, a fibronectin type 2 domain and 8 or 10 CTLDs in the extracellular domain,
and a short cytoplasmic domain. In mammals, the group includes 4 members: Endo180, 
phospholipase A2 receptor (PLA2R), macrophage mannose receptor (MManR), and 
Dec205 (reviewed recently by East and Isacke 2002). The latter is the only group 
member that contains 10 CTLDs. All four proteins are recycling endocytic receptors.
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Monosaccharide-binding properties have been demonstrated only for Endo180 (East et
al. 2002) and MManR (Mullin et al. 1994); in both cases the activity is limited to a 
single domain (4 and 2, respectively), but other domains are required for high-affinity 
binding of multivalent ligands (Taylor et al. 1992; Taylor and Drickamer 1993). Most 
of the CTLDs of the group VI proteins do not contain residue motifs associated with 
Ca2+-binding site 2. 
1.4.7 Group VII – REG proteins
Group VII CTLDcps are soluble proteins which consist of a CTLD preceded by a 
short N-terminal peptide and so far were found only in mammals1. The members of this 
group, which in the initial classification included all other soluble single-CTLD 
proteins, are encoded by a compact gene cluster located on human chromosome 2p12 
(mouse 6C3) and a single gene on human Ch 1p12 (mouse 3F3). The first member of 
the family was identified simultaneously by several groups in different functional 
contexts, which is reflected in the number of alternative names it was assigned (de 
Reggi and Gharib 2001): pancreatic stone protein (PSP), because it was isolated from
pancreatic stones; lithostathine, because it was considered an inhibitor of calcite crystal 
growth (Geider et al. 1996; Gerbaud et al. 2000), which, however, was not confirmed in 
other studies (Bimmler et al. 1997; de Reggi et al. 1998); and regenerating gene (Reg), 
as its overexpression was observed in regenerating pancreatic islets (Terazono et al.
1988). Other family members from several mammalian species were identified 
subsequently and are organized into four groups (Okamoto 1999; Zhang et al. 2003a). 
None of the Reg family members contains a characteristic Ca2+-binding motif, and 
although they have been shown to be involved in various physiological and pathological 
processes, molecular mechanisms of their action are largely unknown (Zhang et al.
2003b). Lithostathine was also studied because of its ability to form amyloid fibrils and
possible involvement in early stages of Alzheimer’s disease development (Duplan et al.
2001; Gregoire et al. 2001; Cerini et al. 1999). Three dimensional structures of 
1 This is based on the phylogenetic definition of the groups (discussed in section 1.4.16). CTLDcps
with the same domain architecture as Group VII are found in a wide variety of species, including
invertebrates, but their phylogenetic relationship to the Reg proteins is uncertain.
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polymerized lithostathine protofibrils (Gregoire et al. 2001), and several monomer
structures have been solved (Appendix A). 
1.4.8 Group VIII – Chondrolectin, Layilin
Group VIII includes type I transmembrane proteins with a single CTLD. Two 
members have been identified: Layilin and Chondrolectin (CHODL/MT75). Layilin 
expression was detected in a wide range of cell lines and tissues (Borowsky and Hynes 
1998). CTLDs of Layilin and CHODL contain a motif associated with Ca2+-binding,
although the motif is unusual (EPS). Layilin binds hyaluronan via the CTLD and 
intracellular proteins from the ERM family (talin and radixin), and may function as
either an endocytic receptor or adhesion molecule (Bono et al. 2001). No hyaluronan 
binding could be detected for CHODL (Weng et al. 2002).
1.4.9 Group IX – Tetranectin
Group IX has three identified members: tetranectin, stem cell growth factor (SCGF) 
and CLECSF1, which all are soluble proteins with a long N-terminal D-helical domain
that is involved in coiled-coil formation. This structure resembles the structure of the C-
terminal domains of collectin. The similarity between group IX and group III is further
supported by the gene structure (intronless CTLD) and molecular phylogeny 
reconstruction based on the CTLD alignment. Although all group members contain a 
Ca2+-associated motif, their sequences suggest that hydrogen-bond requirements for 
monosaccharide binding in the typical mechanism will not be satisfied. 
Although tetranectin contains Ca2+-binding residues in the CTLD and is involved in 
a carbohydrate recognition event (it binds heparin), the CTLD does not participate in 
this interaction (Lorentsen et al. 2000). The CTLD is responsible for tetranectin binding 
to plasminogen (Plg), its main ligand, in a mechanism where Plg and Ca++ compete for 
Ca2+-binding site 2 (Graversen et al. 1998). The phenotype of the tetranectin knock-out 
mouse suggests that the protein is involved in tissue remodeling, which is consistent 
with its ability to stimulate plasminogen activation and expression in developing tissues 
(Iba et al. 2001). 
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Stem cell growth factor (SCGF also known as LSLCL`; Hiraoka et al. 1997; 
Bannwarth et al. 1998; Bannwarth et al. 1999; Mio et al. 1998), contains an N-terminal
mucin-like Ser/Thr rich region and was originally detected in the culture medium of a 
human myeloid cell line (Hiraoka et al. 1987). It acts as a mitogen on human bone 
marrow erythroid and granulocyte/macrophage progenitors (Hiraoka et al. 1997; 
Gehling et al. 2000). The sequence of the original clone of SCGF was identical to 
LSLCL, but contained a deletion of 78 residues (Hiraoka et al. 1997), which could not 
be explained by alternative splicing, as it is located within exon 3 encoding the CTLD 
(Bannwarth et al. 1999): the short and long form are called  SCGFE and SCGFD,
respectively. As the truncated (SCGFE) form was reported to be an active growth factor, 
it is unlikely that this activity is mediated by the CTLD. 
For CLECSF1, only expression data are available (Neame et al. 1999). Its 
homologue from shark was initially reported as shark tetranectin (Neame et al. 1992; 
Neame et al. 1999). 
1.4.10 Group X – Polycystin 1 
PKD1 was identified as one of two genes in which mutations are responsible for the 
onset of autosomal dominant polycystic kidney disease (ADPKD) (Consortium 1995; 
Hughes et al. 1995). PKD1 product – polycystin 1 – is a large multi-domain protein
with 11 membrane-spanning regions, thought to be involved in cell-cell or cell-matrix
interactions. The extracellular domain of PKD1 is ~3000 amino acids long and contains 
16 PKD domains, which have an Ig-like fold (Bycroft et al. 1999), a leucine-rich repeat 
domain, a putative carbohydrate-binding WSC domain, a CTLD and a domain
homologous to the sea urchin receptor egg jelly protein 1 (suREJ1, Moy et al. 1996).
The suREJ1 protein, despite lacking most of the domains present in PKD1 and 
having only a single membrane-spanning region, contains two CTLDs (Moy et al.
1996). Two of the suREJ1 paralogues (suREJ2 and suREJ3) isolated later also contain 
one CTLD (Mengerink et al. 2002; Galindo et al. 2004). Thus, the PKD1 group may be
the most ancient groups of vertebrate CTLDcps as it can be traced back to the early 
evolution of deuterostomes. Of several PKD1 paralogues identified in mouse and 
human, only two (PKD1L2 and PKD1L3) contain CTLDs (Li et al. 2003). 
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The function of the CTLD in polycystin 1, as well as the function of the protein 
itself, remains unknown. A recent study using a GST-fused recombinant PKD1 CTLD 
revealed binding to unsubstituted carbohydrate matrices (Sepharose and Sephadex
G25), as well as to several extracellular matrix proteins, with high affinity and in a 
Ca2+-dependent manner (Weston et al. 2001). This is intriguing taking into account the 
sequences of the Ca2+-binding site 2 motifs (EPH and WCNT). Unfortunately, the
results cannot be interpreted unambiguously because the GST domain was not cleaved 
from the CTLD. 
1.4.11 Group XI – Attractin
Attractin was identified as a glycoprotein expressed by hematopoietic cells (Duke-
Cohan et al. 1998) in either transmembrane or soluble form, due to alternative splicing 
(Tang et al. 2000). The protein contains a CUB domain, which is found in many
developmentally regulated proteins, four EGF-like domains, and four PSI domains,
which are found in plexins, semaphorins and integrins. Attractin orthologues in mouse
and rat have been associated with the mahogany mutation, which affects the 
melanocortin signaling pathway (Gunn and Barsh 2000), and the zitter mutation in 
tremor rats (Kuramoto et al. 2001), respectively. An orthologue of attractin has been 
found in C. elegans, but the protein lacks the CTLD (Duke-Cohan et al. 1998). 
Interestingly, a CTLD occurs very frequently in combination with a CUB domain in C.
elegans. A well-conserved vertebrate attractin paralogue can be found in sequence 
databases (hypothetical protein KIAA0534); no description of this protein has been 
published.
1.4.12 Group XII – EMBP 
Eosinophil major basic protein, which has an estimated pI of 11, is the major
component of the crystalloid core of eosinophil-specific granules and functions as a 
cytotoxic agent against parasites. It is also involved in allergic diseases such as asthma
and causes epithelial cell damage, exfoliation, and bronchospasm (Adkinson and 
Middleton 2003). EMBP is produced in a pre-pro form that includes a signal peptide 
and a highly acidic N-terminal peptide. Despite its highly basic nature, the CTLD of 
EMBP has a typical CTLD fold (Swaminathan et al. 2001). A paralogue of EMBP, 
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EMBP-2, has been identified in mouse (Macias et al. 2000) and human (Plager et al.
1999; Plager et al. 2001), but its function has not been established. 
1.4.13 Group XIII – DGCR2 
Group XIII contains only one member, DGCR2/IDD/Sez-12, which was localized in 
the DiGeorge syndrome (OMIM 188400) critical region (Wadey et al. 1995; Kajiwara
et al. 1996; Taylor et al. 1997). The CTLD of DGCR2 does not contain characteristic 
Ca2+-binding motifs, and the function of the protein is unknown. 
1.4.14 Group XIV – Thrombomodulin
This group includes thrombomodulin (TM), Endosialin/TEM1 and 
CD93/C1qRP/AA4. All members of the group are type I transmembrane proteins with a 
short intracellular domain and an extracellular part that includes a signal peptide, a 
CTLD, a domain referred to as hydrophobic or sushi-like, one or more EGF domains,
and low complexity Ser/Thr-rich regions, which are targets for O-glycosylation. All 
three known members are expressed on vascular endothelium. The specificity of 
expression varies, with Endosialin being found only on tumor vascular endothelium (St 
Croix et al. 2000; Christian et al. 2001; Rettig et al. 1992;  but see Opavsky et al.
2001), while C1qRP and TM are expressed more broadly. 
Thrombomodulin (TM) is by far the best-studied member of the group, and one of 
the best characterized CTLDcps in general, due to its involvement in the coagulation 
pathway. Thrombin binding to EGF domains 5 and 6 of TM promotes protein C (PC) 
activation (up to 1000x), which makes TM a potent tissue anticoagulant (Weiler and 
Isermann 2003). Mounting evidence suggests that in addition to the well-established 
role in anticoagulation, TM is involved in cell adhesion and inflammation control 
(Conway et al. 2002; Huang et al. 2003); this is also a function of another characterized 
XIV group member, C1qRP/CD93/AA4 (McGreal et al. 2002). In both cases, 
experiment indicates that cell adhesion is mediated by the N-terminal domain, which in 
the TM literature is called the “lectin-like domain” and includes the CTLD and the 67-
residue “hydrophobic region” separating the CTLD from the first EGF domain.
Although the TM CTLD does not contain the typical Ca-binding sequence signature, it 
has been shown that deletion of the N-terminal “lectin” domain suppresses TM-
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mediated aggregation of transformed A2058 melanoma cells and, most importantly, that 
TM-mediated aggregation could be abolished by Ca2+ removal or addition of mannose,
chondroitin sulfate A or chondroitin sulfate C (Huang et al. 2003). As the deleted 
regions also contain the second (hydrophobic) domain these results cannot be 
interpreted as proof of CTLD involvement in the carbohydrate binding, but they 
strongly suggest this possibility. 
1.4.15 Proteins with Link/PTR domain
Link domain or protein tandem repeat (PTR) is a special variety of CTLD, which 
lacks the LLR. The major function of Link domains is binding hyaluronan (HA). 
Although proteins containing it have different domain architecture, their number is 
small, and they have not been divided into subgroups. Group I CTLDcps contain both 
canonical and Link-type CTLDs. Other Link-domain containing proteins have four 
types of domain architecture (Figure 1-7). Link proteins’ domain composition is similar
to the N-terminal part of Group I (lecticans). Four Link protein-encoding genes have 
been identified in mammals, each physically linked with one of the lectican genes; this 
suggests that lecticans and Link proteins are of a common evolutionary origin (Spicer et 
al. 2003). Link proteins and lecticans are also functionally associated: cartilage Link 
proteins bind both aggrecan and hyaluronan stabilizing the 
proteoglycan/glycosaminoglycan network (Faltz et al. 1979). CD44 and its recently 
identified close homologue Lyve-1 are type I transmembrane molecules and cell surface 
receptors for hyaluronan (Banerji et al. 1999; Lesley and Hyman 1998). Tumor necrosis 
factor-inducible protein TSG-6 is a soluble protein with a CUB and a Link domain (Lee
et al. 1992; Wisniewski and Vilcek 1997). The structure of the latter in free and 
hyaluronan-bound states has been determined by NMR (Kohda et al. 1996; Blundell et 
al. 2003). Stabilin-1 and -2 (also known as FEEL-1/-2`; Tamura et al. 2003; Adachi and 
Tsujimoto 2002; Politz et al. 2002) are scavenger receptors which have the capacity to
internalize conventional scavenger ligands such as low density lipoprotein, bacteria and 
advanced glycation end products. Unlike Stabilin-2, Stabilin-1 does not bind hyaluronan 
or other glycosaminoglycan (Prevo et al. 2004). 
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Figure 1-7 Domain architecture of the proteins containing Link domain
1.4.16 Criteria for classification of novel CTLDcps 
The classification created by Drickamer has proven to be a useful instrument for 
studies of vertebrate CTLD evolution. Its wide acceptance makes it important to have a 
clear definition of the principles on which the classification is based. As discussed 
below, some of the apparently minor contradictions that were present in the original
grouping often made assignment of newly discovered family members to the existing 
groups, as well as creation of the new groups, ambiguous and led to some confusion in 
the literature. The arguments presented below may seem rather scholastic, but the 
problems I routinely encountered while working on the whole genome analysis of the 
family in Fugu (Chapter 5) and adding newly found mammalian CTLDcps to the 
classification inspired this critical review.
It is not absolutely clear what the classification is based on – phylogenetic 
relationships between CTLDs, or the domain architecture of the proteins containing the 
CTLDs. Although the latter is generally considered to be the case, even Drickamer’s
(1993) initial grouping contained a set of CTLDcps with identical domain architecture 
which was split into two groups – Group V and Group II – based on phylogenetic and
functional considerations. At the same time, all soluble single-domain CTLDcps, which 
are only distantly related to each other and perform different functions were included in 
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one group (VII), which also contained single-CTLD proteins from invertebrates and 
lower vertebrates (Drickamer 1993). The problem of Group VII phylogenetic 
heterogeneity was resolved in the updated classification (Drickamer and Fadden 2002), 
where group VII was split into several groups: VII (lithostathine), IX (tetranectin), and 
XII (EMBP). Although there are differences in sequence composition and size of the 
regions outside the CTLD, these regions do not contain defined, conserved protein 
domains. For example, EMBP in processed functional form contains nothing but a 
CTLD, while an acidic region, similar to EMBP’s acidic pro-peptide, is found in a stem 
cell growth factor, which is a member of the tetranectin family. Also, phylogenetic 
analysis of the CTLD sequence rather than overall domain architecture is the defining 
factor in classification of these sequences. Sometimes domain architecture can be 
misleading, as in the case of scavenger receptor with a CTLD (SRCL), which contains a 
CTLD, a collagen domain and coiled-coil regions – a combination observed otherwise 
only in collectins. SRCL was first described as a placental collectin (Ohtani et al. 2001), 
although both the CTLD sequence and the presence of a transmembrane domain
indicate that SRCL should be assigned to group II rather than group III; the group II 
assignment has been made in the online database described in the recently published 
revised classification (Drickamer and Fadden 2002). 
However, the clearest example of using phylogenetic information as a classification 
basis is the division of type II transmembrane proteins with a single CTLD into groups 
II and V – a division not consistent with the general idea of using domain architecture 
as a basis for classification. Although phylogenetic analysis of CTLD sequence 
alignments strongly indicates that there are indeed two distinct sets of type II 
transmembrane CTLDcps in mammals, it is not possible to correlate this differentiation
with any structural (properties of the neck region) or functional (oligomerization
pattern, tissue expression profile) properties. For example, though group V is often 
called “NK-cell receptors”, according to phylogenetic analysis it should also include
proteins expressed on non-lymphoid cells, e.g. oxidized low density lipoprotein receptor 
(expressed on endothelial cells) or Dectin-1 (macrophages, neutrophils, dendritic cells). 
Also, there is no obvious distinction between domain structures of the group members
which could be used as a basis for (sub)classification. Differentiation cannot be based 
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on oligomerization properties, as some members of group V function as monomers
(LOX-1, Dectin-1).
Therefore, it seems that the current paradigm of CTLD classification is based on 
phylogeny rather than domain architecture, and that the former is more evolutionally 
stable than the latter. I followed this paradigm in annotation of the of Fugu CTLDcps
and grouping the newly found mammalian proteins. 
1.5 Bioinformatics resources related to the CTLD superfamily 
CTLDs are very well represented in domain profile databases. In my experience, the 
hidden Markov model (HMM) for the CTLD used by the SMART web resource 
(Letunic et al. 2002) is very accurate and sensitive, and the resource in general provides
an excellent tool for domain architecture analysis. The PFam HMM profile for the 
CTLD (Lectin_C, PF00059) can be used with similar sensitivity and specificity, but the
seed alignment used to build it does not include the N-terminal region of the long-form 
CTLDs, so the N-terminal boundaries for such domains are defined incorrectly. Both 
PFam and SMART contain separate models for Link-type CTLDs, and PFam also 
contains profiles for bacterial compact CTLDs. The InterPro (Mulder et al. 2003) entry 
for the CTLD (IPR001304) includes two ProSite profiles (Hulo et al. 2004), which 
often give false positive hits. Due to this, a search in the annotation systems that use 
InterPro, such as EnsEMBL, shows a number of sequences mis-annotated as CTLDcps. 
1.6 Conclusions and aims
The CTLD family is a very interesting subject for computational research on protein 
structure and function. The large number of family members and functional versatility 
of the domain allow separation of the mechanisms that control evolution of the fold
from those that affect function, which may have implications for both fields. 
Availability of a large number of determined structures provides enough material for 
comparative generalization. 
Several vertebrate CTLDcp groups play central roles in important physiological 
mechanisms, which are specific to vertebrates. However, the studies of such proteins 
were mostly limited to several higher vertebrate species. Systematic studies of the 
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CTLD family in the lower organisms can reveal the evolutionary origins of the 
important vertebrate functional systems.
The specific project aims can be summarized as follows:
x To study the stability and adaptability of the fold by comparing the available 
CTLD structures, the number of which increased substantially since the last 
reported comparison and now includes highly divergent CTLDs, in order to 
determine which residues and interactions are most conserved, what are their
roles and how (or if) they can be identified by sequences analysis. 
x To study the evolution of the family using the recently determined vertebrate 
genome sequences. 
x To promote the inclusion of uncharacterized CTLDs as targets into the high-
throughput biology projects by providing bioinformatics support. 
x To accumulate, integrate and annotate information on the CTLD superfamily, to 
provide a high-quality dataset for studies of its structure, function and evolution. 
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A database of CTLD sequences 
The CTLD family is large. According to my estimate at the end of 2004 the 
GenBank database contains about 2000 CTLD-containing expressed sequences from
various species. The figure is doubled if all the sequences predicted in various genome
annotation projects are taken into account. The number of distinct domain sequences is 
even bigger, as some CTLDcps contain more than one CTLD. The amount of 
bibliographic and other structural and functional information is also substantial. A 
PubMed search with a CTLD-specific text query returns more than 7000 matches, and 
there are 115 Protein Data Bank entries containing experimentally determined CTLD 
structures.
Many of the studies I planned had a systematic nature and involved analysis of 
complete, non-redundant and annotated collections of CTLD-containing sequences 
selected by certain criteria. I intended selection to be based on the properties that could 
not be derived from the sequence in a straightforward way, but which would require 
manual annotation based on the literature data or analysis involving ad hoc decision-
making. Due to the size of the CTLD family and the heterogeneity of the sequence 
sources, a local system was required for retrieving, storing, clustering, annotating and 
accessing the sequence information. To solve this task I created a relational database for
storing the annotated sequence collations and a set of web-based tools and Perl modules
for accessing and annotating this sequence collection. 
2.1 Tasks 
The local CTLD database was required to be not just a simple collection of 
sequences retrievable by accession number, but to provide a way to answer complex
questions, such as for example: “What is the number of known mammalian Group II 
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CTLDcps?”, or: “What Groups of CTLDcps have representatives in fish?” or to retrieve 
subsequences corresponding to CTLDs from a certain set of proteins.
It would also be useful to associate each sequence with a meaningful identifier, such 
as those used in the SwissProt database, which would represent the name of the protein 
and the species it belongs to (e.g. in SwissProt TETN_HUMAN corresponds to human 
tetranectin). In multi-staged branched bioinformatics analysis protocols, which require
routine result comparison, it is much more convenient to work with sequences that have 
informative identifiers rather than with cryptic database accession numbers.
2.1.1 Integration and clustering of sequence data
The basic task of the system was to maintain a local collection of CTLD-containing 
sequences. The sequences might have come from different sources, such as: databases 
of experimentally verified expressed sequences (NCBI GenPept, SwissProt, TrEMBL,
FANTOM); transcript and protein sequences predicted by genome annotation; 
sequences derived from local genome annotations; and sequences obtained 
experimentally in our laboratory. 
The next major task was clustering the sequence collection at different levels: 
transcript level, gene/locus level, and orthology level. The diversity of transcribed 
sequences deposited in the public databases is higher than the diversity of the protein 
products they encode, due to natural reasons and differences in isolation and sequence 
determination. As the most common mode of protein sequence determination is by 
conceptual translation of its mRNA, the set of protein sequences produced by this 
method from a non-redundant database may be redundant. The first step in sequence 
clustering is to eliminate such redundancy. 
The next step in the transcript clustering is to identify the transcripts produced from
the same gene. As a rule this is a straightforward task, which can be solved without 
referring to the genomic sequence by detecting regions of identical or nearly identical 
(due to polymorphisms and sequencing errors) sequence regions shared by different 
transcripts. The task, however, can be complicated by the presence of very similar
paralogues, in which case it may be hard to discriminate between allelic variation and 
paralogy. In the CTLD family this is the case for Ly49 receptors from rodents.
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The goal of the last clustering step is to identify the phylogenetic relationships 
between the genes and to group orthologous genes together, so as to allow study of the 
evolution of a protein in a lineage of species. This kind of clustering is the most difficult
to automate, as the exact phylogenetic relationships often cannot be defined 
unambiguously. Objective definition of orthology and paralogy relationships between 
related gene families from two species requires complete sequence information for all 
family members in each of the species. However, even when such information is 
available, it is not always possible to determine pairs of orthologues if the members of 
the family are duplicated. On the other hand, high sequence similarity, and common 
domain structure, supported by molecular phylogeny reconstruction, can be a good 
indication of orthology, even in the absence of a complete set of gene family members.
For example, it is quite common in the literature to give newly discovered proteins the 
name of the closest known homologue from the other species, which intuitively implies
orthology. The goal of phylogenetic clustering is to follow this common approach in the 
general case and to verify the definitions of phylogenetic relationships by comparison of 
complete sets of members whenever possible. 
2.1.2 Sequence annotation
The minimum required sequence annotation is specification of CTLD boundaries 
based on a given computational definition of the domain, for example, using a profile 
HMM. Additional description of the domain sequence, such as its subtype (long or short 
form, compact or canonical) and the location of the important landmark residues and 
motifs (conserved cysteines and the WIGL), would also be useful. Annotation of other 
sequence features, such as the location of exon boundaries mapped from the gene model
to the protein sequence, may also be required. 
In addition to individual sequence annotation, ability to define and annotate arbitrary 
groups of sequences is also required. For example, sequences may be grouped based on 
their position in the domain-based CTLDcps classification, or by some functional 
criteria, such as sugar-binding activity. Also, the database must provide a means to keep 
references to the relevant entries in other databases – bibliographic (PubMed), sequence 
(GenBank), genomic (NCBI Genomes, EnsEMBL), clustering (UniGene, LocusLink) or 
structure (PDB).
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2.1.3 Collaborative editing and sharing
Curation of a sequence annotation database is a laborious and time-consuming task, 
and both the quality and the usefulness of such a database depend greatly on scale of 
curatorial effort. Therefore, increasing the accessibility of such a system and providing 
mechanisms for collaborative editing is an important task. In the environment of a small
research group where several investigators work on the same family of proteins, 
availability of a common source of high-quality annotated data is an advantage. Such a 
data source will also help to maintain continuity of the research project and to flatten
the learning curve for new group members.
Finally, sharing the data with a wider community over the Internet, in a read-only, 
controlled-access or fully open form, will help to disseminate the knowledge and to 
attract more experts from the field whose comments and, possibly, direct contribution 
into the annotation will be useful.
2.2 Existing solutions
Many of the tasks outlined above are addressed by publicly available databases and 
services. The NCBI Entrez system contains several integrated databases that aim to 
solve the problem of sequence clustering at transcript, gene and homology levels and 
the problem of integration of the sequence, structural, functional and nomenclature 
information. In the NCBI UniGene database results of the automatic clustering of 
expressed sequences at gene level are stored (Wheeler et al. 2004). The NCBI 
LocusLink is a gene-centric database containing information on official nomenclature,
aliases, sequence accessions, phenotypes, Enzyme Commission (EC) numbers, 
Mendelian inheritance in man (MIM) database numbers, UniGene clusters, homology,
map locations, and related web sites (Pruitt and Maglott 2001). A similar approach is 
used in the GeneLynx database, which contains a gene-oriented collection of hyperlinks 
to information in various databases available via the Internet (Lenhard et al. 2003; 
Lenhard et al. 2001). Phylogenetic clustering is provided by NCBI HomoloGene, which 
is a system for automated detection of homologues among the annotated genes of 
several completely sequenced eukaryotic genomes.
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Sequence feature annotation (e.g. definition of domain boundaries, functional motifs
etc.) is also available from public resources. Most sources of sequence information
provide an option to retrieve the sequence in a rich format, which includes the results of 
computational or curated annotation. For example, sequences from the NCBI GenPept 
and RefSeq databases include annotation of domain structure based on the NCBI 
Conserved Domain Database (CDD) or contributed by sequence submitters. SwissProt
entries are well annotated by curators, including the description of domain structure.
EnsEMBL peptide annotations also include definitions of domain boundaries (based on 
InterProScan and other tools) and other sequence features such as low complexity,
coiled-coil, transmembrane and signal peptide regions etc. 
Despite the usefulness and power of the public databases, they do not fully satisfy 
the needs of a study similar to mine. Three main problems are completeness,
consistency and customization. Regardless of how complete the sequence or annotation 
database is, a specialist will always have to deal with information that is not (yet)
available from it. Such information can be produced by manual sequence assembly or 
annotation, come from sources that are not integrated into the main database, or be a 
result of local experimental or computational work. The consistency problem mainly
applies to sequence annotation. Preexisting sequence annotations can only be relied on 
if the same annotation method is used in all different sequence sources. This, however, 
is not the case, so a universal annotation method is required to ensure consistency. 
Finally, customization of the annotation is the major problem. Public databases provide 
few if any means for the user to participate in the annotation. At the same time,
automated annotation, or even curated annotation, is not always reliable. For example, it 
is not uncommon to see a CTLDcp annotated as a lectin or “sugar binding” based 
merely on the presence of the CTLD, although there is no direct experimental data to 
support this or even the presence of sequence motifs suggesting Ca2+ binding. 
Thus, although public resources can be very helpful in solving most of the tasks 
outlined above, they are not sufficiently flexible to be used directly. 
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2.3 Implementation 
The implementation1 includes a relational database backend, a web-based interface 
for interactive manipulation of the data, and a Perl application programming interface 
(API) that allows accessing sequence and annotation objects programmatically. The 
software components of the system are written in Perl and use modules from the 
BioPerl project (Stajich et al. 2002). 
Figure 2-1 Organization of the CTLD sequence database system
The relational database backend consists of two databases, the sequence database 
and the annotation database (Figure 2-2). The sequence database is based on the 
BioSQL schema and serves two purposes. First, it locally stores the sequence
information imported from the public databases. Second, the results of local annotation 
that can logically be associated with a location within the sequence (rather than being a 
property of the sequence as a whole or a group of sequences) are stored in the sequence 
database as sequence features. The sequence database is accessed via the bioperl-db 
modules.
1 The source code for the software described in this chapter can be found in the CTLD_DB directory
on the supplementary compact disc. Live version of the system is currently accessible at 
http://anz.anu.edu.au/ctld/index.asp. Database schema where designed for and work with the MySQL 
database management system.
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2.3.1 Annotation database
The second database is the annotation database, which is based on a custom schema
(Figure 2-2). The annotation is organized in three main tiers: protein (product), gene 
and cluster of orthologous genes (COG), which correspond to three database tables 
(products, genes, cogs). This three-tiered hierarchical structure is designed to represent 
the results of sequence clustering at different levels, from transcript to phylogenetic. 
Each product is linked to one or more entries from the sequence database, which have 
identical amino acid sequences. The gene object is defined by a set of one or more
products produced by expression of a single gene. COG is a group of genes from
different species, which are considered orthologous. Thus, a COG object is a parent to 
one or more gene objects, while each of the genes is a parent to one or more products.
Classifications and links to external databases 
The classification table is used for storing the controlled vocabularies that can be 
used for description of the primary database objects (products, genes and COGs). The
controlled vocabulary has a hierarchical structure. Hierarchy depth is limited to 2 in the 
Perl API, but no limit is imposed by the database schema. Two examples of the 
controlled vocabularies used to classify CTLD sequences are presented below 
(vocabulary terms are printed in bold, their descriptions in regular font face). 
Drickamer+ – Extended Drickamer’s domain-based classification: 
ٛ I – lecticans
ٛ II – type II transmembrane proteins 
ٛ III – collectins 
ٛ …
ٛ XIV – Thrombomodulin group 
Form – CTLD form:
ٛ long – long-form canonical 
ٛ short – short-form canonical 
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ٛ compact – bacterial CTLDs and Link domains
Information on the controlled vocabulary term assignment to the primary database 
objects is stored in the table seq_classification. Free form textual descriptions of the 
primary objects can also be stored. In the current implementation of the database, the 
number of such textual descriptors is limited to one per object; the descriptions are kept 
in the function field of the object entry. 
Links to external databases are kept in the xrefs table, while the xdbs table describes 
the external databases linked from the main database and specifies URL templates if the 
external database supports web access. A special type of cross-reference stored in the 
xrefs database links product objects to the underlying sequence objects from the local 
sequence database. 
Other database tables store additional information about the primary objects. The 
seq_aka table is used for keeping synonymous names for COGs, genes and products. 
The history table is used for storing the information about record modification history. 
The user table is used for storing the information about the database curators. 
Storing sequence and annotation information in relational databases provides a 
convenient way to analyze the data. For example, one of the questions given as an 
example at the beginning of the Tasks section (“What is the number of known 
mammalian group II CTLDcps?”) can be answered with a singe SQL query: 
SELECT COUNT(DISTINCT p.prod_id) FROM tbl, products AS p, genes AS g, cogs AS c,
    seq_classification AS cl, classifications AS cls, sequence_db.taxa AS tx
WHERE p.gene_id = g.gene_id AND g.cog_id = c.cog_id 
    AND cl.class_id = cls.class_id AND cls.name LIKE "II"
    AND cl.table_id = tbl.tbl_id AND tbl.name = "products" 
    AND cl.item_id = c.cog_id AND g.taxa_id = tx.taxa_id
    AND tx.full_lineage LIKE "%Mammalia%"; 
(assuming the annotation is complete and correct). A similar query can return accession 
numbers for the protein sequences corresponding to selected product objects, which can 
then be used to fetch the sequences. However, the Perl API provides a much more
convenient way of sequence retrieval. 
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Figure 2-2  A diagram of the annotation database schema
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2.3.2 Perl API
The design of the Perl API of the CTLD annotation system is based on the bioperl-
db1 circa 2002, and some of its classes inherit from the bioperl-db classes. Bioperl-db 
has undergone a major re-design recently; the new version is not backwards compatible
with the previous one or with my code. The compatibility issues will be solved in the 
second version of the CTLD DB. The current production version of the database 
schema and Perl API is 1; Perl modules in this version are in the ANZ:: namespace. In 
the second version, which is intended to be more universal than the first one, I switched 
to the Bio::DOIDB:: module namespace. Apart from compatibility with the new 
bioperl-db version and namespace change there are few differences between v.1 and 
v.2, so most of the current production version description will be applicable to the next 
version.
The Perl API includes classes for two types of objects: persistent annotation objects, 
which are called controllers (ANZ::Controller::ProductController,
ANZ::Controller::ClassificationController etc.) and their database adaptors 
(ANZ::Adaptor::ProductAdaptor, ANZ::Adaptor::ClassificationAdaptor etc.). The 
controller objects are used for storing information about the primary objects and 
annotation objects from the database; adaptors provide controller object storage, 
comparison and retrieval. Commonly used adaptor methods are fetch_by_dbid(),
fetch_by_full_name(), create(), update(). Each object adaptor maintains a reference to a 
database adaptor. For “heavy” objects lazy fetch methods, which do not retrieve child 
objects, can be used to increase performance.
Object identifiers
One of the important functionalities added by the Perl API is construction of 
informative identifiers for the primary database objects, which are implemented to 
substitute for sequence accession numbers. The identifiers include the sequence’s 
common name, taxonomic affiliation and functional variant. These identifiers are 
1 Bioperl-db is a separate project within BioPerl and contains modules for storing sequence
information in a relational database.
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referred to as the object’s full name in the code. Each primary object is assigned a 
unique full name when it is retrieved from the database. The full name of an object is 
composed from the full name of its parent object and the name of the object itself.
Unlike full names, which are unique within the whole database, object names are 
unique within the scope of their parent object only. For example, no two products with 
the same name are allowed for a particular gene, and no two genes from the same
species are allowed for a COG. COG and product names are arbitrary strings of 
alphanumeric characters and underscores, while the name of a gene is defined by the 
name of the species it belongs to. As COGs are at the top of the object clustering 
hierarchy and do not have parent objects, their full name is equivalent to their name. For 
example, the full name of a COG that groups orthologues of brevican from different 
species will be BREVICAN.
The full name of a gene is constructed by adding a shortened species name to the 
name of the parent COG. For example, the full name of human brevican will be 
hBREVICAN, where the prefix h stands for Homo sapiens. Predefined species name
abbreviations can be specified by the database maintainer (table taxa_abbrev), which is 
a convenient thing to do for major model organisms (h – human, m – Mus musculus, r – 
Rattus norvegicus, f – Fugu rubripes,  ce – Caenorhabditis elegans etc.). If an 
abbreviated name for a species is not specified manually, it is constructed by a special 
subroutine from the binominal nomenclature to produce the shortest unique identifier, 
which is then stored in the database along with the pre-defined abbreviations. This 
approach is convenient when the majority of sequences in the collection belong to a 
limited number of species. 
The full product name is produced from the name of its parent gene by adding the 
product name as a suffix. Product names are arbitrary strings of digits and lower-case 
letters up to 50 characters long. Products created by automatic sequence import to the 
database are assigned single-letter names (a, b, c, d …), which can later be changed to 
something meaningful (e.g. full – for full-length; or tm – for transmembrane form). The 
product name is enclosed in brackets and added to the full name of the gene to which 
the product belongs, to give a full name, e.g. hBREVICAN(long) – for the long form of 
human brevican. Finally, as the ultimate goal of the database is analysis of the CTLD 
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domain sequences, individual CTLDs are also assigned unique identifiers, which are 
derived from the product identifier by adding a suffix of the form @N, where N is the 
sequential number of the CTLD in the sequence. For example, the fourth CTLD of the 
putative Fugu rubripes macrophage mannose receptor orthologue predicted by 
EnsEMBL will have an identifier fMManR(ens)@4.
Sequence annotation 
The annotation database was intentionally separated from the sequence database to 
minimize dependence on the stability of the bioperl-db code. However, some of the 
annotation elements describe particular sequence locations rather than the sequence as a 
whole. As bioperl-db provides excellent support for localized sequence features, such 
annotations are stored in the sequence database. These features are distinguished from 
the original sequence features imported from the external sequence database by a 
special source identifier and can be filtered out if the locally stored sequence needs to be 
retrieved in its original form.
Sequence annotation is carried out by several filter scripts that are applied to all 
incoming sequences. For example the annotate_sequence.pl script identifies domain
boundaries using several CTLD profile HMMs. As the HMM has a defined number of 
match states, positions corresponding to the landmark residues and motifs can be 
identified from the sequence-to-profile alignment, if the position of the corresponding 
match state in the profile is known. This approach is used to identify the positions of the
four conserved cysteines and the WIGL motif in CTLDs. Also, a sequence can be 
compared with several alternative HMMs representing different varieties of the domain
(e.g. canonical and compact), and based on the highest-scoring match the type of the 
CTLD can be determined.
2.3.3 Web interface
A relational database is a convenient and flexible way to store the data and to search 
it using complex queries. However, if data analysis and editing requires a consolidated 
view of the information, an interactive interface is needed. Based on the considerations
outlined in the Tasks section, a web-based solution is most suitable.
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Site menu: [classifications] [COGs] [Genes] [Products]
Products menu: [list ] [create] [edit ] [delete]
Asialoglycoprotein receptor IhASGPR1 Homo sapiens (human)
Transcript
One of 4 transcripts of gene hASGPR1
MTKEYQDLQH LDNEESDHHQ LRKGPPPPQP LLQRLCSGPR LLLLSLGLSL LLLVVVCVIG
SQNSQLQEEL RGLRETFSNF TASTEAQVKG LSTQGGNVGR KMKSLESQLE KQQKDLSEDH
SSLLLHVKQF VSDLRSLSCQ MAALQGNGSE RTCCPVNWVE HERSCYWFSR SGKAWADADN
YCRLEDAHLV VVTSWEEQKF VQHHIGPVNT WMGLHDQNGP WKWVDGTDYE TGFKNWRPEQ
PDDWYGHGLG GGEDCAHFTD DGRWNDDVCQ RPYRWVCETE LDKASQEPPL L
Function
Products of two genes ASGR1 and ASGR2 form respectively major and minor subunits of
heterooligomeric asialoglycoprotein receptor (ASGPR). As shown in knockout mouse model, both
subunits are required for receptor function [1], but the major subunit is required for stable
expression of the receptor [2] and binds galactose ligands with higher specificity [3]. ASGPR,
which is expressed exclusively on hepatic parenchimal cells, efficiently and specifically removes
partially deglycosylated glycoproteins from plasma. Upon ligand binding, ASGPR is internalized to
acidic-sorting organelle, where ligand dissociates. Receptor is then recirculated to the cell-
-
surface
[4]. Localized expression of ASGR1 and binding specificity make it a good target for site specific
drug delivery [8206921, 7592600]. Another possible therapeutic use of ASGR1 is targeting NK
cells transfected with this gene to tumor cells bearing b1-Gal Thomsen-Friedenreich (TF) antigen
[5] . ASGPR binding to tumor cell glycans is also a cause of liver metastasis development
[8219612, 3345610].
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Figure 2-3  A screenshot of the prod.asp page displaying information about the ASGR1 
protein
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Figure 2-4 COG page in a customized list mode 
(/COG.asp?action=splist&species=Fugu%20rubripes)
Site menu: [classifications] [COGs] [Genes] [Products]
COG menu: [list] [create]
[<<][<]Showing records from 1 to 96 of 96[>][>>] Selected items. OK
Full name Title Number of genes
Afp Antifreeze protein
AFPL-F1 Antifreeze protein-like 1
AFPL-F2 Antifreeze protein-like 1
I Hyalectans
AGGRECAN Aggrecan 18
AGGRECAN-F1 Fugu aggrecan paralogue 2
BREVICAN Brevican 10
BREVICAN-F1 Fugu paralogue of Brevican 1
NEUROCAN Neurocan 9
NEUROCAN-F1 Fugu Neurocan paralogue 1
VERSICAN Versican 16
VERSICAN-F1 Fugu paralogue of versican (fragment containing EGF, CTLD and CCP domains) 3
VERSICAN-F2 Fugu versican paralogue (fragment containing link and Ig domains) 1
II Dendritic cell receptors, mono-ctld macrophage receptors, ASGR.
DC-SIGN-F1 Fugu DC-SIGN paralogue 1 1
DC-SIGN-F2 Fugu DC-SIGN paralogue 2 1
DC-SIGN-F3 Fugu DC-SIGN paralogue 3 1
DC-SIGN-F4 Fugu DC-SIGN paralogue 4 1
DC-SIGN-F5 Fugu DC-SIGN paralogue 5 2
DC-SIGN-F6 Fugu DC-SIGN paralogue 6 1
DC-SIGN-F7 Fugu DC-SIGN paralogue 7 1
DC-SIGN-F8 Fugu DC-SIGN paralogue 8 1
DC-SIGNR DCSIGN receptor 10
HML2 HML2 2
SRCL Scavenger receptor with C-type lectin 4
SRCL-F1 Putative Fugu paralogue of SRCL 1
XLCMCL eXtra Large Coiled coil region containing Membrane C-type Lectin 1
III Collectins
COLEC10 COLEC10 5
MGC3279 MGC3279 5
IV Selectins
SELECTIN-E E-Selectin 14
SELECTIN-L L-Selectin 10
SELECTIN-P P-Selectin 9
VI Multi-CTLD molecules. Macrophage Mannose Receptor (MMR) family.
DEC205 DEC205 6
Endo180 Endo180 3
MManR Macrophage mannose receptor 3
MManR-F1 Fugu macrophage mannose receptor paralogue (fragment) 1
MManR-F2 Fugu macrophage mannose receptor paralogue 1
MManR-F3 Fugu macrophage mannose receptor paralogue (fragment) 1
MManR-F4 Fugu macrophage mannose receptor paralogue (fragment) 1
MManR-F5 Fugu macrophage mannose receptor paralogue (fragment) 2
PLA2R Phosopholipase A2 receptor 6
VIII MT-75, layilin
LAYILIN Layilin 5
LAYILIN-F1 Fugu layilin paralogue 1
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The initial version of the interface was implemented as a set of CGI scripts written 
in Perl, which provided a basic means for data access and modification. However, CGI 
scripting is not particularly suitable for generation of pages with complex structure, 
where the amount of static content is comparable with the amount of dynamically
generated content. There are many Perl-based application servers and toolkits that solve
the task much more efficiently by providing opportunities for embedding Perl code in 
HTML, templating, user session management, request caching etc. (see 
http://perl.apache.org/products/app-server.html for a list of possibilities). I have chosen 
the Apache::ASP (http://www.apache-asp.org) for its power and simplicity.
The web-based interface provides several access points, which correspond to the 
primary annotation objects: /prod.asp1, /gene.asp and /cog.asp and to the classification 
object: /clasif.asp (Figure 2-3(a)). Each page associated with the primary annotation 
object has several modes of action: list, edit, show and create, which can be selected by 
passing an appropriate value in the action request parameter (e.g. /prod.asp?action=list
calls the product page in the list mode; Figure 2-3(b)). Some of the actions require 
additional parameters. The show action (Figure 2-3) displays the information about a 
single object, which can be specified by either id (database accession number) or fn
(object full name) parameters. The edit action works in a similar way and presents 
object-related information in an editable HTML form. The list action allows browsing 
lists of objects presented as a table, in which each row is hyperlinked to the 
corresponding object show page. The default behavior of the list page is to display a list 
of all the objects of the corresponding type that are available in the database. Currently 
there is no option to perform flexible database queries from the web interface and 
display the results using the list action. However, configuration can be done on the 
server side and there are several pre-configured listing modes that output results of 
certain queries as a formatted list. For example, the cog.asp page accepts a special 
action splist. This action requires a species parameter, which can be set to a name of a
taxon of any level, and will produce a list of COGs that contain genes from species 
whose lineage includes the taxon passed to the script. The list is displayed with entries 
1 Locations used here are relative to the web interface location on the web server.
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grouped according to their position in Drickamer’s extended domain-based
classification (Figure 2-4).
The web interface has a modular structure, and several re-usable elements, located in 
the /asp/Gadgets directory, are included from multiple pages. The most important of 
such components is the list.inc module (as used for the query shown in Figure 2-4), 
which is a customizable element lister. The number of fields in the list table can be 
specified in the argument list, and field text and the address linked to the field can be 
flexibly set by passing a reference to the delegate methods or subroutines. Another 
reusable module is called textwithrefs.inc (Figure 2-3 (c)). This module parses a string 
of text containing references to literature indexed by PubMed, attempts to retrieve the 
full citation from the local database and displays the original text with formatted
bibliography. These and other modules can be used for building other web interfaces 
based on Apache::ASP. 
Finally, the web interface provides some simple sequence feature visualization 
capabilities. The prod.asp page called in the show mode displays a diagram showing the 
position of CTLDs in the sequences. Under this diagram each CTLD is drawn at a 
larger scale with the positions of conserved cysteines  and WIGL domain indicated and 
exon/intron structure shown, if it is known (Figure 2-5). 
Figure 2-5 Visualization of CTLDcp sequence features
The image was created by the web interface for human macrophage mannose receptor (MManR)
sequence. At the top a diagram of MManR showing the positions of 8 CTLDs (green boxes). At the
bottom each of the CTLDs is drawn at a larger scale with the positions of four cysteines (black dots) and
the WIGL motif (black box) are shown. Alternating colors (green and pink) are used for exons, exon-
intron boundaries are shown as grey vertical lines. 
2.4 Conclusions and future development 
The database and web-based annotation system created for the project have proven 
to be very useful tools for CTLD family analysis. I extensively used them in several 
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studies, one of which I report in this thesis (Chapter 5). The system has some
shortcomings: for example, the orthology identification algorithm is not reliable 
enough; the web interface provides very limited search functionality etc. Despite these 
problems, the system provides a much more flexible way to access the sequence 
collection and the annotation. 
Apart from the purely utilitarian purpose of maintaining and annotating a CTLD 
sequence collection, the system had several other ideas behind it, that due to the lack of 
time were not fully implemented or tested in practice. The most obvious next step in the 
project development is releasing the software suite as a laboratory database 
management system and a knowledge-sharing tool. It is difficult to estimate how many
groups working on projects similar to mine would find the software worthwhile, but the 
only way to answer this question is by making it public. The first version of the code, 
which is the current production version, has some elements that limit it to the CTLD 
domain. The second version is designed to allow annotation of any collection of 
sequences related to each other. A platform implementing similar ideas has been 
described recently (Navarro et al. 2004).
Although the system was designed to allow multiple users to access and modify the 
data, it has not been tested in a real collaborative environment, neither within our 
laboratory nor on the Internet. However, this aspect of the system may be very 
interesting. Curated databases provide higher quality information than un-curated
databases of similar purpose, irrespective of how sophisticated the algorithms used for 
automated annotation are or how many sources of information they integrate. This is 
true for different types of biological information – structural (e.g. SCOP), expressed 
sequence (e.g. SwissProt, LocusLink), genomic (Vega project for vertebrate genome
annotation, curated annotations of C. elegans and Drosophila genomes, MIM database 
etc.).  Institutions that maintain the curated databases have teams of curators dedicated 
to the task of annotation, and hold special meetings to bring together specialists from
different fields to improve the annotation quality. At the same time, although free online 
access to the curated data is always provided, the web interfaces work in read-only 
mode, making it impossible for a user to change the annotation if it is incomplete or 
incorrect.  As the information stored in such databases is very specialized, most of the 
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users accessing it are likely to be specialists, whose contribution to the annotation could 
greatly improve its quality and, therefore, should be welcomed. There are numerous
examples in the information technology (IT) field where users are invited to contribute 
to the resource content, either by its direct creation and modification or in the form of 
comments linked to the curated content, and where the quality of information in 
resources that use this approach meets high standards. Some examples include: the 
Wikipedia encyclopedia (http://www.wikipedia.org), which has recently passed the one 
million entries landmark, and where each entry can be freely modified by any user; the
community-run news portal Slashdot (http://slashdot.org), which is arguably the most
popular, informative and reliable of the IT-related news sites; interactive online 
documentation for open source software, such as the MySQL and PostgreSQL database 
management systems, where user-added comments are often more informative than the 
main content. The biological community differs in many respects from the IT 
community, and scientific information needs to meet more rigorous requirements than 
the content of news posts or general-purpose reference sources. However, it is possible 
that a system can be created which would combine high quality scientific content with 
the possibility for any interested user to contribute. This idea can be tested by 
publishing the annotated CTLD sequence collection and inviting the CTLD community
to use and modify the annotation.
Finally, the reusable modules developed for the system, may be useful for other 
projects that require complex web interfaces. BioPerl provides a rich set of modules for 
acquisition, transformation and graphical representation of biological information, but 
to my knowledge there is no ready-made solution to common tasks presenting such 
information on the web. 
The implementation gave rise to a collection of software modules, which not only 
solve the particular task of managing a database of CTLD sequences and annotations, 
but which potentially have more general applications in collaborative database curation 
and the creation of web-interfaces to bioinformatics applications written using the 
BioPerl modules.
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CTLDs in C. elegans – target selection 
for structural genomics 
This study is being carried out in collaboration with the RIKEN Genomic Sciences 
Center (GSC, Yokohama, Japan) Protein Research Group led by Prof Shigeyuki 
Yokoyama and has two main motives. At the time when the study was conceived, GSC 
had developed facilities for high-throughput in vitro protein production and structure 
determination by NMR (Yokoyama et al. 2000). The group was looking for targets for 
structure determination that would meet their scientific goals and the technical
requirements. The technical requirements for the target, apart from applicability to the
NMR technique (Mw <15,000 Da), included target redundancy, so that for each primary 
target a ranked set of alternatives would be available. The success rate of the in vitro 
protein production, according to Prof Yokoyama, was about 20%, depending on the 
target, and the overall success rate is further reduced at the stage of spectrum acquisition 
and structure solution. 
My research supervisor, Dr Jill Gready, was invited to propose a project that would 
fit these requirements. She suggested high-throughput structure determination of the 
CTLDs encoded by the C. elegans genome. The CTLD family is particularly large in 
the worm genome, but nothing is known about the functions of its members.
Determining the structure of these domains would be an important step towards 
understanding their function. Also, the C. elegans CTLDs show very low sequence 
similarity with the sequences from vertebrates and other invertebrates, and often lack 
elements that are considered crucial for fold integrity. Therefore, determining the 
structures of such CTLDs could extend our understanding of fold evolution and 
stability.
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The suggested project was accepted and at the time of writing one structure has been
completely finished by the RIKEN team and deposited in the PDB. I contributed to the 
collaboration by identifying the CTLDs encoded by the C. elegans genome, clustering 
their sequences and ranking them according to their usefulness for homology modeling
of other C. elegans CTLDs. 
3.1 The task
Whole-genome studies of the CTLD superfamily of model organisms has revealed a 
surprising lack of similarity in family compositions between vertebrates and 
invertebrates and between the two invertebrates studied (C. elegans and D. 
melanogaster`; Drickamer and Dodd 1999; Dodd and Drickamer 2001). In C. elegans,
the CTLD is the seventh most common domain (Consortium 1998), but none of the 
proteins containing it have vertebrate homologues and none of them has been 
functionally characterized. Therefore, from the point of view of potentially interesting
biological functions, all CTLDs were of equal importance. For this reason, and because 
none of the C. elegans CTLDs was within reliable homology modeling range from
known high-resolution structures, the whole set of C. elegans CTLDs was our target. 
The main assumption on which my approach was based was that 30% sequence 
identity between two CTLDs is sufficient to provide a reliable homology model. This 
value is often used in the literature as a reliability cutoff for modeling by similarity
(Rost 1999). In the case of CTLDs, which have several very well conserved landmark
motifs in the sequence, a model can be built with a lower similarity score. However, 
modeling loop regions, which comprise almost a half of the fold and form ligand-
binding sites, is usually problematic if similarity is low and especially if gaps are 
present.
Due to the requirement of target alternatives, the task was not merely to pick the 
minimal number of targets that would represent all the C. elegans CTLDs, but rather to 
cluster the sequences into groups of close homologues, and to rank each member of the 
group based on how well it represents the group. A convenient way to do this is to 
represent the sequence set as a weighted graph, where each vertex corresponds to a 
sequence and edge weights represent similarity between the two sequences. The graph 
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can be simple undirected if a combined similarity score is produced from a pairwise 
comparison, or directed multigraph if the score is computed asymmetrically for each of
the sequences in the pairwise comparison. In the case of CTLDs sequences, which are 
all of approximately the same length, combined similarity scores are sufficient. A 
complete graph is initially created from the distance matrix produced from an all-to-all
sequence comparison, after which the edges with weights lower than a certain threshold, 
which represents the minimal significant relationship score (such as 30% residue 
identity required for homology modeling) can be eliminated. The resulting graph can be 
subjected to cluster analysis, to detect groups of closely related sequences, and 
visualized. The graph clustering approach is widely used for analyzing large sets of 
sequences (Sasson et al. 2003; Yona et al. 2000; Enright et al. 2003; Kriventseva et al.
2001), and several bioinformatics-oriented visualization tools are available 
(PhyloGrapher (see Methods), Enright and Ouzounis 2001). 
3.2 Methods
C. elegans CTLDcp sequences were obtained by up to 20 iterations of PSI-BLAST 
search (Altschul et al. 1997) in the GenPept database. Sequences of 16 C-type lectin 
domains with determined structure were used as PSI-BLAST queries: 1msb, 1b08, 
1c3a, 1bj3, 1byf, 1dv8, 1egg, 1esl, 1fm5, 1lit, 2afp, 1hq8, 1b6e, 1htn, 1h8u, 1qo3 
(Appendix A). The set of sequences identified by these searches will be referred to as ce
(Figure 3-1). To reduce redundancy, the original sequence database was processed with 
the cd-hi program (Li et al. 2001b) with a 95% sequence identity threshold producing 
the ce95 sequence set (268 sequences). 
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Figure 3-1 Selection of CTLD targets for structural genomics 
An HMM profile was used to define CTLD boundaries and produce a multiple
alignment of all CTLD sequences. To build the profile, 16 sequences from the CTLDs 
with known structure were aligned with ClustalW. The alignment was corrected 
manually on the basis of structure comparisons. The HMM model was created from the 
alignment using the hmmbuild and hmmcalibrate programs from the HMMER package 
(Eddy 1998). The ce95 set of sequences was searched with the HMM, subsequences 
corresponding to the CTLDs were selected and formed a ce95ctld set (295 sequences). 
For multi-CTLD sequences, domain sequence identifiers were created by adding a 
suffix with the domain number to the identifier of the original sequence (e.g. second 
CTLD of T29200 has sequence id T29200_d2). To identify the sequences for which a 
homology model can be produced based on one of the solved CTLD structures, ce95ctld
sequences were used as a query for a BLAST search in the PDB sequence database 
(October 2002). Only three sequences out of 295 gave matches with identity to any 
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solved CTLD structure above 30% (AAB70944_d1, 30% with 1lit, T29200_d2 31% 
with 1lit, T29754_d2 32% with 1bj3). 
The ce95ctld sequences were aligned with hmmalign. As the sequences used in the 
analysis originated from a genome annotation and it was not known whether they are 
expressed and functional, it was expected that some may be pseudogenes or 
misannotations. Therefore, CTLDs which lacked the absolutely conserved C1-C4 
cystine bridge were designated as “bad” (45 domain sequences), but were not excluded 
from the analysis. 
The PhyloGrapher8 program was used for ce95ctld clustering and to visualize the 
clustering information. Similarity matrices were derived from the ClustalW distance 
matrices for the ce95ctld alignment. It should be noted that pairwise percent of identity 
(PID) scores used for this study were calculated on the basis of the ce95ctld multiple
alignment and, thus, are less than the scores that would be calculated on the basis of 
pairwise alignment. The difference, however, does not exceed 3-5% for the cases tested.
PhyloGrapher was configured to visualize similarity relationships above 30% of 
identity. At the first stage, the graph representing the sequence set was organized 
manually using visual information provided by PhyloGrapher to separate outliers 
(vertices without any edges) and to determine the most obvious clusters. At the next 
stage, the largest clusters were separately organized with the Fruchterman-Rheingold
algorithm implementation available within the program.
A large portion of sequences formed a single cluster of highly interconnected 
vertices (the Big cluster), which could not be organized manually or using the 
Fruchterman-Rheingold algorithm. The mcl program from the MCL package 
(http://micans.org/mcl/`; van Dongen 2000) was used to identify the sub-clusters within 
this cluster (version used: mcl-02-063; parameters: initial inflation 2, prune number
2000). For each sequence within a cluster, a score was calculated by averaging percent 
of identical residues in pairwise alignments with each of the other sequences in the 
cluster.
8 http://www.atgc.org/PhyloGrapher/PhyloGrapher_Welcome.html
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Perl scripts were written to convert between distance and similarity matrices and 
their different formats (ClustalW, MCL, PhyloGrapher), and to manipulate the 
sequences.
3.3 Results 
A graph showing relationships (defined by percentage of identical residues) between 
the sequences from the ce95ctld set is shown on Figure 3-2. Each vertex corresponds to 
a single CTLD sequence from the ce95ctld set; color-coded edges represent similarity
relationships. Only edges with weights 30% are shown, so each edge represents a 
possibility for homology modeling. In the graph layout presented in the figure, vertices 
were organized manually with the assistance of the built-in algorithm available in 
PhyloGrapher. Manual clustering of the nodes reveals several clearly defined groups:
x Unlinked nodes (outliers), corresponding to sequences that are less than 30%
identical to any other sequence in the set, constitute a group of 27 sequences. 
x The rest of the nodes are organized into 3 big (>10 sequences) and 4 small
clusters. Clusters were assigned arbitrary names to facilitate description:
o “yellow” cluster contains 25 vertices each corresponding to a mono-
CTLD sequence. Most of the vertices in this cluster are joined by high-
weighted edges (> 60% ID) and thus constitute a good target for a 
structural genomics study. 
o “Big” cluster – the largest cluster containing 161 nodes. Most of the 
links within the cluster correspond to 40-50% identity and most of the 
vertices have multiple edges. There are several outliers however, which 
are within successful homology modeling distance from only one other 
sequence. Some of the big cluster sequences are linked to the “yellow” 
cluster sequences by ~30% ID edges.
o “Ursa” cluster contains 13 nodes; all of them correspond to mono-CTLD 
sequences.
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o “star” cluster contains four sequences, which are highly similar (>60% 
ID) and one outlier, which is 30-40% identical to the other cluster 
members.
Small clusters (“square”, “diamond”,“3” and three dyads) all contain mono CTLD 
sequences (except one dyad, which includes domain 2 from the T19474 sequence). 
Figure 3-2 Graph representing similarity relationships between ce95ctld sequences
To refine the structure of the Big cluster, I selected the corresponding subgraph and 
used the mcl program to cluster it. Parameters for mcl were chosen arbitrarily so that the
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number of clusters produced was between 5 and 20. As a result, the Big cluster was sub-
divided into 19 sub-clusters (B.1-B.19). To visualize the relationships between the 
sequences, I generated a PhyloGrapher coordinate file for the Big cluster graph, which 
produced the layout shown in Figure 3-3. In the figure, only edges with a weight above 
0.35 (which corresponds to 35% identity between the sequences) are shown. Some of 
the node clusters are highly interconnected, which suggests that granularity of the 
clustering is too high with the mcl parameters that were used. The interconnected 
clusters were merged into groups (BA-BD) and were considered jointly. Weights of the 
edges connecting the clusters in the BD group are between 0.3 and 0.35 and are not 
visible in Figure 3-3. 
Figure 3-3 Subclusters of the Big cluster
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The results of clustering and the relationships between the groups are shown in 
Figure 3-4. Sequences within each group were re-aligned and similarity scores were 
calculated. After this, rankings were produced as described in Methods. As an example,
ranking results for the Ursa group (13 sequences) are given in Table 3-1. The third 
column contains the number of homology models that can be built with the
corresponding template, while the second column gives the average similarity to the 
template. For example, solving the structure of the top-scoring target in the group 
(T21758) will allow building homology models for 10 other CTLDs, which leaves only 
two of the domains not covered. 
Figure 3-4 Groups of C. elegans CTLDs revealed by cluster analysis
Table 3-1 Ranking of CTLDs from the Ursa group.
Sequence identifier Average identity
score
Number of sequences
covered (out of 13) 
T21758 0.39 10
T27947 0.40 9
T27948 0.42 8
T21756 0.42 8
T27946 0.41 8
T26745 0.41 8
T21755 0.39 8
T20972 0.36 5
T27950 0.36 5
T21759 0.35 3
T29846 0.33 3
T27952 0.48 2
T21757 0.38 2
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The ranking of targets was sent to our collaborators at RIKEN GSC. Of the 295 
possible targets, to my knowledge, 70 have been tested for expression and solubility so 
far. One structure has been fully completed and was deposited in the Protein Data Bank 
(ID 1WK1, currently on hold; Kobayashi et al., unpublished). This CTLD belongs to 
the T16199 sequence, and is one of the low-ranking targets in the Big cluster 
(subcluster B.18) and can serve as template for homology modeling of 7 other CTLDs 
with an average identity score 0.32. The T16199 sequence is large (2229 AA), and 
contains several regions matching domains from SMART or PFAM (Figure 3-6 D; EGF
– epidermal growth factor domain, VWA – von Willebrand factor type A domain, MD 
– un-annotated C. elegans domain from SMART, only found in nematodes). As all 
recognized domains are only found in extracellular proteins, and a signal peptide is 
predicted at the T16199 N-terminus, the protein is most likely extracellular. Apart from 
several paralogues in C. elegans and their orthologues in C. briggsae (CBG14163 in 
Figure 3-5), no T16199 homologue can be found in the NCBI non-redundant nucleotide 
database and in vertebrate genomic databases. 
T16199   1   -CDNGWESFGQYCVKFLTVNDDILSMPQARNFCASAGGYLADDLGDDKNNFYSSIAANTQ 59
Q20219   1   -CDEGWEPIGQYCIKFMATVENILPMPQAKAFCASAGGFLVDDLTDDKNGFLKSVAANTQ 59
CBG14163  1   -CDEGWDNYGQYCLKFVIGNDDIMTMPQARKFCANAGGYLADDTSDGQNGFLNMAASRTQ 59
hDC-SIGN  1   PCPWEWTFFQGNCYFMSNSQR---NWHDSITACKEVGAQLVVIKSAEEQNFLQLQSSRSN 57
T16199   59  --FWIGLFK-NSDGQFYWDRGQGINPDLLNQPITYWANGEPSNDPTRQCVYFDGRSGDKS 116
Q20219   59  --FWTGLFK-NNDGQFYWDRGTGINPDLLNQPITYWADGEPSDDPTRQCVYFNGRSGDAN 116
CBG14163  59  --FWIGLFK-DSDQQFYWDRGQGNNPDPLNPAVTYWADNQPSNDPVDQCVYFDGRSSDGN 116
hDC-SIGN  58  RFTWMGLSDLNQEGTWQWVDGS----PLLPSFKQYWNRGEPNNVGEEDCAEFSGNG---- 109
T16199   117 KVWTTDTCATPRPFICQ---- 133
Q20219   117 KVWTTDTCAEPRAFACQ---- 133
CBG14163  117 KVWVTDTCSTPRPFVCQ---- 133
hDC-SIGN  109 --WNDDKCNLAKFWICKKSAA 128
Figure 3-5 Alignment of the TC16199 CTLD with homologous nematode CTLDs and the most
closely related CTLD with solved structure (DC-SIGN). 
Residues in the columns with conservation levels >70% are highlighted according to their chemical
properties (dark green – hydrophobic, light green – aromatic, red – acidic, blue – basic, grey – neutral-
polar, pink – glycine, yellow – proline, dark red – cysteine).
The structure of the T16199 CTLD is typical for CTLDs, with two usual cystine 
bridges. Terminal E strands are somewhat disordered and the E1-E5 sheet is poorly 
defined. This may be a result of domain boundary definitions that were used to produce 
the fragment whose structure was solved. Sequence analysis predicts that the T16199 
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CTLD is long-form, but the fragment does not include the N-terminal extension with 
two cysteines. 
Figure 3-6 T16199 CTLD structure
As the NMR experiment was carried out in Ca2+-free buffer, it cannot be concluded 
from the structure whether the CTLD may contain Ca2+-binding sites, as Ca2+ release 
could causes conformational changes. Remarkably, the structure of the N-terminal part 
of the LLR is very similar to the structure of MBP-A loops 3 and 4, including the 
presence of a proline (P929) in cis conformation, which is flanked by two oxygen-
containing side chains (corresponds to the “EPN” motif, in T16199 - EPS). The 
positions contributed to the Ca2+-binding site 2 by the E4 strand (the “WND” motif) in 
the Ca2+-binding CTLDs are occupied by WTTD (positions 114-117) in the T16199 
9 Residue numbers used in the discussion correspond to the numbering in the PDB file. The first 
CTLD residue corresponds to residue 1185 in the T16199 sequence.
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CTLD. The conformation of the T116 is similar to the conformation of Asp from the 
WND motif in Ca2+-binding CTLDs, and its backbone carbonyl and sidechain hydroxyl 
oxygens could potentially be Ca2+ ligands (Figure 3-6, B; possible position of Ca2+ is 
indicated by a dashed circle). The mentioned residues can form up to 5 coordination 
bonds with the Ca2+, if E91 acts as a bidentate ligand. Although several other oxygen-
containing sidechains are present in the vicinity, they are in conformations that would 
not allow coordination of Ca2+ in site 2. Arg98 might interfere with Ca2+-binding, but its 
conformation varies in different states of the NMR ensemble (Figure 3-6, C). An 
arginine is found in the vicinity of Ca2+-2 in another CTLD structure (surfactant protein 
A, PDB: 1r14, 1315), which does not interfere with Ca2+ binding.
The CTLD of T16199 was the first fully completed project target and the first 
determined structure of a CTLD from a protostome. Several other targets have 
successfully progressed to the advanced stages in the structure determination pipeline. 
Further successful structure solutions will provide more insight into the evolution of the 
CTLD fold and its function in C. elegans.
.
70
Chapter 4.
Comparative analysis of the known 
CTLD structures 
The study presented in this chapter was carried out in 2002 and its results were 
published in the Proteins journal (Zelensky and Gready 2003). Although since that time
a number of new CTLD structures appeared, none of them can be considered as a 
structural outlier, so the findings presented below should remain valid. 
4.1 Goals of the project 
The purpose of the study described in this chapter was to extend knowledge of the 
properties of the CTLD fold by comparing all CTLD structures that were available in 
the Protein Data Bank (PDB, Berman et al. 2002) at the time the study was carried out 
in order to identify the most conserved positions in the fold. The study was structure-
focused, as the CTLDs compared have a variety of biological origins and perform
different functions. Hence, my interest in ligand binding was limited to constraints that
function imposes on the structure and on its variation. Thus, it is expected that 
conservation patterns found indicate the most general principles of CTLD fold 
organization.
It has been demonstrated by similar studies carried out for SH3 (Larson and 
Davidson 2000), globin (Bashford et al. 1987), immunoglobulin (Chothia et al. 1998), 
and legume lectin (Chandra et al. 2001) folds, the alkaline phosphatase superfamily
(Galperin and Jedrzejas 2001) and the chymotrypsin family of serine proteases (Lesk 
and Fordham 1996), that  comparison of many homologous structures combined with 
sequence analysis can reveal much more definitive information about fold organization 
than analysis of individual structures. Although limited structural comparisons of the 
CTLD fold have been reported previously (Drickamer 1999; Hakansson and Reid 2000; 
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Weis et al. 1998), they included only the small number of CTLD structures available 
then, none of which was beyond the twilight zone (25-35% identity, Rost 1999) of 
sequence homology. It was particularly interesting to compare the most deviant 
examples of the CTLD fold, such as bacterial CTLDs, with the canonical ones, as 
features common to these two groups were not revealed by sequence alignment
(Rossjohn et al. 1997; Kelly et al. 1999; Hamburger et al. 1999). Indeed, I find that 
neither simple pairwise nor more sophisticated profile-based alignments can correctly 
identify pairs of structurally equivalent residues in such evolutionarily remote (or 
unrelated) CTLD species as eukaryotic and bacterial CTLDs.
Careful comparison of CTLD structures also allows building of a common scheme
for residue and secondary structure element numbering. This was done for other 
abundant domains such as the Ig-like domain (Honegger and Pluckthun 2001) or SH3 
domain (Larson and Davidson 2000) and is an important tool for describing domain
variation.
Structural alignment, although itself hard to define unambiguously (Godzik 1996), is 
considered to be a gold standard for assessing protein similarity. Recent comparison of 
the quality of sequence vs structure alignments demonstrated that the latter detect 
homologous sites more accurately than the former (Marchler-Bauer 2002). In addition 
to discovery of important structural features of the fold, structure alignment allows 
creation of a structure-verified sequence alignment, which can be used to create valid 
position-specific scoring matrices or HMM profiles for the domain.
4.2 Methods
4.2.1 Structure Alignment
Pairwise structure superpositions were generated using the Combinatorial Extension 
(CE) algorithm,(Shindyalov and Bourne 1998) which is available from the San Diego 
Supercomputer Center’s web site (ftp://ftp.sdsc.edu/pub/sdsc/biology/CE/src/), with the 
hierarchical protein structure superposition program LOCK (Singh and Brutlag 1997), 
kindly provided by the authors, and with the DALI program
(http://www.ebi.ac.uk/dali/`; Holm and Sander 1993). Pairs of structurally equivalent 
residues were used as established by the structure alignment algorithm or, in order to 
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overcome some discrepancies in structural correspondence assignments I noticed, 
alignments were generated from the superimposed structures by a dynamic 
programming algorithm in the following manner. A matrix of inter-residue distances
between two superimposed structures was used to generate a position-specific
substitution matrix, with distances below a selected threshold producing an arbitrary 
positive score (+5), or negative score(-5) otherwise. A fixed gap penalty of –1 was used 
to calculate gap costs. 
The alignment description formalism used below was adopted from Godzik et al
(1993). Position x in sequence A was considered structurally conserved in a given set of 
structures if it satisfied two simple criteria: 
- alignment at this position was consistent regardless of which of the two structures 
was used as a query, i.e. x = BA(AB(x)) is true for all possible Bs, where AB(x) is 
the position in structure B which corresponds to position x in structure A in a 
pairwise structural alignment of query A to target B;
- alignment at this position is stable, i.e. x is aligned to a non-gap in more than a 
specific percentage of possible alignments that involve A.
Additional distance thresholds (3-5Å) were applied to the definition of a conserved 
position as described in the text.
4.2.2 Hydrophobicity and solvent accessibility
A hydrophobic core was defined as a cluster of at least 4 residues, sidechains of 
which were not more than 10% solvent exposed, and with each sidechain having at least 
one atom within a distance of 5Å from at least one other sidechain of a residue 
belonging to the same cluster. Similar parameters and algorithm were used in one of the 
previous studies (Chandra et al. 2001). Although parameters for the HFC detection 
algorithm have not been comprehensively tested, I attempted to optimize them to avoid 
obvious false positives and false negatives. Solvent accessible area was determined with 
the surfv program (Nicholls et al. 1991), which was downloaded from
http://trantor.bioc.columbia.edu/programs/surf.html.
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4.2.3 Sequence entropy
For each alignment position containing less than 20% gaps, Shannon entropy 
(Shenkin et al. 1991) was calculated according to the formula:
¦
 
 
Y
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ii xPxPXH ).(ln)()(  (1)
where i is each of 20 amino acids (A,C,D … Y) and P(xi) is the frequency of residue 
i in position x. Positional entropy N is plotted in Figure 4-2 in exponential form:
)()( XHeXN   (2) 
Sequence analysis. A database of the CTLD-containing protein sequences was built 
by searching the GenPept (Benson et al. 2002) database with PSI-BLAST (Altschul et 
al. 1997; up to 20 iterations, default settings) using sequences of CTLD domains whose
structures were solved as seed queries. The resulting database (cdb) contained about 
1300 sequences. Non-redundant (95%) derivatives of the database were created (cdb95)
with the cd-hi sequence clustering algorithm (Li et al. 2001b). To build a structure-
verified sequence alignment, sequences of CTLDs used in structure comparison
analysis were aligned in Clustal W (Thompson et al. 1994). The alignment was then 
corrected manually according to the structure comparison results. A HMM profile was
built on the basis of the alignment with the hmmbuild program from the HMMER 
package (Eddy 1998). This profile was used for identification of CTLD boundaries 
within cdb95 sequences. Regions corresponding to CTLDs were extracted from the 
sequences (cdb95ctld) and aligned with the hmmalign (Eddy 1998) or Clustal W
programs.
4.2.4 CTLD collection
A collection of CTLD structures (Table 4-1) available in PDB was built by 
searching the PDB sequence database with PSI-BLAST (Altschul et al. 1997) and 
HMMER (Eddy 1998) and by analyzing automated (FSSP`; Holm and Sander 1996) 
and manual (SCOP`; Murzin et al. 1995) classifications of protein structures. This 
approach allowed me to create a comprehensive list of 92 known CTLD structures, 
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including theoretical models: 1afa, 1afb, 1afd, 1b08, 1b6e, 1bch, 1bcj, 1bcp, 1bj3, 1buu, 
1bv4, 1byf, 1c3a, 1cwv, 1dv8, 1e5u, 1e87, 1e8i, 1egg, 1egi, 1esl, 1f00, 1f02, 1fif, 1fih,
1fm5, 1fvu, 1g1q, 1g1r, 1g1s, 1g1t, 1gie, 1h8u, 1hli, 1hlj, 1hq8, 1htn, 1hup, 1hyr, 1ijk, 
1iod, 1ixx, 1ja3, 1jsk, 1jwi, 1k9i, 1k9j, 1kcg, 1kg0, 1kja, 1kjb, 1kjd, 1kje, 1kmb, 1kwt, 
1kwu, 1kwv, 1kww, 1kwx, 1kwy, 1kwz, 1kx0, 1kx1, 1kza, 1kzb, 1kzc, 1kzd, 1kze, 1lit, 
1msb, 1pre, 1prt, 1pto, 1qdd, 1qo3, 1rdi, 1rdj, 1rdk, 1rdl, 1rdm, 1rdn, 1rdo, 1rtm, 1tlg, 
1tn3, 1tsg, 1ytt, 2afp, 2kmb, 2msb, 3kmb, 4kmb. Each of the structures found has 
already been attributed to the CTLD superfamily either in the SCOP classification or in 
the publication describing the structure. For structures solved more than once in mutant
or variously complexed forms, the PDB entry for wild type with the highest resolution 
was used: this gave the 37 structures in Table 4-1. Theoretical models were excluded 
from the analysis.
I employed two approaches for structure analysis. The first involved detection of 
conserved positions and interactions in CTLDs by manual comparison of the CTLD 
structures. The second was to produce structural alignments with several computer
programs: DALI (Holm and Sander 1993), LOCK (Singh and Brutlag 1997) and CE 
(Shindyalov and Bourne 1998). 
Table 4-1 Representative structures of C-type-lectin-like domains used in the analysis.
Name PDB ID Chain CTLD
residues
Origin
Asialoglycoprotein receptor (ASGR) 1dv8 A 153-280 Homo sapiens
DC-SIGN 1k9i A 285-382 Homo sapiens
DC-SIGNR 1k9j A 265-394 Homo sapiens
Mannose-binding protein (MBP) 1hup 110-228 Homo sapiens
Mannose-binding protein A (MBP-A) 1rtm 1 108-221 Rattus norvegicus
Mannose-binding protein C (MBP-C) 1rdo 1 115-225 Rattus norvegicus
Pulmonary surfactant protein D (PSP-D) 1b08 A 235-355 Homo sapiens
E-selectin 1g1t A 1-121 Homo sapiens
P-selectin 1g1s A 1-121 Homo sapiens
NKG-2D 1kcg A 103-215 Homo sapiens
NKG-2D 1hq8 A 110-232 Mus musclulus
CD69 1e87 83-199 Homo sapiens
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CD94 1b6e 59-179 Homo sapiens
Ly49A 1qo3 C 140-258 Mus musclulus
Macrophage mannose receptor (MMR) 1egg B 625-768 Homo sapiens
Lithostathine 1qdd A 18-144 Homo sapiens
Tetranectin 1tn3 45-181 Homo sapiens
Eosinophil major basic protein (EMBP) 1h8u A 3-117 Homo sapiens
Flavocetin-A 1c3aA A 1-135 Trimeresurus
flavoviridis
Flavocetin-A 1c3aB B 201-325 Trimeresurus
flavoviridis
IX/X-binding snake venom protein 1ixxA A 1-129 Trimeresurus
flavoviridis
IX/X-binding snake venom protein 1ixxB B 1-123 Trimeresurus
flavoviridis
IX-binding snake venom protein 1bj3 A 1-129 Trimeresurus
flavoviridis
Botrocetin 1fvuA A 1-133 Bothropos jararaca
Botrocetin 1fvuB B 401-525 Bothropos jararaca
Coagulation factor X-binding protein 1iodA A 1-129 Deinagkistrodon
acutus
Coagulation factor X-binding protein 1iodB B 201-323 Deinagkistrodon
acutus
Bitiscetin 1jwiA A 4-127 Bitis arientans
Bitiscetin 1jwiB B 3-125 Bitis arientans
Fish antifreeze protein 2afp A 16-129 Hemitripterus
americanus
Polyandrocarpa lectin 1byf A 2-124 Polyandrocarpa
misakiensis
GP42 1kg0 C 104-221 Epstein-Barr Virus
TSG-6 link module 1tsg 1-98 Homo sapiens
Intimin 1f00 I 840-939 Escherichia coli
Invasin 1cwv A 885-986 Yersinia
pseudotuberculosis
Pertussis toxin 1bcp B 3-89 Bordetella pertussis
Proaerolysin 1pre A 2-85 Aeromonas hydrophila
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4.2.5 Nomenclature
I will use the following naming conventions to discuss structurally important
positions. A residue identifier is built from three fields: (i) the secondary structure
element (SSE) the position belongs to; (ii) the most frequent residue in the position, or 
the group name symbol if a group of residues occupies the position with similar
frequencies (4 for aliphatic, ) for aromatic, : for aliphatic or aromatic, \ for charged); 
(iii) and a sequential number if combination of fields (i) and (ii) doesn’t give a unique 
identifier. For example, the second of the two conserved hydrophobic positions in E3
will be named E3:2. The four highly conserved Cys residues are labeled C1-C4. If a 
reference to a residue number is required to unambiguously define a position, the rat 
MBP-A (PDB:1rtm) structure will be used as the template. This is for historical reasons,
as the MBP-A structure was the first CTLD structure solved and has been often used as 
a reference structure in the literature. It is not, however, the best consensus structure 
from the set, as in some conserved positions it has residues that rarely occur in the same
position in most of the other structures. For SSE numbering I will use the universal
scheme described the section 1.2.2. 
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4.3 Results from the Manual Structure Comparison 
Figure 4-1 An example of a long-form CTLD (DC-SIGN, 1k9i)
Residues discussed in the text are displayed in ball-and-stick, thick-wire or thick-tube mode and colored
as in the alignment in Figure 4-2(a). Secondary structure labels are according to the SSE naming scheme
described in Section 1.2.2.
Groups of structurally equivalent residues that were identified are listed in order of 
decreasing conservation (Figure 4-1): 
- absolutely conserved Cys residues – “cystine staple” joining the N- and C-termini of 
the structure (C1, C4);
78
Chapter 4 Structure comparison
- highly conserved pair of consecutive aliphatic residues in E1’ defining the primary
and the small hydrophobic cores, and other highly conserved residues that form the 
primary hydrophobic core;
- small hydrophobic  core – pair of orthogonal Trp residues forming a hydrophobic 
interaction between D1 and E2 (D1W and E2W) and two aliphatic residues;
- highly conserved Glu in D2;
- highly conserved Cys pair in the base of the E3-E4 hairpin (C2,C3);
- residues comprising the hydrophobic core of canonical CTLDs;
Each of the groups is discussed in more detail below (Figure 4-2(a,b)). 
Primary hydrophobic core
The primary hydrophobic core (PHC) of the CTLD fold is formed by interacting 
residues that come from five distinct regions of the structure and can be subdivided into 
5 subgroups on this basis. Two positions at the C-terminus of the E1’ strand (E1’L and 
E1’V; V135 and A136 in MBP-A) are the most conserved structurally, and tightly 
interact with E5. The direction of the side chain of the first residue of the pair, which is 
highly conserved in all structures, is parallel to E5 and is a part of the small hydrophobic 
core. The second position is occupied by a less conserved residue, the sidechain of 
which projects into the middle of the PHC. There is only one deviation from
hydrophobicity of this E1’ pair: in tetranectin the second position is occupied by Ser. At 
least one E1 residue (E1); F112) is always involved in PHC formation by interacting 
with hydrophobic residues in D2, while many structures have another position C-
terminal to E1) (E1:; T114), which is also involved in PHC formation. In canonical 
CTLDs, E1) is occupied by either Tyr or Phe; in compact CTLDs the aromatic residue
is replaced by an aliphatic one. It doesn’t seem possible to identify structurally
equivalent conserved positions in D2 from different structures, although the general 
conservation pattern is obvious. Three to five hydrophobic residues (D2:1-D2:5) on 
the inner side of the amphiphilic D2 helix towards its C terminus, interact both with the
upper part of the PHC (E2, E3) and its lower part (E1). Only the second of the two 
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conserved positions in E2 (E2: and E24; A155 and L157) always contains a 
hydrophobic residue (either aliphatic or methionine), and this “stacks” over the E1’L-
E1’V pair. The E2: position is in most cases either aromatic or aliphatic, but is very 
weakly conserved and can also be occupied by a polar or charged residue. At the same
time it is always buried from solvent (~5% average exposure), projects towards the 
PHC center and was recognized as a part of the hydrophobic core by my algorithm. This 
promiscuity of E2: can be partially explained by its dual structural role as, apart from
PHC formation, it may be involved in stabilizing the loop joining D2 to E2. For 
example, in 1g1t (E-selectin) E2: is occupied by Y49, which forms a hydrogen bond 
with the S46 backbone carbonyl. A similar interaction is observed in 1kcg and 1hq8 
(human and mouse NKG2D), where E2: histidine is H-bonded to the backbone 
carbonyl of the position -3 relative to it. E3 also contains a pair of conserved residues 
(E3:1, E3:2; V196, I198), usually aliphatic; the orientation of their sidechains is quite 
similar to that of the corresponding pair in E2 (E24 and E2:, respectively). E3:2 is 
involved in PHC formation, while E3:1 in canonical CTLDs is involved in formation
of the LLR hydrophobic core, but projects into the PHC in compact CTLDs. In some
cases where the second of the two PHC positions contributed by E5 (E54, E5\; V216, 
E218) is occupied by a large charged or polar residue (Glu, Lys, Tyr) it may play a dual 
role, with its apolar part being a part of the PHC and the charged part interacting with 
D2E. Where E5\ is E, this interaction is mediated by a Ca2+ ion.
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Figure 4-2 Sequence alignment of CTLDs with solved structure
(a) Structure-verified alignment of the sequences of 37 CTLDs, whose structures have been solved (order
as in Table 4-1). Sequences were first aligned with ClustalW, followed by manual correction of mis-
aligned structurally equivalent positions. Corrections were not made when structural feature was
conserved but transferred to a different position in the structure. Residues are colored according to their
presumed role in fold maintenance. Absolutely conserved Cys are in blue. Cys specific for canonical
CTLDs are lavender. Glu at D2 N-terminus is red, and its partners in E1 and E5 are yellow or orange,
depending on whether the interaction is observed or presumed, respectively. Primary, small and LLR 
hydrophobic core residues are light-green, green and brown respectively. Conserved positions are labeled
above the alignment. Letters below the alignment indicate residues that were identified as the sequence
motif characteristic of the CTLD by Drickamer in ref. 2; red letters are for Ca2+- and carbohydrate-
binding residues. Boxed residues are those that were included into hydrophobic cores by the computer
algorithm described in Methods. (b) Consensus diagram of secondary structure element positions. (c)
Average sidechain solvent accessibility of the aligned residues. (d) Positional entropy plot. Entropy was
calculated only for positions containing less than 20% gaps.
Small hydrophobic core 
This hydrophobic core is formed by two bulky aromatic residues, one of which is in 
the initial part of D1 (D1W; F121), and the other is in E2 (E2W, F156); their sidechain 
planes are orthogonal to each other. The small hydrophobic core also includes two 
positions occupied by aliphatic residues: E1’L and a residue in the +3 position to D1W
(D1A; V124). In MBP-A, the D1W and E2W residues are Phe, while in most other 
structures they are Trp. The residue type and orientation in the D1W and E2W positions 
is highly conserved in canonical CTLDs, but more variability exists in several compact
structures both in relative residue orientation (in link module of TSG-6 the sidechain 
planes are almost parallel) and composition (D1W mutated to Y or S). Two similar
structures – proaerolysin and pertussis toxin – both lack the D1 helix, which is replaced 
by a loop, and the small hydrophobic core, having Gly or Ala in the D1W and E2W
positions. In the pertussis toxin structure, the hydrophobic interaction between E2 and 
D1 is mediated by F78, which is in the loop between E4 and E5. In proaerolysin this 
mediator is absent.
Long loop region hydrophobic core 
Long loop region hydrophobic core (LLRHC) is present only in canonical CTLDs 
and is formed by residues coming from the LLR itself (E2’’ũ, E2’’W, Lũ, LY, LW),
and from 3 E strands: E2 (E2L; L159), E3 (E3ũ1; V196) and E4 (E4W; W204). It is 
interesting to note that snake venom CTLDs which dimerize by swapping the LLR, 
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have most of the LLRHC residues conserved. There is no clear spatial margin between
the LLRHC and PHC, but conservation of the latter and absence of the former in 
compact CTLDs indicates that these two hydrophobic clusters are independent.
I also performed an automated detection of clusters of hydrophobic residues (see 
Methods) to confirm that my definition of hydrophobic cores is correct. As can be seen 
from Figure 4-2(a,c), most of the positions with conserved low solvent exposure are 
covered by the hydrophobic cores described. 
Residues from the so called “WIGL” motif (positions E2W, E24 and E2L), which is 
extremely conserved in canonical CTLD sequences (Drickamer 1993) are involved in 
formation of all 3 hydrophobic cores described. Therefore, the WIGL motif can be 
considered as an integrating component of the structure, which unites clusters of 
hydrophobic residues that stabilize all parts of the structures. The role of the almost
completely conserved Gly residue in WIGL (E2G) is less clear. Dihedral angles for the 
E2G residue in canonical CTLD structures lie within the "allowed" area of the 
Ramachandran plot (Phi [-90,-60], Psi [-30,75]), which rules out unusual backbone 
conformation as a reason for the Gly conservation. Although there is some limitation on 
the size of the sidechain in this position, simple modeling shows that the side chains of 
Ala or Ser would fit without clashing with the backbone or structurally adjacent regions.
The fact that it is not conserved in compact CTLDs suggests that it is required for LLR
formation, possibly by maintaining the E2-E2’ turn. 
Conserved D2 glutamate and D2-E1-E5 interaction
A highly conserved Glu residue (D2E; E143) in the beginning (within 1-3 N-
terminal residues) of D2, forms in most cases an ionic and/or hydrogen bond with a less 
conserved partner(s) in E1 (E1) and other N-terminal positions) and/or E5 (E5\). Only
in EMBP (1h8u) is this position not occupied by a Glu; this may be due to the inherent 
high basicity of the protein. The importance of the interaction maintained by D2E is 
emphasized by the manner in which it is conserved in bacterial CTLDs. In invasin, the 
D2-E1 interaction is mediated by a Glu which is N-terminal to the usual position. 
Pertussis toxin has an Asp in the +2 position, which forms an interaction with a E1
partner similarly to canonical CTLDs. Although both proaerolysin and intimin have Glu 
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in appropriate positions and orientations, these residues do not mediate an interaction 
with E1 or E5 in the X-ray structures. In about half of the structures a second Glu 
residue is present upstream to D2E and in a few cases (1dv8, 1k9i, 1rtm) forms an 
interaction with E1/E0 analogous to D2E. However, this position is much less conserved 
both conformationally and in the sequence, and in the majority of cases the Glu 
occupying it just protrudes into the solvent. 
E3-E4 disulfide bridge (C2-C3) 
Previous descriptions of residues conserved in CTLDs (Weis et al. 1991b; 
Drickamer 1993) usually included 2 pairs of cysteines. It can be seen from the 
alignment, that while the outer Cys pair (D1-E5 bridge) is indeed one of the most
conserved CTLD features, the inner pair is only present together with the LLR, which 
suggests that its role is LLR stabilization. Moreover, there are many examples of both 
mammalian and C. elegans  canonical CTLD sequences which lack one or both E3 and 
E4 Cys residues, suggesting that  their presence is not essential.
Comparison with previous findings 
Results of this manual structure comparison of 37 currently available nonredundant 
CTLD structures reproduce many of the findings made by other authors on the basis of 
analysis of individual or small groups of CTLDs (Drickamer 1993; Hakansson and Reid 
2000; Weis et al. 1991b; Weis et al. 1998) and the CTLD profile deposited in the 
curated pattern-based protein domain and family database PROSITE (accession number
PDOC00537`; Falquet et al. 2002), but provide a more general view of the residue 
positions which determine the CTLD fold.  For example, my definition of hydrophobic 
cores is different from that introduced by Weis et al. in the first paper describing the 
CTLD structure (Weis et al. 1991b). In particular, the large hydrophobic core from ref. 
4 is a combination of PHC and LLRHC defined by me. I consider such a separation 
valid and important, as the absence of the LLRHC doesn’t significantly affect the PHC 
structure, as may be seen from the analysis of the compact CTLD structures. Also, some 
of the conserved positions identified by me were not described in the previous studies 
(e.g. E1ũ, E1’V, E2ũ, E2’’W, E5ũ, E5<). Another set of differences is due to the fact 
that sequence signatures often used for CTLD analysis such as the one presented in ref.
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2 include positions involved in Ca- and carbohydrate-binding. As these functions are 
not general for CTLDs, structure comparison fails to detect corresponding positions as 
conserved.
4.4 Results from the automated structure alignment 
To test whether automated structural alignment methods are able to detect 
similarities found by manual structure comparison, I applied three different methods –
CE (Shindyalov and Bourne 1998), DALI (Holm and Sander 1993) and LOCK (Singh 
and Brutlag 1997) – of structure alignment to determine structurally corresponding pairs 
of residues. Alignments were done for all structures against all, followed by analysis of 
the residue pairing persistence. A residue in a given structure was considered 
structurally conserved if it satisfied criteria of consistency (aligned to the same position
in another structure regardless of which of the two structures was used as a template)
and stability (included in more than 90% of all possible alignments for the structure). 
These two simple constraints were used to eliminate sporadic matches. As expected and 
can be seen from Figure 4-3(a) for the CE method, structure alignment algorithms
produce consistent and stable superpositions of canonical CTLDs, but noticeably vary
in aligning compact and canonical CTLDs. LOCK and DALI produced similar results 
(not shown). It is also clear that a high level of structural similarity among the available 
canonical CTLDs prevents discrimination of truly conserved positions from the rest. 
Non-conserved positions cluster mostly in the LLR, which can be explained by the 
difference in LLR structure in snake domain-swapped CTLD dimers and mammalian 
CTLDs. Of the bacterial CTLDs, pertussis toxin and proaerolysin appeared to be the 
hardest targets for automated structure alignment.
Analysis of the residue pairs equivalenced by the structure alignment programs,
suggested two ways to improve automated detection of conserved residue pairs. The 
first was to introduce a minimal distance threshold in the range of 3-5 Å for inclusion of 
residue pairs in the alignment, while the second was to use points other than CD centers 
to measure pairwise distances between residues. The latter correction was inspired by 
the observation that many of the equivalenced positions had different sidechain
orientation, while positions involved in fold integrity maintenance did not, and the 
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expectation that functionally similar sidechains would project into the same part of the 
structure and form similar interactions. It has also been reported previously that residue 
interaction maps can be a good source of structure similarity information (Godzik et al.
1993). To apply these corrections I implemented an algorithm (see Methods) for 
detection of structurally equivalent positions important for structure maintenance, which 
allowed filtering of equivalenced pairs based on maximal pairwise distance (measured
either between CD centers, residue geometric centers or sidechain geometric centers), 
and optional creation of an alternative sequence alignment by dynamic programming
with pairwise distance as a similarity measure.
Figure 4-3 Structurally conserved positions in CTLDs superimposed by CE structure alignment 
program
Sequence alignment is same as in Figure 4-2. Non-gap conserved and unconserved positions are shown as
black and gray squares, respectively, and gaps as white squares. (a) Conserved pairs as defined by CE
alignment. Residues that satisfy alignment consistency and stability criteria in more than 90% of the
structures are displayed (see Methods for details). No distance threshold. Circles above the alignment
indicated conserved positions shown in Figure 4-2(a). The filled circles indicate C1 and C4, the partly-
filled circles indicate D2E and its partners, the gray circles indicate small hydrophobic core residues, the
empty circles indicate PHC and LLRHC residues. (b) Same as (a), but 3Å pairwise distance threshold
between CD atoms was applied. (c) Positions conserved in alignments built with a dynamic programming
algorithm (described in Methods) using distances between sidechain geometric centers as a measure of 
similarity. Distance cutoff 3Å, 95% conservation threshold.
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Simple filtering of the equivalenced pairs with a maximal pairwise distance
threshold between CD centers dramatically reduces the number of structurally 
conserved positions (Figure 4-3(b)). The most invariant parts of the structure detected 
with these criteria were E1’ and E2 which, if compared with the results of the manual
structure analysis, include the highly conserved pair of aliphatic residues in E1’ and the 
WIGL motif in E2. Conservation of the D1 and E5 regions containing the absolutely 
conserved cystine staple is also observed, though less pronounced than in the E1’ and 
E2 regions. D2 contains effectively no conserved positions, which is consistent with the
variability of relative position and orientation of SSE even in closely related 
mammalian CTLDs. Therefore, although distance filtering allows elimination of most
of the false positive matches, it is not able to detect all positions that I consider to be 
structurally important (produces false negatives).
Using sidechain geometric centers as pivot points for pairwise distance 
measurements followed by re-alignment of the structures does improve the correlation 
of automated detection of structurally conserved residues with the results of manual
analysis (Figure 4-3(c)). For the most important residues the change in number of 
correctly detected conserved cases compared with the CD-distance filtering approach 
was: +11% for C1 (20/18), +76% C4 (30/17), -26% E1’L (23/29), -8% E1’V (25/27), 
+8% E2W (27/25), -20% E1W (16/20), +160% D2E (8/3) while the total number of
conserved positions changed hardly at all (834/808). Therefore, the third approach 
improves specificity for most of the positions, but also produces a significant number of
false negatives.
Overall, despite the good superpositions generated by the structure alignment
programs, in essence I failed to reproduce the results of the manual comparison with an
automated structure-based sequence alignment algorithm I developed. It might be 
possible, however, to improve the performance of my algorithm by other choices of 
parameters, or to explore other approaches to solving this problem, which would 
produce more satisfactory results.
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4.5 Sequence Comparison
As the set of CTLDs with solved structure is neither representative nor complete, I 
derived a database of all CTLD-containing sequences available in the GenPept
database. CTLD sequences were extracted from the full length sequences and aligned 
with ClustalW or HMMER; results of the sequence and structure conservation analysis
are compared in Figure 4-4. Shannon entropy (see Methods) was used as a measure of 
position conservation, with the cutoff being selected arbitrarily depending on the 
number of sequences in the alignment: 2 for alignment of 10 link domains, 4 for 111 
human CTLDs, 4 for 141 mouse CTLDs and 6 for 295 C. elegans  CTLDs. In general, 
structurally conserved residues are also significantly conserved at the sequence level, 
with 8 positions being conserved through all groups. These include the absolutely 
conserved cystine staple (C1-C4), three residues from the small hydrophobic core 
(E2W, E1’L and D1A), one of the Cys residues of the inner disulfide (C2, or a position 
structurally corresponding to it in link domains) and E2G and E2L from the WIGL
motif. The latter two positions in the link domain alignment are occupied by residues
that are not consistent with the WIGL motif (Ala and Asp, respectively), but yet are 
conserved. Interestingly, the E2W partner in D1 is conserved above threshold only in 
human and mouse CTLDs, although in the structures the nature of interaction between 
the two residues and the correlation of the sidechain size is observed almost always. 
Also, D2E and its partners are not detectable by sequence comparisons, while the 
second position in the E1’ aliphatic pair has relatively high entropy.
This and other discrepancies between sequence and structure conservation analysis 
results may indicate that conserved positions not detectable by sequence alignment are
subject to only partial structural constraints, which permit a broad range of residues. In 
particular, the E1’V conserved orientation may be determined by the highly conserved 
orientation of the preceding E1’L, and may allow any small non-charged side chain 
(ALVIPST). Other possibilities are that (as in case of D2E and its partners) a conserved 
structural feature (i.e. D2-E1-E5) may be maintained by structurally slightly dissimilar
positions, or that sequence alignment algorithms fail to align the structurally equivalent
positions correctly. Finally, it is possible that the limited number of CTLD structures
available for the analysis is biased and can’t reveal all the important information about 
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the CTLD fold organization. For example, a significant number of C. elegans putative 
CTLDs do not contain even the most conserved CTLD fold features such as the outer 
cystine staple or key hydrophobic core residues. If these outliers are expressed and 
functional, they would be good targets for structural genomics initiatives, as they 
represent new groups of this otherwise structurally well characterized domain
superfamily.
Figure 4-4 The most conserved positions in different CTLD groups revealed by sequence
alignments
Consensus secondary structure diagram is shown at the top. Positions of conserved residues relative to 
secondary structure elements are shown in the table below. First row, CTLD sequence signature from ref. 
2, + indicate residues involved in Ca- and carbohydrate-binding, * – other conserved residues. Second
row, circles – structurally conserved positions detected by manual structure comparison as in Figure 4-3.
Rows 3,4,5,6 – residues with the lowest positional entropy in sequence alignments of several groups of
CTLDs: 95% non-redundant set of 111 human CTLD sequences, positions with entropy below 4 are 
plotted; 95% non-redundant set of 141 mouse CTLD sequences, positions with entropy below 4 are 
plotted; 95% non-redundant set of 295 C. elegans  CTLD sequences (entropy cutoff 6); 10 distinct
mammalian link domain sequences (entropy cutoff 2), respectively. Triangles at the bottom of the table
indicate positions conserved in all four sets of sequences, and labeling is as in Figure 4-2(a).
4.6 Insights from the Study
The combined results provide several insights into the fold structure. There is both 
evolutionary (existence of compact CTLDs) and structural (LLRHC separation from the 
PHC) evidence that the LLR is a structurally independent part of canonical CTLDs. 
Thus, it is possible that canonical CTLDs might have arisen from compact CTLDs by 
insertion of an exogenous sub-domain. The structural independence of the LLR makes
it a very flexible unit for adaptive evolution. Indeed, sequence analysis (Figure 4-4) 
shows that LLRs of CTLDs from several species are largely devoid of consistently 
conserved positions. In this regard, CTLDs could be regarded as analogous to Ig-like
domains, where hypervariability regions are maintained on a conserved scaffold. The 
relatively large size of the LLR and its structural independence provide scope for the 
functional plasticity observed in the CTLD fold, which can bind carbohydrates, proteins 
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and inorganic substances. The very variable structure with low proportion of formal
secondary structure in the LLR is also the reason why the CTLD overall has a relatively 
low secondary structure content.
On specific points, an interesting observation is that structural reasons for the 
extremely high E2G conservation in canonical CTLDs are lacking, as already noted, 
suggesting a different role for it than previously proposed (Weis et al. 1991b), perhaps 
involvement in the folding process, or maintaining some dynamic properties of the LLR
which cannot be understood from the crystal structure. Another interesting point is that 
in addition to the E1-E5 ribbon formation which joins the N- and C-termini, E5 makes
interactions with the N-terminal helices by a disulfide bridge and salt bridges or H-
bonds with the conserved Glu. Thus, there appear to be several mechanisms stabilizing
this part of the structure.
Finally, although structure alignment methods produce good superpositions for most
of the CTLD structures analyzed, some of the interesting features which were detected 
manually were generally missed by the algorithms I tested, while others were difficult 
to discriminate unambiguously from the noise. Automated structure-based sequence 
alignment methods would be a useful analytical tool, but my experience is that they are 
not easy to develop.
4.7 Conclusions 
A combination of careful manual structure comparison, automated structure 
alignment, and analysis of structural properties together with extensive study of 
sequence space has allowed detection and annotation of the key conserved structural 
features which underlie CTLD-fold stability. Verification of the structure comparison
data against alignments of all available human, mouse and C. elegans CTLD sequences 
showed that conservation patterns are preserved throughout the whole of CTLD 
sequence space. This study also provides an example of performance tests of several 
automated structure alignment algorithms in detection of structural features, against
those found by manual comparison. I suggest my observations provide a better 
understanding of CTLD structure and help in identification of new CTLDs and the 
mechanisms which drive and constrain the fold evolution. 
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CTLDs in Fugu rubripes 
5.1 Background 
Three studies using the whole-genome approach have been published analyzing the 
distribution of the CTLD family in C. elegans (Drickamer and Dodd 1999), D.
melanogaster (Dodd and Drickamer 2001) and human (Drickamer and Fadden 2002). 
These whole-genome studies demonstrated that although the family is relatively 
abundant in all the species analyzed, domain composition of the CTLD-containing
proteins varies greatly, suggesting that the family has been evolving independently. The 
goal of this study was to analyze the role of CTLDcps in the evolution of vertebrates by 
comparing the family composition in mammals with its composition in a (more) simple
vertebrate Fugu rubripes, whose genome sequence was determined recently. 
5.1.1 Known fish C-type lectins 
A number of fish CTLDcp sequences have been reported separately in the literature
and public sequence databases. The best-studied and most distinct set are serum
antifreeze proteins (AFPs) from several cold-water-living species (Ng et al. 1986; 
Achenbach and Ewart 2002; Ewart et al. 1998). These sequences consist mostly of just 
a CTLD, and were classified as group VII members based on domain architecture. A 
three-dimensional structure of the sea raven antifreeze protein has been determined
experimentally (Gronwald et al. 1998).
Apart from AFPs, several other soluble bony-fish CTLDcps have been described: 5 
isoforms of Salmo salar serum lectin (SSL`; Richards et al. 2003), three collectins from 
different Cyprinidae carp family species (Vitved et al. 2000), skin mucus protein AJL-2 
(Tasumi et al. 2002) and two C-type lectins (eCL-1 and eCL-2) from gills of Japanese 
eel (Mistry et al. 2001), two lectins from rainbow trout liver (Bayne et al. 2001), a carp 
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lectin (Fujiki et al. 2001), goldfish lectin OL-1 (GI: 26000685, unpublished), and a liver 
lectin from Gillichthys mirabilis (long-jawed mudsucker), annotated as “mannose
receptor C” (Gracey et al. 2001). 
Known membrane-bound CTLDcps from bony fishes include a polycystic kidney 
disease protein 1 (PKD1) orthologue from Fugu (Sandford et al. 1997), a rainbow trout 
Kupffer cell receptor homologue (Zhang et al. 2000), and a set of putative killer cell 
receptors (KLR) identified recently (Sato et al. 2003). Although predicted coding 
sequences for CTLDcps from winter flounder (GI:28394504, unpublished) and medaka
fish (Matsuo et al. 2002) do not contain a recognizable transmembrane (TM) domain,
based on CTLD sequence and, in the case of the medaka CTLDcp, domain structure, 
they should be assigned to group II, as the absence of TM regions may be a result of 
incomplete prediction.
The only known CTLDcp sequence from cartilaginous fishes is a tetranectin 
homologue from reef shark cartilage (Neame et al. 1992). 
5.1.2 Fugu genome sequence 
The Fugu rubripes genome, available since 2002 (Aparicio et al. 2002), is the 
second vertebrate genome sequenced. It is 8 times smaller than the human genome and 
is proving to be an effective instrument in analyzing the human genome because of its 
compactness, low content of repetitive elements and the relatively large evolutionary
distance between fish and mammals, which is estimated to be about 430 Myr (Ahlberg 
and Milner 1994). 
Currently three versions of the Fugu rubripes genome assembly are publicly 
available. The second version of the assembly (v.2), constructed from 4.1 million
sequencing reads (5.4X sequence coverage), was reported in the original publication 
announcing the completion of the Fugu rubripes genome sequencing (Aparicio et al.
2002). The third version (v.3) was released in August 2002, has slightly better coverage 
(5.7X) and improved scaffold contiguity. Sequence data for all three assembly versions 
can be downloaded from the Joint Genome Institute web site1. The JGI site and the 
1 http://genome.jgi-psf.org/fugu6/fugu6.info.html
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EnsEMBL web site1 are the two main portals to the Fugu rubripes genome annotation. 
Although EnsEMBL and JGI annotations and genome browsers are different, they share 
the same gene and transcript structure predictions created by the EnsEMBL pipeline. 
Several analyses of the draft Fugu genome sequence targeting different protein 
families have been published recently (Maglich et al. 2003; Oshiumi et al. 2003; Jones
et al. 2003; Jiang and Doolittle 2003; Zimek et al. 2003), which showed its usefulness 
for evolutionary and functional studies as well as gene discovery. The goal of this 
project was to analyze the presence of the CTLD superfamily in the draft assembly of
the Fugu rubripes genome.
5.2 Methods
Corrected gene predictions are made available as a distributed annotation system
(DAS`; Dowell et al. 2001) resource,2 which can be viewed in the EnsEMBL genome
browser. The data source names for predictions based on assemblies v.2 and v.3 are 
fugu_ctld_1 and fugu_ctld_2, respectively. Transcript sequences (in FASTA format) for 
the CTLDcp-encoding genes created or modified by me (stable IDs starting with ANU) 
and their translations are also provided in the additional files 1 and 2, respectively.
Searches and gene annotations were done on version 2 of the Fugu rubripes genome
assembly (Aparicio et al. 2002) downloaded from the EnsEMBL web site (Clamp et al.
2003; Hubbard et al. 2002). When the third version of the assembly was released, I 
mapped gene annotations onto it. Mapping was done on the basis of SSAHA (Ning et 
al. 2001) matches in the v.3 assembly for exons predicted on the v.2 assembly. The v.2 
assembly is currently accessible at the Singapore IMCB site3 and on our server4, which 
is pre-configured to display the DAS track with my annotations and contains a reference 
table with hyperlinks for all of the Fugu CTLDcp genes discussed. Version 3 of the 
assembly can be found on the main EnsEMBL web site. The EnsEMBL genome
browser can be easily configured to display my gene models as a DAS track. 
1 http://www.ensembl.org/Fugu_rubripes/
2 http://anz.anu.edu.au/das/
3 http://www.fugu-sg.org/assembly.htm
4 http://anz.anu.edu.au:8080/Fugu_rubripes/
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I used a multi-step approach to find genes encoding CTLDs. First, a hidden Markov 
model (HMM) profile of the CTLD was used to scan a FASTA database of EnsEMBL-
predicted genes with the hmmsearch program from the HMMER package (Eddy 1998). 
To detect orthologues and paralogues, the set of Fugu sequences found was compared
with the 95% non-redundant set of sequences of human CTLDcps that could be found 
in the Entrez proteins database, using the Inparanoid program (Remm et al. 2001). All 
of the 25 orthology links detected by Inparanoid were checked manually.
Because of systematic and sporadic errors in EnsEMBL gene predictions, I had to 
manually revise the structure of each of the 69 genes encoding proteins detected by the 
HMM-based search. This was done using the Apollo genome annotation software 
(Lewis et al. 2002) connected to a local installation of the EnsEMBL database. To 
facilitate annotation, several additional feature tracks were added to the EnsEMBL
database:
a) Similarity features detected by GeneWise (Birney and Durbin 2000) search of 
Fugu scaffold sequences with a CTLD HMM built in a global alignment mode. 
This was done to detect well conserved CTLDs while avoiding many false 
positives.
b) Same as a), but with an HMM built in the local alignment mode; this was done 
to detect highly conserved fragmented CTLDs; 
c) Similarity features detected by a TBLASTN search of Fugu scaffold sequences 
using all known human CTLD sequences; this was done to detect CTLDs that 
are less conserved; 
d) ORFs encoding putative transmembrane (TM) domains. To create this track a 
database of all possible ORFs longer than 45 bp was produced and translated 
into protein sequence using the EMBOSS programs. This was then scanned with 
the TMHMM program (Krogh et al. 2001) to detect ORFs that encode putative 
TM domains.
To verify whether there are CTLDs that were not covered by EnsEMBL gene 
predictions, I searched for all significant CTLD similarity features detected by 
GeneWise which do not overlap with any of the genes analyzed in the first stage. This 
95
Chapter 5 CTLDs in Fugu 
step led to detection of 25 new CTLD-coding genes, including most of the ones that 
have previously uncharacterized domain organization. At the next stage I analyzed the 
loci with different CTLD similarity features detected by genewisedb search with a local
alignment HMM. Finally, the features identified by BLAST and not overlapping with 
already detected genes were analyzed. This set of features mostly contained only partial 
CTLD matches.
I translated both the new and already predicted gene coding sequences (CDSs) into 
protein sequences and performed another Inparanoid comparison. Phylogenetic 
relationships were analyzed with the programs from the Phylip package (Felsenstein 
1993). ClustalW (Thompson et al. 1994) guiding trees were used for quick phylogeny 
estimation and in cases where a proper multiple alignment could not be made.
BioPerl (Stajich et al. 2002) and EnsEMBL Perl modules were used to automate all 
stages of the analysis. Domain architectures were analyzed with the SMART web 
service (Letunic et al. 2002). 
To estimate the proportion of substitutions in synonymous sites, I aligned translated 
sequences of the duplicated CTLDcp-encoding genes with ClustalW, using either whole 
sequence or sequence for the CTLD-encoding region only, and built nucleotide
sequence alignments based on the protein alignments. Ks estimations were performed
with four methods: Lynch and Connery (Conery and Lynch 2001) and Li (Li 1993), 
both implemented in the ntdiffs package (Conery and Lynch 2001); and Nei and 
Gojobori (Nei and Gojobori 1986) and Yang and Nielsen (Yang and Nielsen 2000), 
both implemented in the yn00 program from the PAML package. 
Duplication dating using the calibrated molecular clock approach was performed as 
in (Gu et al. 2002). Alignments of CTLD-containing regions of Fugu paralogues and 
their mammalian orthologues were made with ClustalW. The MEGA2 program (Kumar
et al. 2001) was used to build linearized trees from Poisson-corrected distances, p-
distances and Gamma-corrected distances by the neighbor-joining method with 1000 
bootstrap samplings. The global clock was calibrated using divergence times 96 Myr 
and 430 Myr for human-mouse and fish-mammal splits, respectively (Gu et al. 2002; 
Nei et al. 2001; Ahlberg and Milner 1994). 
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5.3 Results 
5.3.1 Comparison of assembly versions 2 and 3 
At the time this study was started, annotation of the v.3 assembly was not yet 
published; hence, most of my analysis was done with v.2 of the assembly and later 
mapped to the v.3 assembly. From my experience, there is no substantial difference 
between v.2 and v.3 assemblies in the amount of sequence information and its quality, 
although the v.3 assembly contains longer scaffolds due to more extensive linkage. 
Despite very high similarity at the sequence level, the v.3 assembly annotation contains 
no history information that would provide links between contigs, genes, and transcripts 
in the second and the third versions of the assembly. None of the stable identifiers for
genes, transcripts or peptides from v.2 are present in v.3. This information cannot be 
generated by usual procedures used in EnsEMBL (e.g. ID Mapping Application, which 
is a part of EnsEMBL Java APIs) and has to be obtained by sequence comparisons. This 
lack of correspondence creates difficulties for the sequence analyzer and end point 
reader. To facilitate analysis and allow comparison, references to feature identifiers for
both of the assemblies are given in Appendix B. 
5.3.2 Protein database searches 
Due to almost complete lack of cDNA or EST sequences for Fugu rubripes, most of 
the EnsEMBL gene structure predictions are based on homology with known protein 
sequences from other organisms, mostly mammals. I expected a significant fraction of 
CTLDcps to be conserved between fish and human, and, therefore, to be predicted 
correctly by EnsEMBL in the Fugu genome. So my first approach to detecting Fugu
CTLDcps was to search a sequence database of predicted Fugu proteins with a hidden 
Markov model (HMM) for the CTLD. This search returned 69 significant matches.
Some of the identified genes had a description assigned to them, apparently derived 
from the description of the sequence they were found to be homologous to. These 
descriptions, however, could not be used as a reliable basis for assigning orthology and 
paralogy relationships. For example, a sequence, which I later identified as an Endo180 
orthologue (SINFRUG00000058766 in v.2 assembly annotation) is described as “80 
KDA SECRETORY PHOSPHOLIPASE A2 RECEPTOR PRECURSOR PLA2“, while
97
Chapter 5 CTLDs in Fugu 
another gene, which I designated as an aggrecan orthologue 
(SINFRUG00000069597 in v.2 annotation) was annotated as 
“ADRENOLEUKODYSTROPHY PROTEIN (ALDP)”. Therefore, I reviewed 
domain architecture and sequence similarity matches for each of the sequences found to 
verify phylogenetic relationships.
5.3.3 Homology detection
The results of Inparanoid (Remm et al. 2001) comparison (see Methods) of all 
human to all Fugu CTLDcps were used to initially cluster the set of Fugu proteins and 
detect approximate orthology/paralogy links. Inparanoid has an important advantage 
over phylogenetic tree reconstruction software, as it does not require a multiple
alignment of sequences but creates a distance matrix of the local pairwise alignments.
This method assigned putative human orthologues to 25 Fugu proteins. Orthology 
relationships for the other 44 sequences from the set were established by individual 
analyses.
5.3.4 Revision of CTLDcp gene structure predictions
While analyzing phylogenetic relationships predicted by Inparanoid, I discovered 
several systematic and sporadic mistakes in the EnsEMBL gene predictions. The most
widespread mistake was a failure to include exons encoding TM domains into gene 
structure prediction. Consequently, almost all EnsEMBL-predicted Fugu CTLDcps 
were soluble proteins, whereas very few human CTLDcps are. Simple comparison with 
the GenScan (Burge and Karlin 1997) features overlapping the CTLD-encoding genes 
showed that absence of TM domains is a result of coding sequence (CDS) mis-
prediction rather than a fundamental difference in Fugu CTLDcps. GenScan 
predictions, in turn, could not be used as a basis for my analysis because they 
sometimes contain regions that are absent from human or mouse orthologues, and often 
merge neighboring genes. Another general problem was observed with proteins that had 
a previously unknown domain architecture (see below). In such cases individual 
domains were split into separate gene models.
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Figure 5-1 Fugu genome sequence and annotation
(A) Fugu selectin gene cluster annotation in the EnsEMBL database (v.2 annotation is shown, v.3
annotation is almost identical to v.2). Gene models predicted by me based on comparison with human
selectins are shown in the grey box. As shown, the CTLD is encoded by the 5’ exon in fSELP, fSELL and
fSELE; the TM segment is encoded by the 3’ exon. EnsEMBL predicted transcripts, GenScan predictions
and similarity features are shown on the tracks below. Stable IDs for EnsEMBL transcripts are given. The
TMHMM track shows ORFs encoding TransMembrane regions predicted by the TMHMM program (see
Methods). (B) Fragments of group VI genes found on various scaffolds. CTLD numbers indicate
sequential number of CTLD in full-length MManR, while numbers for the CTLD in the partial sequences
indicate the MManR CTLD sequence they are most closely homologous to.
In addition to these systematic problems, there were multiple sporadic ones. For 
example, my analysis of the Fugu genome showed that, similarly to the human and 
mouse genomes, the selectin cluster is well conserved and contains all three selectin 
genes in tandem (SELE, SELL, SELP), located on scaffolds 1045 (32046–41921) and 
166 (83937–93826) in the v.2 and v.3 Fugu genome annotations, respectively. 
However, the EnsEMBL annotation contains a prediction of two overlapping genes 
(v.2: SINFRUG00000085188 and SINFRUG00000085187; v.3: 
SINFRUG00000123102 and SINFRUG00000123101), one of which is located in the 
intron of the other (Figure 5-1). 
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To solve these problems, I had to manually revise the predicted structure for all 
genes encoding proteins detected by the protein-level searches, and correct them using 
supporting evidence available in the EnsEMBL database, as well as additional evidence 
generated by me. The latter included similarity features produced by genome-wide
GeneWise and BLAST searches with CTLD profiles and sequences, transmembrane
domain predictions, and similarity matches to the complete sequence of supposed 
human or mouse orthologues. 
As the final stage of the CTLDcp identification process, I performed a set of DNA-
level comparisons to ensure that the CTLD-containing loci that are not covered by 
EnsEMBL-predicted genes, or for which transcript predictions are wrong and, thus, not 
detectable by protein database searches, were not omitted from the analysis. This 
“quality control” step led to identification of an additional set of 25 well conserved 
CTLDcps, which had both new and known domain architectures, as well as additional 
individual CTLDs, which were merged with neighboring CTLDcp loci if appropriate.
5.3.5 Groups of Fugu CTLDcps 
After all these searches, I had identified a set of 94 Fugu rubripes loci encoding 
CTLDcps (Appendix B), which in total contain 173 individual CTLDs, including 
PTR/Link-type CTLDs (Brissett and Perkins 1996). Fugu CTLDcps were named
according to their human orthologues, established on the basis of domain composition
and sequence similarities. Where more than one homologue was present in Fugu, a 
name was produced by adding a suffix of the form “–FXX”, where XX is a sequential 
number of the paralogue, to the name of the closest human homologue. Predicted 
CTLDcps that do not have homologues among the known CTLDcps have identifiers of 
the form ANZ000. A few of these novel genes were orthologous to loci in other 
vertebrate genomes supported by expression data, but otherwise are un-characterized, 
and were assigned descriptive names (CBCP, Bimlec, SEEC, CETM, NLSLH;
abbreviations defined below). 
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Figure 5-2 CTLDcps with novel domain architectures
Fugu CTLD-containing proteins, which do not fit into the existing CTLDcp classification are shown.
Domain abbreviations are explained in the text. Roman numbers near names indicate suggested new
group names for the new Fugu sequences, which also have new predicted human homologues. C-terminal
CTLDs of DEC205-FUSE that are not present in the v.3 assembly are shown in light pink.
I have clustered Fugu CTLDcps using the classification scheme for human
CTLDcps based on domain composition; this comprises 14 groups (Drickamer and 
Fadden 2002). Link/PTR-domain-containing CTLDcps, apart from hyalectans, were 
placed into a separate group. Among the Fugu CTLDcps that did not have mammalian
homologues I detected a distinct group of soluble dual-CTLD sequences, which I have 
called F1 (Figure 5-2). The remainder of the Fugu-specific CTLDcps were assigned to 
the U (Unclassified) group. Gene structure prediction for members of the U group is the 
lowest in quality, due to lack of supporting evidence apart from similarity to CTLD 
sequence profiles and GenScan predictions. 
All but two groups of human CTLDcps have detectable representatives in the Fugu
genome (Figure 5-3, Appendix B). I did not detect any orthologues for groups V (NK 
cell receptors) and VII (lithostathine/Reg family). The member repertoire for most of 
the other groups is very well conserved between Fugu and human. However, groups II 
and III, which include some of the best-studied mammalian CTLDcps, have a 
significantly different member composition in Fugu. In summary: 
Group I. All four members of the lectican group that are present in human have 
orthologues in the Fugu genome. Each of the Fugu hyalectan genes is duplicated. One 
of the Fugu versican copies is split between two scaffolds in the v.2 assembly. 
Group II. I found only one representative of the asialoglycoprotein receptor (ASGR) 
family in Fugu (HML2), while in human this family has 3 members encoded by a gene 
cluster on Ch 17 (ASGR1, ASGR2, HML2). The Fugu sequence was identified as an 
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HML2 orthologue by phylogenetic analysis based on the alignment of CTLD 
sequences. Another clearly identifiable member of group II is the orthologue of 
scavenger cell receptor C-type lectin (SRCL), which is duplicated in Fugu and is 50% 
identical to the human SRCL. The rest of the group II Fugu CTLDcps (DC-SIGN-F1 – 
DC-SIGN-F8, XLCMCL) do not have clearly identifiable orthologues among known 
human CTLDcps, although phylogenetic analyses based on CTLD sequence alignment
indicate that they are homologous to members of the group II subgroup containing DC-
SIGN, Mincle and Dectin-2, which also appear as top hits in BLAST searches. 
However, this subset of group II Fugu sequences co-clusters in phylogenetic trees and is 
not similar enough to any tetrapod sequence to establish orthology. Four of the 
sequences (DC-SIGN-F2, DC-SIGN-F3, DC-SIGN-F4, DC-SIGN-F5) are located in a 
cluster on scaffold 75 in the v.3 assembly. Two members of the subgroup (DC-SIGN-
F1 and DC-SIGN-F6) have unstable placements in phylogenetic trees, and may appear 
on a branch containing human/mouse group V sequences, if the latter are included in 
the alignment. This association is, however, unstable and may be due to mistakes in 
CDS prediction or phylogeny reconstruction. Alternatively, it is possible that these 
sequences are homologous to the common predecessor of group V and group II 
CTLDcps.
Group III. Although Fugu has two collectins, there are no orthologues for mannose-
binding proteins (MBPs) or pulmonary surfactant proteins (PSP), which are the best 
studied members of the group in human. Both of the Fugu collectins (COLEC10, 
MGC3279) are well conserved compared with their human orthologues and co-cluster 
with them in phylogenetic trees. No functional information is available for the novel 
collectin MGC3279, which was discovered in a large-scale cDNA sequencing project 
and maps to chromosome 2p25.3 in the v.31 NCBI assembly of the human genome, but 
the exceptionally high level of conservation between human and fish (~76% identity)
strongly suggests that it is functional and important in both organisms. COLEC10 
(collectin liver 1, CL-L1) was originally reported as limited to birds and mammals
(Ohtani et al. 1999) based on the Zoo-blot analysis.
Group IV. As already mentioned, all three selectin genes found in other vertebrates 
are present in Fugu and have the same genome arrangement.
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Group VI. I identified Fugu orthologues for all four human group VI members:
macrophage mannose receptor (MManR), DEC-205 (CD205), phospholipase A2 
receptor (PLA2R) and Endo180. In addition, there are 5 sequences (MManR-F1 – 
MManR-F5) showing high similarity to members of the group, four of which do not 
contain the minimal number of CTLDs (8) present in the known group VI sequences 
(Figure 5-1). The fragments belong to at least 3 group VI CTLDcps. Although the most
parsimonious explanation of the presence of these fragments would be that each of the
genes encoding an eight-CTLD molecule (MManR, Endo180 and PLA2R) was copied 
in a chromosome or genome duplication event, phylogenetic analysis indicates that all 
five sequences are paralogues of the MManR gene, which, thus, appears to have been 
duplicated several times.
There is one more potential group VI member in Fugu. A GenScan-predicted DEC-
205-FUSE gene, which was assigned to the U group, encodes a large protein (~2000 
residues) with multiple CTLDs clustered in two groups: 5 at the N terminus and 10 (7 in 
v.3 assembly) at the C terminus, with an LCCL domain (named after its presence in 
Limulus factor C, cochlear protein Coch-5b2, and late gestation lung protein Lgl1`; 
Trexler et al. 2000) and a coagulation factor 5/8 C-terminal domain (discoidin domain,
FA58C) lying in the middle separating the two groups of CTLDs (see Figure 5-2). 
EnsEMBL predictions in the DEC-205-FUSE locus in both versions of the assembly
contain a large (4 kb) intron in the region encoding LCCL, FA58C and 8 CTLDs at the 
center of the molecule. LCCL has been observed in a combination with a CTLD in an 
invertebrate protein (Muta et al. 1991), while FA58C has been found only in 
combination with LCCL, but not with a CTLD (Kobuke et al. 2001). Although there is 
no supporting cDNA or EST evidence for my predicted gene structure, the small intron 
sizes (e.g. LCCL is separated by 135 bp from the downstream CTLD) and well-
conserved CTLDs, suggest that the prediction may be correct if the corresponding 
region was correctly assembled. There is no orthologue for DEC-205-FUSE in the 
human genome.
Groups VIII and IX. I have identified Fugu orthologues for all known human members
of groups VIII and IX. One member in each of these groups is duplicated in Fugu
(Layilin and Tetranectin).
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Figure 5-3 Phylogenetic relationships between fish and human CTLDs 
A phylogenetic tree built on a ClustalW alignment of a 95% non-redundant collection of predicted Fugu
CTLDs and known human and fish CTLDs. Link domains and group VI CTLDs were excluded from the
alignment. The tree was built by the neighbor-joining method with 100 bootstrap trials using the
ClustalW program. PhyloDraw was used to draw the radial cladogram shown. Branches containing
CTLDs from CTLDcps belonging to the same group are shaded; group numbers are marked. Lower case
prefixes in the identifiers indicate taxonomic origin: h – Homo sapiens, f – Fugu rubripes, zbrfs – Danio
rerio (zebrafish), g – Gillichthys mirabilis, gldhs - Carassius auratus (goldfish), carp – Cyprinus carpio
(common carp), rsmlt – Osmerus mordax (rainbow smelt), slmn – Salmo salar (Atlantic salmon), wfldr –
Pseudopleuronectes americanus (winter flounder), ahrng – Clupea harengus (Atlantic herring), servn – 
Hemitripterus americanus (sea raven), jpeel – Anguilla japonica (Japanese eel), medak – Oryzias latipes
(Japanese medaka), c – Paralabidochromis chilotes (cichlid fish).
Group X. In addition to the PDK1 orthologue, which was identified previously 
(Sandford et al. 1997), there is at least one more putative group X member, orthologous 
to a recently identified human and mouse PKD1 homologue PKD1L2 (Li et al. 2003). It 
is interesting to note that the GenScan-predicted Fugu PKD1L2 sequence is very similar
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to the sequences of human and mouse PKD1L2 cDNAs, even though the latter were 
deposited in GenBank at the beginning of June 2003 – after GenScan prediction. This 
example indicates that ab initio GenScan predictions on the Fugu genome can be very 
accurate.
Group XII. I found a single sequence resembling mammalian eosinophil major basic 
proteins (EMBPs) in Fugu (EMBPL). Although the similarity between the mammalian
and the fish sequences is very low (~30% identity), several observations suggest that the 
Fugu EMBP-like sequence is an orthologue of one of the two mammalian genes. First, 
the overall domain architecture of the fish protein is similar to that of the EMBPs.
Although the fish CTLD has a neutral pI (7.1), it is preceded by a 30-residue peptide
with a predicted pI of 3.62, analogous to the longer acidic neck of the mammalian
EMBPs. In the existing classification (Drickamer and Fadden 2002), the presence of the 
acidic neck is used as the defining feature of group XII distinguishing it from the other 
group of single-CTLD soluble proteins (VII). Second, in the phylogenetic trees EMBPL 
usually appears on the same branch as EMBPs (e.g. Figure 5-3), albeit with low 
bootstrap support. Third, the exon-intron structure of the CTLD region is identical in 
fish and mammalian genes. Finally, the fish sequence has the same rare substitution in 
the fourth position of the WIGL motif as the EMBP sequences (discussed in more detail 
below).
Group XIV. The thrombomodulin family is fully represented in Fugu, with one gene 
duplicated (C1qRP). In addition, a novel member of the family conserved between 
Fugu and mammals was identified, which I named CETM (for CTLD, EGF, 
TransMembrane domain; see Figure 5-2). Multiple full-length cDNA and EST 
sequences from different tissues found in nucleotide databases indicate that mammalian
CETM is ubiquitously expressed. The sequence of the CETM CTLD contains a putative 
carbohydrate-binding motif (EPN), which is normally associated with mannose
specificity.
Antifreeze-protein-like sequences. I identified two putative CTLDcp-encoding loci 
with similarity to antifreeze proteins: AFPL-F1 and AFPL-F2 (antifreeze-protein-like),
almost identical to each other and positioned in tandem on scaffold 1930 in the v.2 
assembly. In v.3 of the assembly, the AFPL-encoding region was rearranged and one of 
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the AFPL loci disappeared. The intron-exon structure of the CTLD-encoding region is 
identical to the structure of the sea raven antifreeze protein gene (Loewen et al. 1998) 
with three intron insertions (upstream of C1, downstream of the WIGL motif, and 
between C2 and C3 (Zelensky and Gready 2003)), and very similar to the structure of 
the Salmo salar serum lectins (Richards et al. 2003), where only the first two splice 
sites are present. The Fugu AFPL gene expression is confirmed by an EST sequence 
BU806418, which covers the whole predicted CDS.
Link domain containing CTLDcps. All link domain-containing proteins identified in 
mammals are represented in Fugu and often are highly conserved between fish and 
human (e.g. TSG-6, 72%; Stabilin-1, 45% identity); I will consider them as a single 
group despite their different domain architectures. Predicted members of the CD44 
family (CD44 and lymphatic vessel endothelium-specific hyaluronan receptor (Lyve-
1)), however, are much more divergent from their human homologues, and it is not 
clear whether the two loci found in Fugu are orthologues of the two human genes or 
paralogues which arose by duplication of an ancestral gene.
In a recently published comprehensive study of another family of the Link group, 
the hyaluronan and proteoglycan binding link proteins (HAPLN), four homologues 
were identified in vertebrates (mouse, human and partially zebrafish) each linked to one 
of the four lecticans (Spicer et al. 2003). As all lecticans (i.e. group I) are duplicated in 
Fugu, I was expecting to also find duplicate copies of all HAPLN members. However, 
orthologues of only three HAPLNs were found (CRTL1, BRAL1, HAPLN3), two of 
which are linked to hyalectans in the same way as in mammalian genomes (CRTL1 
with Versican, BRAL1 with Brevican).  The state of the assemblies does not allow to 
determine conclusively whether HAPLN3 is linked to Aggrecan or not. Only two of the 
Fugu lectican gene duplications are accompanied by corresponding HAPLN genes: 
Aggrecan-F1 is linked to HAPLN3-F1 and the CRTL1 paralogue is present downstream
to Versican-F1 in two tandem copies (CRTL1-F1 and CRTL1-F2). In neither version of 
the assembly could the HAPLN4 homologue be identified downstream to Neurocan or 
Neurocan-F1. Sequence conservation levels within the HAPLN proteins compared with 
their human orthologues is quite high (e.g. 76% identity for CRTL1). 
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Fugu dual-CTLD CTLDcps. The members of this group are soluble proteins with two 
or three CTLDs, which I initially characterized as fragments of putative macrophage
mannose receptor paralogues. However, phylogenetic analysis showed that these 
proteins constitute a separate group, with no mammalian orthologues detectable in 
sequenced genome and protein databases. The domain structure prediction is confirmed
by three zebrafish cDNAs (CAE17649, CAE17650, CAE17651), which have the same
domain organization, although conservation between zebrafish and Fugu sequences is 
only moderate (~30%). Another homologue with the same domain structure and 
similarity to the F1 group members, which was returned as the top-scoring hit by 
BLAST searches in the nrdb, is the SCARF2 protein from a planarian Girardia tigrina
(Shagin et al. 2002). A hypothetical dual-CTLD protein from Drosophila (NP_609962), 
which presumably corresponds to the single member of group B in the Drosophila
CTLDcp classification of Dodd and Drickamer (2001), was also detected as a F1 
homologue by BLAST. 
5.3.6 Novel CTLDcps conserved between Fugu and mammals
Discovering novel superfamily members in existing database sequences is one of the 
most important and exciting outcomes of a systematic computer-based study such as 
this. I predicted putative Fugu orthologues for several uncharacterized mammalian
CTLDcps (Bimlec, MGC3279, KIAA0534, CETM, SEEC, CBCP, NLSLH) that are 
well conserved between Fugu and mammals. Most of the predictions were supported by 
mammalian cDNA sequences from public databases, but for two of them (NLSLH and
CBCP) no full-length cDNA from any organism was found in DBs. The high level of 
genomic sequence conservation over evolutionary time from fish to human, as in the 
case of NLSLH, and the presence of partial cDNA and EST sequences from rodents and 
human, as in the case of CBCP, were strongly suggestive that the predictions are 
correct. The novel CTLDcps that could be attributed to one of the 14 known groups 
have been discussed in the preceding sections for the corresponding groups; those that 
do not fit into the existing classification are described below.
A large (~2100 aa) proteoglycan (CBCP), containing a set of chondroitin sulphate 
proteoglycan (CSPG) repeats (Staub et al. 2002), which are homologous to the NG2 
ectodomain (Nishiyama et al. 1991a), a calcium-binding Calx-E domain (Schwarz and 
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Benzer 1997) and a CTLD, is a novel member of a protein family which had not been 
reported previously to have members containing CTLDs; examples of this family also 
include the human MCSP/CSPG4 (Pluschke et al. 1996) and mouse FRAS1 (McGregor
et al. 2003) genes. The prediction was supported by three overlapping but incomplete
cDNA sequences from human and mouse, high levels of conservation between human 
and Fugu (~50% identity), and the compact structure of the predicted Fugu gene. CBCP 
has been placed in a new CTLD group, XVII; its domain structure is shown in Figure 
5-2. I have cloned a full-length cDNA of mouse CBCP confirming the domain structure 
predicted in this study (Chapter 6). The CTLD of CBCP lacks Ca2+-binding residues, 
and its long loop region is short, resembling that of the group V CTLDs. 
Another protein with a novel domain organization, whose prediction is strongly 
supported by available cDNAs, is SEEC (SCP, EGF, EGF, CTLD-containing protein) 
(see Figure 5-2), which is well conserved between human and Fugu. Although not 
described in a publication, a full-length human SEEC cDNA (AK074773) was 
sequenced in the NEDO high-throughput sequencing project. The predicted Fugu SEEC 
is 63% identical to the human sequence. The sperm-coating glycoprotein (SCP) domain, 
which is present in a broad set of organisms from yeast and plants to mammals, but 
whose function is unknown (Szyperski et al. 1998), is rarely observed in combination
with other domains in proteins; in only one other known protein (from sea urchin) is it 
found together with an EGF domain (Ohbayashi et al. 1998). Interestingly, a protein 
containing both CTLD and SCP domains, but no EGF domains, has been described in 
Hydra attenuata, where it is associated with the nematocyst (Engel et al. 2002). The 
potential Ca2+/carbohydrate-binding motif (QPD) characteristic of galactose specificity 
is present in the CTLD. SEEC has been placed in a new CTLD group XVI. 
A predicted protein named “novel L-selectin homologue” (NLSLH) because its 
CTLD is most similar to selectin CTLDs is duplicated in Fugu (NLSLH and NLSLH-
F1) but only moderately conserved (32% identity) between Fugu and human. The 
putative human orthologue is located on Ch1q25.1 about 18 Mb further from the 
centromere than the selectin cluster and is supported only by EST sequences 
(AA912157, AA889574), but not cDNAs. No conserved domains except for the CTLD 
could be detected in the human and Fugu NLSLH loci so, if the predictions are correct,
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NLSLH is a soluble single-CTLD-containing protein. Carbohydrate-binding motifs are 
not present in the NLSLH and NLSLH-F1 CTLDs. 
Finally, a type I transmembrane protein Bimlec, whose prediction is supported by a 
full-length human cDNA, was placed in a new group XV. 
5.3.7 Dating the CTLDcp duplications
I found 12 groups of unlinked Fugu-specific CTLDcp paralogues (Appendix B), and 
attempted to determine the duplication dates using two approaches: (1) based on the 
estimation of the number of synonymous nucleotide substitutions (Ks) in the coding 
sequences and (2) based on the molecular clock hypothesis. 
For all but two pairs of duplicated genes, Ks values estimated with four different 
methods (see Methods) were between 1.5-2.5, which indicates a complete saturation of 
the synonymous sites (Figure 5-4 (a)). Ks values so high cannot provide an accurate 
estimation of the duplication age, but it can be concluded with confidence that the 
CTLDcp gene duplications are at least 150 Myr old, which is the time required for 
complete saturation of silent sites assuming a mutation rate of 2.5 substitutions/silent 
site/billion years in fish (Li 1997). If, however, Ks values presented in Figure 5-4(A) 
and the silent mutation rate are close to correct, the corresponding duplication 
timeframe is predicted to be 300-500 Myr. 
In order to date the duplications based on molecular clock measurements, I aligned 
duplicated Fugu CTLD sequences with their vertebrate orthologues present in 
GenBank, and built linearized phylogenetic trees based on the alignments. As human
and mouse sequences were invariably available, the divergence time between these two
species (96 Myr`; Nei et al. 2001) was used to calibrate the clock, together with the 
divergence time between Actinopterygii and Sarcopterygii (430 Myr`; Ahlberg and 
Milner 1994).
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Figure 5-4 CTLDcp duplication dates
A. Average number of synonymous substitutions per synonymous site (Ks) for CTLDcp paralogue pairs
based on full-sequence (triangle) and CTLD-only (diamond) alignments, measured with four different
methods (see Methods). Error bars show one standard deviation in the CTLD-only measurements. All
possible pairwise alignments between the MManR fragments and between the three CRTL1 paralogues
were analyzed. Only homologous regions were used for MManR fragment alignments. B. A linearized
phylogenetic tree built by the neighbor-joining method from Poisson-corrected distances between
ClustalW-aligned sequences of CTLDs 3-5 from Fugu, mouse and human MManRs. Sequence of the
human PLA2R region containing CTLDs 3-5 was used as an outgroup. Thm – time of separation between
human and mouse (96 Myr`; Nei et al. 2001), Tfish – time of separation between ray-finned and lobe-
finned fishes (430 Myr`; Ahlberg and Milner 1994). Time of duplication (Tdupl) was calculated using
average between molecular clock calibrated with Thm and with Tfish.
Symmetrical tree topology ((H, M) (F, F1)), expected for a Actinopterygian-specific 
duplication, was revealed by at least one phylogeny reconstruction method I used for 
the following six homologue groups (data not shown): brevican, neurocan, MManR, 
SRCL, tetranectin and HAPLN3, with duplications dated 369, 284, 397, 377, 360 and 
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312 Myr, respectively. A typical tree with symmetrical topology is shown for MManR 
in Figure 5-4 (b). The other six alignments (aggrecan, versican, layilin, attractin, 
C1qRP, CRTL1) produced trees with topologies suggesting a duplication predating the 
split between Actinopterygian and Sarcopterygian.  The portion of symmetrical 
topologies (50%) in the CTLD set is similar to the ratio reported by Taylor and 
coworkers in fish: 15 of 27 (55%`; Taylor et al. 2001), and 25 of 53 (45%`; Taylor et al.
2003) for bigger and more heterogeneous gene collections. 
5.4 Discussion 
5.4.1 Draft assembly limitations
A systematic study based on draft-quality whole-genome data for an organism like 
Fugu rubripes has some limitations, as the genomic sequence is incomplete, fragmented
and sometimes misassembled, and the expressed sequence information is scarce. On the 
other hand, many of the genomes that are currently being sequenced will be released 
and remain for sometime in the same state as the Fugu genome data are now. Indeed, 
more than a year after the initial release (Aparicio et al. 2002) very few improvements
to the Fugu genomic data (v.3 assembly and EST sequencing project`; Clark et al.
2003) have been published. Therefore, it is essential to extract useful biological 
information from draft-quality whole-genome sequences. This study is such an attempt.
I have mentioned four limitations of the draft-state assembly – incompleteness,
fragmentation, misassembly and lack of expression information. While the last might
appear the biggest problem, I found that ab initio predictions combined with manual
curation and interspecies comparison have proven to be very accurate (e.g. see PKD1L 
example), thanks to the compactness of the Fugu genome, smaller ratio between intron
and intergenic region sizes compared with mammalian genes, wealth of data for 
comparative analysis etc. I do not expect that sequencing the remaining 5% of the Fugu
genome, which is mostly heterochromatic regions, will lead to discovery of many new 
CTLDcps. From the comparison of the Fugu CTLDcp repertoire found by me and 
discovered in other fish species independently, the only surprising omission in my
results is a MBP orthologue. MBP sequences have been found in several other fish 
species. Their absence in Fugu may represent a bona fide gene loss. As to the 
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fragmentation, only a few of the CTLDcps are split between scaffolds, namely versican
and some MManR paralogues (Figure 5-1). All of the fragmented genes are big, and in 
most cases the fragments can be combined easily to reveal the full sequence. Finally,
misassembly signs were observed in several CTLDcp loci while comparing two 
versions of the assembly. These showed as presence of repeated regions in the v.2 
assembly, which disappeared in the v.3 assembly.
5.4.2 Two groups identified in higher vertebrates are not detectable
in Fugu
I could not detect CTLDcp representatives for groups V (NK cell receptors) and VII 
(lithostathine) in the Fugu genome. CTLDs in the members of these groups have lost 
their carbohydrate-binding activities, and perform functions that have, apparently, 
evolved after evolutionary separation of tetrapods from fish, or which are mediated by
other proteins in fish. For example, group VII members are secreted into the digestive 
tract – a system that is very flexible evolutionally. Group V is probably one the 
youngest and most rapidly evolving sets of CTLDcps; its component members vary 
significantly even between rodents and human, a phenomenon connected to the co-
evolution with the acquired immune system proteins that group V CTLDcps interact 
with.
My conclusion on the absence of group V CTLDcps in the Fugu genome is at odds 
with the conclusions of two studies describing group V CTLDcp evolution in chordates. 
A recent paper describes possible CD94 homologues (cichlid killer cell lectin receptor,
cKLR) in bony fishes Paralabidochromis chilotes and Oreochromis niloticus, which are 
encoded by a large multi-gene family with at least 10 members (Sato et al. 2003). 
Another recent work described sequencing of a CD94 homologue in a tunicate
(Khalturin et al. 2003). 
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Figure 5-5 Relationships between fish, mouse and human group V and II CTLDs
Non-redundant set of CTLD sequences from known human and mouse CTLDcps classified as groups II
and V, Fugu CTLDcps classified as group II, and putative killer cell receptor from Paralabidochromis
chilotes (cKLR) were aligned with ClustalW. A consensus phylogenetic tree was built from 100 bootstrap
trials using the protdist (with PAM distance matrix) and neighbor programs from the PHYLIP package.
Black triangle shows position of cKLR. Bootstrap values higher than 40 are indicated.
The decision by Sato et al. (2003) to assign putative fish killer cell receptors to 
group V rather than to group II was based on several considerations, including gene 
structure, absence of canonical Ca2+/carbohydrate-binding residues, and 
phylogenetic analysis based on the CTLD alignment. The latter consideration is 
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mentioned as the most important one. However, as the authors themselves note, 
bootstrap values for placing cKLR on the group V branch, are “low to moderate”. 
Indeed, I found that in phylogenetic trees built using different methods (maximum
parsimony, distance estimation method with PAM matrix followed by neighbor-joining 
tree reconstruction, maximum likelihood) from the ClustalW alignments of cKLR 
sequences with group V and group II CTLD sequences from Fugu, mouse and human,
cKLR placement is unstable. As shown in Figure 5-5, on a tree built by the neighbor-
joining method we found cKLR on the branch containing the Fugu-specific subset of 
group II CTLDcps (DC-SIGN-F1 - DC-SIGN-F8), most of which do contain residues 
required for Ca2+/carbohydrate binding. On a tree built by the maximum parsimony
method, cKLR was on a separate branch equally related to group II and group V 
sequences (not shown). Also, a BLAST search with the complete cKLR sequence (GI 
31789959) in the non-redundant NCBI protein database returns members of the ASGR 
subgroup of group II as top matches. Therefore, I judge that sufficient support for 
assignment of cKLR to group V is lacking and the question of the presence of the NK-
cell receptor family in fishes is still open.
As to the putative CD94 homologue from tunicates, it is indeed more similar to 
CD94 than to any other CTLDcp. However, the low level of sequence homology and 
the lack of evidence for existence of group V CTLDcps in more advanced taxa does not 
allow a confident statement that the sequence from tunicates is a CD94 orthologue, 
rather than a result of convergent evolution.
5.4.3 Expansion of the innate immunity CTLDcp groups in Fugu
Unlike pairwise unlinked duplications (see below), tandem duplications and other 
gene family expansions are limited to two groups, namely the DC-SIGN subgroup of 
group II and MManR. In mammals, members of these subgroups play an important role 
in innate immune responses. In particular, DC-SIGN is actively studied due to its ability 
to bind and internalize a broad range of bacterial and viral pathogens, including HIV-1 
and Mycobacterium tuberculosis (reviewed by Van Kooyk and Geijtenbeek 2003), 
while MManR is also implicated in binding and phagocytosis of a wide range of 
microorganisms (Linehan et al. 2000). Expansion of these groups, most notably the DC-
SIGN subgroup, in Fugu may reflect a larger role for innate immunity in host defense in 
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lower vertebrates. Interestingly, multi-copy clusters comprising at least 10 genes 
encoding close cKLR homologues were identified in another cichlid fish species 
Oreochromis niloticus (Sato et al. 2003), which suggests another parallel between the 
expanded DC-SIGN subgroup in puffer fish and cKLRs of cichlids.
There are no extra members, however, in the Fugu collectin group – another CTLD 
group directly involved in innate immunity in mammals. Moreover, the mannose-
binding protein (MBP), which is the best-studied mammalian collectin involved in 
lectin complement activation pathway, was not detected by me. The absence of MBP 
orthologues in Fugu is rather puzzling, as MBP sequences have been found in several 
other fish species (Danio rerio, Cyprinus carpio and Carassus auratus; (Vitved et al.
2000)), and are well conserved within the Cyprinidae carp family. The collectin family
is also present and expanded in the Urochordate Ciona intestinalis with nine collectin
genes identified in the draft genome sequence (Azumi et al. 2003), although it is not 
clear whether one of these nine genes is an MBP orthologue. Given the role of MBPs in 
complement activation in mammals, and their presence and level of conservation in the 
carp family, it is possible that the Fugu MBP orthologue does exist but is not covered 
by the draft genome sequence. Complement-activating C-type lectins from lower 
organisms have been identified but not completely sequenced (Nair et al. 2000); they 
have multiple CTLDs as in CPL-III from the protochordate Clavelina picta (Vasta et al.
1999) or lack the collagen domain and show more similarity to other CTLDcps such as 
the glucose-binding lectin (GBL) from another tunicate, Halocynthia roretzi (Sekine et
al. 2001). 
5.4.4 Fugu dual CTLD molecules – a missing link between vertebrate
and invertebrate CTLDs? 
Previous whole-genome studies of the CTLD superfamily in two invertebrates
(Dodd and Drickamer 2001; Drickamer and Dodd 1999) failed to identify any groups of 
CTLDcps common to both invertebrates and vertebrates. A group of predicted dual 
CTLD-containing proteins in Fugu (F1) may be the first vertebrate group that has 
detectable homologues in invertebrates. Alternatively, it is possible that none of the 
Fugu F1 group members are in fact orthologous to the invertebrate sequences, as 
sequence similarities are only moderate (~30% ID) and the domain architecture is 
115
Chapter 5 CTLDs in Fugu 
simple and could have evolved independently in different lineages. However, several 
observations suggest that at least F1 members from Fugu and zebrafish and SCARF 
proteins from Girardia tigrina evolved from the same predecessor. First, similarity
levels between fish sequences and between fish and planarian sequences are about the 
same. It is unlikely that the fish sequences are unrelated, which implies that F1 
members are evolving quickly, and only major structural features of these molecules are 
under selective pressure (Zelensky and Gready 2003). Second, the CTLDs of planarian 
and, in all cases at least one CTLD of the fish dual-CTLDcps, contain residues 
characteristic of Ca2+/carbohydrate binding. In vertebrates, ability to bind carbohydrates 
is associated with the oldest CTLDcps groups, and is considered to be an ancestral 
feature of the CTLD. Indeed, both vertebrate CTLDcp groups that I failed to find in 
Fugu (V and VII) have lost sugar-binding properties. This is also the case for the 
antifreeze proteins from fish and snake venom CTLDcps, which have only been found 
in the corresponding clades. Third, similar domain organization (two CTLDs, no 
transmembrane domain) is also observed in two other known groups of invertebrate 
CTLDcps: immulectins from various insect species (Yu et al. 1999; Kim et al. 2003) 
and nine proteins from C. elegans, classified as group D1 by Drickamer and Dodd 
(1999). Despite identical domain structure, none of these proteins shows statistically 
significant homology to the fish F1 group members or their putative homologues from
planarian or Drosophila. Altogether, this indicates that domain structure alone cannot 
establish an evolutionary link between the fish and invertebrate sequences. Hence, the 
suggestive link between the F1 group fish members and the planarian and Drosophila
proteins is even more interesting. 
5.4.5 CTLDcp classification update
The existing classification of CTLDcps is generally accepted and popularly used in 
studies of the superfamily and recently has been updated (Drickamer and Fadden 2002). 
The classification divides CTLDcps into monophyletic groups of proteins with identical 
overall domain architecture based on a combination of structural and phylogenetic 
information. Although two previous large-scale studies (Dodd and Drickamer 2001; 
Drickamer and Dodd 1999) showed it to be inapplicable for description of invertebrate 
CTLDcps, my analysis of the puffer fish genome indicates that it is sufficient to 
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describe the superfamily in all vertebrates, with only minor modifications and some
extensions.
The newly discovered CTLDcps, with a few exceptions, do not fit into the existing
classification because of their unique domain architecture. I propose several new groups
to accommodate the novel CTLDcps which have been found in both higher and lower 
vertebrates and are supported by cDNA sequences: 
x XV – Bimlec (type I transmembrane protein), which in phylogenetic trees is not 
placed on the same branch as group VIII sequences, has a distinct exon-intron 
structure of the CTLD region and a neck not similar to the neck region of the 
group VIII sequences;
x XVI – SEEC, based on unique domain architecture; 
x XVII – CBCP, based on unique domain architecture; 
Additional groups may be required for the sequences not supported by sufficient 
expression data (NLSLH) and other sequences from the “unclassified” group whose 
presence in higher vertebrates is not clear. Also, clade-specific groups, such as fish 
antifreeze proteins (AFP), dual-CTLD sequences (group F1) predicted by me and so far 
identified only in fish, or snake venom CTLDcps which lack orthologues in other 
vertebrates, are required.
It has been suggested previously (Richards et al. 2003; Loewen et al. 1998) that 
AFPs belong to group VII based on their domain architecture and exon-intron structure. 
However, my phylogenetic analysis of an alignment of CTLD sequences from all 
known human and mouse CTLDcps and 26 different fish CTLD-containing protein 
sequences identified by searching the NCBI protein database with BLAST, indicates
that they constitute a phylogenetically distinct group including all known soluble fish 
CTLD-containing proteins, except Cyprinidae collectins. As to the exon-intron 
structure, introns in the group XII (EMBP) CTLDs are at exactly the same positions as 
in group VII and AFP-like CTLDs, which suggests that all three groups are closely 
related but does not allow classification of the fish AFP-like sequences to either of the 
mammalian groups. Interestingly, just like most of the AFPs, mammalian EMBPs 
contain an atypical WIGL motif with a glycine in the fourth position, a substitution not
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observed in any other mammalian CTLD I analyzed. Taken together, these observations 
indicate that in a broader evolutionary perspective the differences between some of the 
groups including CTLDcps with a very similar domain architecture (V||, XII and AFP; 
II and V) become less distinct, which makes classification of the “intermediate” or 
“ancestral” sequences, equally related to more than one group, problematic.
5.4.6 Selective duplication of the Fugu CTLDcp-encoding genes and 
the whole-genome duplication hypothesis
The hypothesis that whole-genome duplications were one of the main driving forces 
in vertebrate evolution, providing genetic material for increased diversity and 
progressive development (Ohno 1970), and that there were two rounds of whole-
genome duplication in vertebrate phylogeny (the 2R hypothesis`; Ohno 1970; Ohno 
1999), is actively debated (Wolfe 2001; Hughes and Friedman 2003). A more recent
whole-genome duplication is suggested for the Actinopterygian branch (Taylor et al.
2001). Ray-finned fish are the most diverse group of vertebrates, and based on the 
initial observation that each of the four human HOX gene clusters has two homologues
in zebrafish (Amores et al. 1998) it was suggested that they have undergone an 
additional round of a whole-genome duplication after the divergence from 
Sarcopterygian about 430 Myr ago (Taylor et al. 2001). Analysis of the genome
duplication in fish can give a picture of a duplicated genome after 300-400 Myr of 
evolution and fill the gap between the now generally accepted recent tetraploidizations
in plants (Blanc et al. 2003) and yeast (Wong et al. 2002) and the alleged more ancient 
duplication(s) of the ancestral vertebrate genome.
Although many fish genes are indeed duplicated (Amores et al. 1998; Taylor et al.
2001; Williams et al. 2002; Robinson-Rechavi et al. 2001a; Wittbrodt et al. 1998), it is 
not clear whether the copies were created by a complete genome duplication 
(autopolyploidy), merge of different genomes (allopolyploidy), regional duplication, or 
simply a series of tandem duplications. Attempts to show that ancient tetraploidization
(has not) occurred usually involve: (i) searching for an excess of paralogue groups 
where the number of members is double the number of alleged duplications (i.e. 2 in 
case of Actinopterygian duplication, and 4 in case of vertebrate duplication, the “one to 
four rule”`;  Hughes and Friedman 2003; Ohno 1999); (ii) showing that a statistically 
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significant number of duplications took place at approximately the same time by 
molecular clock estimation or synonymous substitution counting (Gu et al. 2002; Lynch 
and Conery 2000); (iii) using phylogenetic methods to assess the relation between 
duplication and speciation events (Taylor et al. 2001); and (iv) showing that duplicated 
genes are arranged in paralogous blocks on chromosomes (paralogons`; Wolfe and 
Shields 1997; McLysaght et al. 2002; Taylor et al. 2003). I used these approaches to 
analyze the nature of the observed CTLDcp duplications in Fugu.
The results presented here clearly show that tandem gene copying is a mechanism of 
CTLD family evolution and led to generation of three gene clusters: DC-SIGN-F2 – 
DC-SIGN-F5 (4 genes), CRTL1-F1 and CRTL1-F2, and AFPL-F1 and AFPL-F2. 
Members of the two latter clusters are nearly identical and may be an assembly artifact. 
Twelve other duplicated genes are not linked in the current assembly and have 
sequences much more diverged than tandem duplicates. Of the 12 genes only MManR,
which has 3 paralogues, is present in more than two copies. I consider this is important
evidence in favor of a whole-genome duplication, as sporadic duplications cannot 
explain such a strong bias towards two-member paralogue groups. Unfortunately, the 
results of duplication time estimations are less conclusive as they give only a broad 
timeframe for the possible duplication events of about 300-400 Myr. As in the case of 
some other fish gene families reported previously (Taylor et al. 2001; Taylor et al.
2003; Van de Peer et al. 2003; Robinson-Rechavi et al. 2001b), molecular phylogeny 
reconstruction that I performed often indicates that duplications occurred before the 
divergence between fish and tetrapods. However, this could be an artifact of the method
caused by different selection pressures on duplicates. Unfortunately, there is practically 
no overlap between vertebrate and invertebrate CTLD families, so I could not use 
invertebrate sequences to refine phylogenetic analysis. To conclude: phylogenetic 
relationships between CTLD paralogues and estimated duplication time distribution 
indicate that there was a burst in duplication activity in the Fugu genome 300-400 Myr 
ago. While I cannot determine definitively the nature of the duplications (tandem,
regional or whole-genome), a pronounced bias in the number of two-member paralogue 
groups strongly suggests that there was a single large-scale or whole-genome
duplication event in fish.
119
Chapter 5 CTLDs in Fugu 
Another interesting observation is that CTLDcp genes were either duplicated, or 
retained after a large-scale duplication, in a pronounced selective manner. One group (I) 
is duplicated completely, while in other groups only partial duplications are found. 
Interestingly, group I (lecticans), which in tetrapods contain four large (>2000 amino
acids) proteins, very similar to each other in sequence and domain structure, is a good 
candidate for demonstrating the 2R hypothesis. If the four lecticans arose as a result of 
the alleged two rounds of the whole-genome duplication early in vertebrate history, the 
fact that the family was also completely duplicated in fish and retained after the 
duplication appears very non-random and implies some functional explanation. In the 
human genome, all four genes encoding lecticans are located on different chromosomes
(1, 5, 15 and 19), but it is not clear whether they are linked in Fugu.
Another group that conforms to the 2R hypothesis is group VI, which in tetrapods 
has four members with almost identical domain structure in mammals (Pla2R, MManR, 
DEC-205 and Endo180). Though in the Fugu genome we identified 7 group VI 
sequences, some of which are fragmented (Figure 5-1), phylogenetic analysis shows 
that only one member of the family (MManR) was quadruplicated, while others are 
present in a single copy. Both molecular clock and Ks-based methods date the MManR 
duplications at approximately the same time as other CTLDcp gene duplications. 
Phylogenetic trees, built on alignment of the overlapping portions (Figure 5-1) of the 
complete sequences and three largest fragments (fMManR-F1, fMManR-F2, fMManR-
F3) have symmetrical structure, with fMManR-F1, fMManR-F2 and fMManR-F3 
forming a separate branch (Figure 5-4 (b)). A whole-genome duplication, generating 
fMManR and fMManR-F1, followed by tandem duplications of fMManR-F1, 
producing fMManR-F2 and fMManR-F3, can explain this topology. 
5.5 Conclusions 
I have performed an analysis of the CTLD superfamily composition in Fugu
rubripes. Although the sequence assembly is in the draft state and lacks physical 
mapping information and native cDNA sequences that could be used to make and verify
gene predictions, the quality of the data is good enough despite these limitations to 
answer many important questions. My study demonstrates that all but two groups of 
CTLDcps present in mammals are also found in fish, that most of the groups have the 
120
Chapter 5 CTLDs in Fugu 
same composition as in mammals, and that the missing groups are the evolutionarily 
most dynamic ones involved in physiological processes that may be specific to higher 
vertebrates. I also identified at least one distinct fish-specific CTLD group, which could 
be the first known vertebrate CTLD group also found in invertebrates. 
The compactness of the Fugu genome makes it an extremely convenient reference 
sequence for identification of new genes based on supporting similarity features, which 
allowed to identify and predict the structure of several new CTLD-containing genes 
highly conserved between Fugu and human. The new sequences are supported by 
cDNA and EST sequences from databases and have previously unknown domain
architectures. I also show that CTLDcp-encoding genes are selectively duplicated in 
Fugu, in a manner that suggests an ancient large-scale duplication event in fish. 
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Cloning and initial characterization of 
mouse Calx-E and CTLD-containing 
protein (CBCP) 
6.1 Identification 
CBCP was identified in the course of the annotation of CTLD-containing genes 
found in the draft sequence (assembly v.2) of the Fugu rubripes genome (Figure 6-1). A 
highly significant GeneWise match for a CTLD HMM on contig 2037 overlapped a 
small EnsEMBL-predicted transcript (SINFRUG00000052154) comprising a single 
exon encoding a CTLD. A GenScan feature overlapping this region included 
SINFRUG00000052154 and three other predicted genes situated upstream to it. The 
short distances (100-300 bp) separating these four predicted transcripts suggested that 
the GenScan prediction was correct, and features on the various expressed sequence 
tracks supported each of the four predictions. Therefore, I created a new transcript 
prediction based on the GenScan feature, EnsEMBL-predicted transcripts and expressed 
sequence track features. 
Analysis of the domain architecture of the predicted transcript using the SMART
server (Letunic et al. 2002) revealed two well-conserved domains, Calx-E and CTLD, 
preceded by a long region with no domains recognized by SMART (Figure 6-1). Based 
on this domain architecture, I named the protein CBCP (Calx-E and CTLD containing 
protein). To identify the nature of the long region containing no know domains, I used 
its sequence as a query to search the GenPept database and found a significant similarity
to a small group of proteins homologous to the rat NG2 protein. 
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Figure 6-1 Structure of the CBCP locus in the Fugu genome
The GenScan and EnsEMBL gene models overlapping the Fugu CBCP locus are shown at the top. Exons
that I used to create my gene models are shown in red. Bottom panes show the structures of my gene 
models, and the results of the CBCP domain architecture analysis with SMART.
Using the conceptual translation of the predicted CBCP transcript as a query 
sequence, I found putative orthologous loci in the human and mouse genome sequences. 
Although neither genome annotation I looked in (NCBI and EnsEMBL) contained a 
gene prediction matching the one I created based on the predicted Fugu CBCP 
transcript, all three major portions of the CBCP prediction (NG2 region, Calx-E and 
CTLD domains) were present next to each other. Due to the much higher distances
between predicted exons in the mammalian genomes and the absence of any cDNA 
sequences covering all three domains of the predicted CBCP, it was not clear whether 
my prediction was correct, as it was only supported by the short intron sizes in Fugu.
However, there was plenty of evidence that the genes were expressed in mammals.  A 
human cDNA sequence (BAB71709) encoding a “putative protein FLJ25461” covered 
the 3’ region of the predicted CBCP, including both Calx-E and CTLD domains, and 
several mouse cDNAs from the Fantom database covered various regions of the NG2 
domain (D430009N09 from lung, D630008K06 from kidney, E030022N22 from lung, 
D230019N10 from eye (unspliced)). Predicted human CBCP matched a number of 
ESTs from different tissues: lung (adult and fetal), kidney, spleen and liver, ovary, 
uterus, sciatic nerve. Surprisingly, I couldn’t find any mouse ESTs for CBCP. 
To demonstrate that the previously unknown domain architecture of the novel 
CTLD-containing protein CBCP was predicted correctly, I decided to clone the full-
length mouse CBCP and to determine in which tissues it is expressed. 
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6.2 Molecular cloning of the mCBCP 
6.2.1 Methods
RNA extraction from mouse tissues was done using the Trizol reagent (Invitrogen) 
following the protocol supplied by the manufacturer. First strand cDNA was 
synthesized from the total RNA using the Invitrogen SuperScript III first-strand 
synthesis kit according to the manufacturer’s instructions with oligo-dT or gene-specific
primer (M11 or M12, Figure 6-2, Table 6-1). For amplification of regions up to 4 kb 
long I used Platinum Taq DNA polymerase (1 U/rxn) from Invitrogen and a  “standard” 
PCR program (94º:3' x 1; 94º:20", 60º:30", 72º:(1'/kb) x 40; 72º:7’; hold at 4º). For 
long-range PCRs (4-7.5 kb), an enzyme mixture containing 1 U of Platinum Taq DNA 
polymerase (Invitrogen) and 0.05 U of the proof-reading Platinum Pfx DNA 
polymerase (Invitrogen) per reaction and a “touch-down” program (94º:3" x 1; 94º:20", 
72º:TE x 5; 94º:20", 70º:TE x 5; 94º:20", 68º:TE x 35; 72º:7; hold at 4º, where
TE=1’/kb) were used. PCR product cloning into a TA vector pCR2.1 was done using 
the TOPO TA cloning kit (Invitrogen) following the manufacturer’s instructions. 
The cloned fragments were sequenced with 1-2x coverage with the CBCP-specific 
primers (Table 6-1). BigDye 3.1 chemistry was used for sequencing; extension products 
were purified with ethanol-sodium acetate-EDTA method (Applied Biosystems 2002), 
and then submitted to the Biomolecular Resource Facility (JCSMR, ANU) for analysis
on the ABI 3730 sequencer. Sequence reads were assembled using the phred and phrap
programs and the consed assembly editor (Ewing et al. 1998). 
3’ RACE (rapid amplification of cDNA ends) was done using the step-out PCR 
approach described by Matz et al. (1999). 5’ RACE was done similarly on the cDNA 
synthesized with the template-switching method (Matz et al. 1999), modified as 
described by Schmidt and Mueller (1999) by including a 15' incubation step in the 
presence of 2 mM MnCl2 at 37º after a the first-strand cDNA synthesis with SuperScript 
II1 reverse polymerase in the buffer supplied by the manufacturer (Invitrogen). An 
1 I used the SuperScript III reverse polymerase for all cDNA synthesis because it is more
thermostable than the previous version of the enzyme (SuperScript II) and allows running the first-strand
reaction at a temperature up to 55ºC compared with 42º for SuperScript II, thus reducing RNA secondary
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alternative 5’ RACE protocol described in Sambrook and Russell (2001, p. 8.55) based 
on the use of a terminal transferase was also used, but didn’t give a positive result.
Table 6-1 Sequences of primers used for mCBCP cloning and sequencing. 
M1 GTAGCAAAGGCAAGGCTCAC M33 GCCACTCTGTCCACAGGCACAGTC
M2 AGGTGGATGGCTCCTTCATT M34 CACTGGGAGTGGATCGGAGGTGAAC
M9 ATATCACCTTTGCCCATGTC M35 CCCTCTGCACCCAAAACCTGGAAAG
M11 GGTTCTTCAAGCCTATCCAGA M36 ACCCCGTCAGCAGAAACTCCTCACA
M12 TGGTGCTGTTCTCTGCAAGC M37 GCCCAAGGCTCAGTGGTTCTTGCT
M13 CCATCTCGCCACCTGTATG M38 GGGCCCCTCTCCTCCAGTTGGTAA
M14 TCTCTCCACAGGTCTTTGATTG M39 GGCATTGGAGGAGACCTGCAAACAG
M15 AGACATTACACGATGGAGCTG M40 CCAGCCACAACAACGCATCTTCACT
M16 AACGCTAAGCAAGAAGGCTG M41 AGGATATGTGGAATAAGGAGTG
M17 CCTTTCCCCTCTCGTACTGT M42 CGCGGCACAGCTAGTTT
M18 AGCCCCTAGCTCTGTCTCAG M43 CATACAGGTGGCGAGATTGG
M19 CCCTCATACACAGTGATGTTCTG M44 CAACTGGTGCTGACTAATTTCTG
M20 ACGCGTGGGCTGGAGGACAGATCC M45 GCAAGTGACTTCCGATATCCTG
M21 GACTTTGTTCAGAGTTTCCTTGAGCACM46 GCATTCACAGGGGAGTTCAG
M24 CCTGGACCTCAAGCTGACAC M47 ACCCACCTGCTGGATCATAC
M25 CAATCAAAGACCTGTGGAGAGA M48 CCTGAGTGCTGGTAGGCAAC
M26 GCTTGCAGAGAACAGCACCA M49 TTCCTCCTCTTCCCTGGAGT
M27 TTCCTGGGTCAAATTGAAGC M50 CTGGTCGTGGTGAATCGTAA
M28 GACATGGGCAAAGGTGATAT M51 CTGGTGCCTGCACTGTTCT
M29 AGGTTCCCGAGGTATTCACC M43 CATACAGGTGGCGAGATTGG
M30 GGTGAATACCTCGGGAACCT M44 CAACTGGTGCTGACTAATTTCTG
M31 GAGTTGTCCGCTATCATCACG M45 GCAAGTGACTTCCGATATCCTG
M32 GCTTCCTGCACTTCTTCCCCAAGTGTC M46 GCATTCACAGGGGAGTTCAG
structure formation and facilitating full-length cDNA synthesis on long transcripts. However, SuperScript
III turned out to be unsuitable for the template-switching 5’RACE because the enzyme has a greatly
reduced cap-dependent oligo-C addition activity.
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Figure 6-2 Cloning of the mCBCP cDNA.
A. CBCP locus on mouse chromosome 4. All exons detected from the cDNA clones are shown. Exons
and introns are drawn to scale. B, C. Cloned CBCP cDNA fragments. Location and splicing in the partial
CBCP cDNA clones are shown. Grey boxes correspond to the exons from panel B that the partial clone
contains. Clone names are indicated. D. The initial cDNA prediction. Predicted mouse CBCP cDNA, 
which was used for primer design is shown as a horizontal yellow bar. The grey bars at both ends of the
cDNA show the untranslated regions, which were not a part of the original prediction and are presented to
show the UTR primer location. Glyphs of different shape on top of the cDNA show regions encoding
CSPG repeats (rectangle), Calx-E domain (hexagon) and CTLD (rounded rectangle). Exon boundary
positions are shown as vertical lines (blue if they match the boundaries determined from the cloned
sequence, red if not), with predicted exon numbers indicated next to them. Primer locations are shown as
green (annealing temperature ~60º) and brown (annealing temperature ~70º) arrows above (forward
primers) and below (reverse primers) the cDNA.
6.2.2 Results 
Tissue specificity of expression 
To identify the best source of RNA for CBCP cloning and to characterize the tissue 
specificity of the CBCP expression, I screened a panel of first-strand cDNAs 
synthesized with random hexamer first-strand primers from total RNA from 13 mouse
tissues and found that CBCP is expressed in skin, skeletal muscle, spleen, brain, liver, 
heart, kidney and lung (Figure 6-3). I also observed CBCP expression in small intestine 
and bone marrow, but the results were inconsistent for different sets of primers (data not 
shown). Lung and kidney cDNAs gave the most reproducible results in the PCR 
amplifications, so I mainly used them for cloning. The specificity of amplification with
different primer combinations was always higher in lung than in kidney. 
Figure 6-3 RT-PCR analysis of CBCP expression specificity
A CBCP region of 400 bp was amplified with primers overlapping exon boundaries from the random-
hexamer primed first-strand cDNA synthesized from RNA extracted from different mouse tissues. 35 and
40 amplification cycles were used. E-actin was used as a housekeeping control. 
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Cloned fragments
The structure of the predicted mouse CBCP (mCBCP) CDS is shown in Figure 6-2. 
I consecutively cloned and sequenced 8 fragments of CBCP from mouse lung: 3-1-11 
(primers M14 and M9), 2.5K (M12 and M16), RACE-5 (reverse primer M18), RACE-3 
(forward primer M26), CBCP-5 (M24 and M18), Lung-long (M37 and M38), mCBCP-
CDS1-5 and mCBCP-CDS1-6 (Appendix C). The last two fragments were amplified
with primers M39 and M40 that anneal to the 3’- and 5’ untranslated regions, and thus 
include the whole CDS of the mCBCP. mCBCP-CDS1-6 corresponds to the predicted 
full-length sequence, while mCBCP-CDS1-5 is 2.5 kb shorter and lacks most of the 
NG2 domain. It is not clear whether the mCBCP-CDS1-5 fragment is a product of 
alternative splicing or represents a PCR artifact. However, the fact that the sequences of 
the splice sites that must be used to produce mCBCP-CDS1-5 do not match the GU/AG 
consensus suggests that the latter is the case. 
Comparison of the sequence of the longest cloned fragment (mCBCP-CDS1-6, 
Appendix D) with the similarly spliced transcript predicted from the genomic DNA 
sequence from the v.30 NCBI mouse genome assembly revealed five differences
between the two sequences. As the differences were not observed at the same positions 
in other overlapping cloned fragments, they most likely represent PCR artifacts. Four of
the five differences were single-nucleotide substitutions, two of them non-coding. The 
fifth difference corresponded to a two-nucleotide frame-shifting deletion in the cloned 
fragment. To correct the frame shift, the region containing the two-nucleotide deletion 
in the mCBCP-CDS1-6 clone was replaced with the corresponding region from the 
mCBCP-Lung-long clone using the Acc I  restriction endonuclease, whose two 
recognition sites are conveniently located at both ends of the region containing the 
deletion, The re-engineered clone (mCBCP-CDS1-6L) was partially sequenced to 
confirm that the deletion was eliminated and that the restriction digestion sites were
properly re-ligated (Appendix E). 
The sequences of the cloned fragments confirmed that the overall domain structure 
of CBCP was predicted correctly. Moreover, about 2/3 of the actual exon-intron 
boundaries matched the ab initio GenScan predictions made on the Fugu genomic
sequence and mapped to the mouse CBCP locus.
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The 3’ and 5’ untranslated regions (UTRs), which were not covered by the 
prediction, were determined using the rapid amplification of cDNA ends (RACE) 
technique. The 3’ UTR of the mouse CBCP transcript is 2.5 kb long, which suggests an 
explanation for the absence of EST sequences for mouse CBCP from the databases. The 
predicted transcription initiation site (ATCATGC) does not match the Kozak consensus 
sequence (ACCATGG: Kozak 1987), but is preceded by several stop codons in all three 
reading frames, which suggests that the prediction is correct. 
Alternative splicing 
There are differences in splice-site positions and exon usage between the various 
mCBCP fragments I cloned and the sequences of partial mouse CBCP cDNAs from the 
Fantom database. Alternative splice-site usage in most cases leads only to minor
changes of the overall transcript size, which are beyond the resolution of agarose gel 
electrophoresis. For example, my clones 3-1-11 and Lung-long, and a cDNA fragment
D430009N09 from the Fantom database have a different exon 6 acceptor splice-site 
position. In each case the AG consensus is maintained. Because of these differences 
Lung-long has additional 2 amino acids compared with D430009N09, while 3-1-11 
contains a 2 bp insertion generating a frameshift and a premature stop codon in the 
same exon. Another similar variation is observed in the CTLD-encoding region, where I 
identified two variants of the acceptor splice site of exon 36, which are separated by 6 
nucleotides, in the cloned CTLDs.
Two cDNA sequences suggest that major exon skipping events may contribute to 
CBCP product diversity. The first one is the short variant of the mCBCP CDS (clone 
mCBCP-CDS1-5), which is produced by skipping of 18 exons (6-23) in the NG2 
region. Interestingly, alternative splice sites are used in the short-form sequence at both 
ends of the skipped region, maintaining the reading frame. None of the other known 
CBCP sequences uses these splice sites and they don’t match the GT-AG consensus. 
The second example is the human CBCP cDNA HSM806203, which appeared in the 
database after I cloned most of the mCBCP CDS. In HSM806203, the region 
corresponding to exons 21-30 is skipped, leading to a stop codon in exon 31 and the 
absence of the Calx-E-CTLD region from the translation. 
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6.3 Discussion 
The most prominent feature of mCBCP is the long domain at its N-terminus, which 
makes it part of a poorly studied family of large transmembrane or extracellular proteins 
defined by the presence of a region homologous to the region between amino acids 400 
and 2200 of the rat NG2 protein (the NG2-like domain). It has been shown recently 
(Staub et al. 2002) that NG2-like domains have a repetitive structure and contain a 
variable number of chondroitin sulphate proteoglycan (CSPG) repeats. Although 
phylogenetic distribution of the NG2 domain is very similar to that of the CTLD, it is 
found in a limited number of very well conserved proteins that perform specific 
functions. Therefore, the function of CBCP will be largely defined by the function of 
this domain.
6.3.1 Known NG2 family proteins
Six different members of the NG2 family have been described so far in the 
literature, and protein database searches reveal uncharacterized sequences from C.
elegans, Drosophila and prokaryotes (Staub et al. 2002). The characterized group 
members include: NG2 protein from rat, and its mouse (AN2) and human
(MCSP/HMW-MAA) orthologues, ECM3 protein from sea urchin and Fras1 proteins 
from mouse and human. All characterized members are transmembrane proteins with a 
large (2200-3900 AA) extracellular part and a small intracellular domain. The NG2-like 
domains of the characterized group members contain between 12 and 15 CSPG repeats 
(Figure 6-4). 
NG2/MCSP/AN2
The first member of the family, the NG2 (nerve/glial antigen 2) protein from rat 
brain, was discovered more than 23 years ago (Stallcup 1981) and its full-length cDNA 
cloned and sequenced in 1991 (Nishiyama et al. 1991a). Both human and mouse
orthologues were isolated subsequently. The human sequence is known as human
melanoma-associated chondroitin sulphate proteoglycan (MCSP`; Pluschke et al. 1996), 
or human high-molecular-weight melanoma-associated antigen (HMWMAA), while the 
mouse sequence is called AN2 (Schneider et al. 2001; Niehaus et al. 1999). All three 
mammalian orthologues are very well conserved (83% identity between human and 
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rodent sequences over the whole length of >2300 amino acids), and I’ll refer to them
jointly as NG2 (reviewed recently by Stallcup 2002).
Figure 6-4 Domain structure of the NG2 family members
Domains and proteins are drawn to scale. The NG2-like domain containing 12-15 CSPG repeats is
enclosed between dashed lines. Other symbols for uncharacterized domains are used to indicate 
homology of the corresponding regions in different proteins
The NG2 protein is expressed on glial cells in the CNS and on various cells of 
mesenchyme origin in other tissues, and its expression seems to be connected to a semi-
differentiated state of the cell, characterized by increased proliferation and migration. In 
CNS, NG2 is expressed on the O2A glial progenitor cells capable of differentiating into
oligodendrocytes or type II astrocytes (Stallcup and Beasley 1987), but not on mature
cells of the same lineage or undifferentiated neural progenitor cells (Stallcup 2002). 
Similarly, NG2 is expressed on immature chondroblasts and down-regulated during 
their differentiation into chondrocytes (Nishiyama et al. 1991b), on developing 
cardiomyocytes, on microvasculature pericytes during both normal (Ozerdem et al.
2001) and pathological (Burg et al. 1998) angiogenesis, and on epidermal stem cells 
(Legg et al. 2003; Ghali et al. 2004). Consistent with these observations, NG2 
expression is induced during oncogenic transformation. NG2/MCSP becomes expressed 
early in melanoma progression (Pluschke et al. 1996), is found on >90% of melanoma
tissues and cultures (de Vries et al. 1986) and increases metastatic and tumorigenic 
properties of mouse melanoma cells (Burg et al. 1998). NG2 is also found on 
glyoblastomas (Chekenya et al. 1999), chondrosarcomas (Leger et al. 1994), and 
lymphoid leukemias (Smith et al. 1996).
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The extracellular domain of NG2 has been shown to bind platelet-derived growth 
factor-AA (PDGF-AA) and basic fibroblast growth factor (bFGF) (Goretzki et al.
1999), matrix metalloproteinase MT3-MMP (Iida et al. 2001), kringle domains of 
plasminogen and angiostatin (Goretzki et al. 2000) and collagen VI (Burg et al. 1996). 
The NG2 core protein has an expected molecular weight of ~250 kDa and is 
modified by N-glycosylation, increasing MW to 300, 330 and 250 kDa in rat, mouse
and human NG2, respectively, and chondroitin sulfate (CS) chain attachment, which 
generates a smear of higher-molecular weight species on the NG2 immunoblots that can 
be removed by chondroitinase ABC treatment (Spiro et al. 1989; Schneider et al. 2001; 
Bumol and Reisfeld 1982; Niehaus et al. 1999). Binding experiments have shown that 
CS attachment is not required for, but in some cases affects, NG2 binding to collagen 
VI (Burg et al. 1996), bFGF and PDGF-AA (Goretzki et al. 1999), and kringle-domain
proteins (Goretzki et al. 2000). Another set of experiments has shown that although CS 
is not involved in the interaction, its attachment may induce conformational changes in 
the core protein required for binding of collagens V and VI (Tillet et al. 1997). In the 
sequence analysis presented in Nishiyama et al. (1991a), two putative CS attachment
sites at serines 999 and 1342 were predicted. Experiments with the S999A and S1342A 
NG2 mutants have shown that only Ser-999 is used for CS attachment in the two cell 
lines tested (B28 glyoma and U251 astrocytoma) (Stallcup and Dahlin-Huppe 2001). 
NG2 glycanation is dependent on the physiological status of the tissue and age and is 
higher in developing or regenerating tissues (Schneider et al. 2001; Morgenstern et al.
2003).
ECM3
The ECM3 protein from sea urchin (Lytechinus variegatus) was identified from a 
cDNA library screen using a polyclonal antiserum raised against partially purified 
blastocoelar ECM (Wessel and Berg 1995). The ECM3 cDNA sequence, which was 
determined from overlapping cDNA library clones (Hodor et al. 2000), translates into a 
transmembrane protein of 3103 amino acids with a small cytoplasmic domain. The 
extracellular part contains an NG2-like domain with 12 CSPG repeats, a tandem of 5 
Calx-E domains and two regions (at the N-terminus and between the Calx-E and TM 
domains) not similar to other known proteins. The anti-ECM3 antibody stains distinct 
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fibers underlying the basal lamina of the sea urchin embryonic epithelium and 
interacting tightly with the migrating primary mesenchyme cells. On Western blots 
ECM3 appears as bands of 240, 180 and 50 kDa, the intensity of which varies at 
different stages of embryonic development (Wessel and Berg 1995). However, a single 
full-length band is seen on RNA blots at all stages, suggesting that multiple ECM3 
variants are generated post-translationally. It is not clear why all detectable ECM3 
forms are significantly smaller than the predicted full-length core protein (~338 kDa) 
and there is no information on ECM3 glycosylation. 
Fras1
The Fras1 protein is encoded by a locus associated with the Fraser syndrome
(OMIM 219000) in human (McGregor et al. 2003) and a similar bl/bl blebbed 
phenotype in mouse (Vrontou et al. 2003). Both conditions are multisystem
malformations comprising cryptophtalmos, syndactyly and renal defects and are caused 
by loss of tight association between epidermis and dermis (Vrontou et al. 2003; 
McGregor et al. 2003). Fras1 is expressed in kidney, pancreas and thalamus (McGregor
et al. 2003). Vrontou et al. did not report any immunoblotting experiments, so the 
properties of the expressed Fras1 protein are not known. In the Fras1 knockout mouse,
out of the several ECM proteins tested, only collagen VI distribution was different from 
the wild type (Vrontou et al. 2003), which is intriguing, taking to account the well 
established interactions between collagen VI and the rat NG2 protein (Burg et al. 1996). 
Another parallel between NG2 and Fras1 has been revealed in a recent study which 
showed that both the NG2 and Fras1 cytoplasmic domains interact with the PDZ 
domain-containing protein Grip1 (Takamiya et al. 2004). Moreover, it has been shown 
that Grip1 knockout mice have a blebbed phenotype and that NG2, Fras1 and collagen 
V and VI distributions are altered in these animals, suggesting that there is a direct 
interaction between epidermal Fras1 and dermal NG2 (Takamiya et al. 2004). 
Fras1 is the largest of the known NG2 family members – the predicted full-length 
product is 4010 amino acids long. The C-terminal region of Fras1 is similar to the
C-terminal region of ECM3 and contains an NG2-like domain with 12 CSPG repeats, 5 
Calx-E domains, a region not similar to any other protein, and a transmembrane and a 
cytoplasmic domain (Figure 6-4). However, unlike ECM3, Fras1 has two additional N-
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terminal repeat regions, containing von Willebrand factor type C and furin-like
domains.
Blebbed phenotype has been associated with five mouse mutations, four of which 
have chromosomal localization: bl, my, eb, heb. It is now known that bl is caused by a 
null mutation of Fras1. Interestingly, my and heb mutations map to the chromosomal
regions harboring two other NG2 family genes I found (see the NG2 genomics section), 
ECM3-M1 (Ch 3) and CBCP (Ch 4), respectively. The heb locus was mapped to 4 cM 
from the pintail (Pt) locus on Ch 4 (Varnum and Fox 1981), which is approximately the 
CBCP location. As to my, there are two indications that it is caused by a mutation in the 
mECM3-M1 gene. First, ECM3-M1 in the current mouse genome assembly is very 
close to the mapped my position (Ch 3 D). Second, Takamiya et al. found a partial 
ECM3-M1 cDNA sequence in the database (they refer to it as BAC27425) because of 
its similarity to Fras1 (32%). The partial cDNA contains a fragment of the unknown C-
terminal domain and transmembrane and intracellular domains of the predicted 
mECM3-M1. Takamiya et al. have shown that the cytoplasmic domain of the identified
sequence can also bind Grip1 (Takamiya et al. 2004). Takamiya et al. have also shown, 
that the eb mutation maps to the Grip1 locus. These observations suggest an interesting 
hypothesis that all known mutations causing blebbed phenotype may be associated with 
the NG2 protein family.
Uncharacterized sequences containing CSPG repeats 
Staub et al. who discovered the repetitive nature of the NG2-like domain identified
several uncharacterized sequences apart from the NG2 and ECM3 proteins containing 
the same repeat(s) (Staub et al. 2002), including the C48E7.6 protein from C. elegans
(GI:7497613), the CG10275 protein from D. melanogaster (GI:7298451), two 
hypothetical proteins from human, which are fragments of the true NG2 family
members1, and a hypothetical sequence HieB from Nostoc cyanobacteria (GI:9858192). 
A search in the current GenPept database with the CSPG profile HMM reveals several
new CSPG repeat-containing sequences that have been added to the database since 
1 KIAA1920 maps to Ch, 15 8.26 M (NCBI 31) and corresponds to hNG2-H8 in my current naming,
while FLJ22031 is a fragment of hFras1.
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2002. These include full-length Fras1 sequences from human and mouse described 
above (McGregor et al. 2003; Vrontou et al. 2003) and a fragment of human Fras1 
(GI:32443381) from a high-throughput sequencing project; NG2/AN2 from mouse
(GI:17225630) (Stegmuller et al. 2002); two small fragments of mouse (GI: 26342825) 
and human (GI:21410278) CBCPs; a partial cDNA (3’-end fragment) of the mouse
NG2 paralogue (NG2-2 in my annotation, see the NG2 genomics section) and a 
predicted protein from a marine planctomycete Pirellula sp. (GI:32443381). The latter 
sequence, which is 7716 amino acids long and is encoded by the biggest ORF in the 
genome of that bacterium (Glockner et al. 2003), is the most interesting of the new 
sequences, as together with a single CSPG domain it contains several CTLD, laminin G 
and cadherin domains, all of which are almost exclusively found in Metazoa. 
6.3.2 Structure of the NG2 domain
Although NG2 homologues have been studied for more than 20 years, the repetitive 
nature of their extracellular domain, which is its key structural feature, was only 
recognized recently (Staub et al. 2002). Prior to that, a model was used in which the 
NG2 extracellular domain was divided into three domains, two globular (D1, D3) and 
one extended (D2) (Nishiyama et al. 1991a; Stallcup 2002). Staub et al. named the 
repeating region chondroitin sulfate proteoglycan (CSPG) repeat and noted its weak 
similarity to the cadherin domain. Secondary structure prediction results in a series of 
short E-strands, which is in a good agreement with the E-sandwich cadherin domain
structure (PDB ID 1ncj).
CSPG repeats have a distinct sequence signature (Figure 6-5 and Figure 1 in Staub 
et al. 2002). The most prominent feature is a conserved residue motif at the C-terminus
(Figure 6-5, alignment columns 114-131), containing an almost absolutely conserved 
phenylalanine residue. The following QXD motif is also highly conserved. Although 
Staub et al. reported only two negatively charged residues in the CSPG repeat and 
suggested that it is not likely to bind Ca2+ in a similar manner to the N-cadherin domain,
my alignment suggests that in NG2 and CBCP repeats there are a few more well 
conserved positions occupied by negatively charged residues (columns 28-30, 46, 62, 
65, 141, 149). In fact, almost all of the CSPGs repeats of both NG2 and CSPG are 
mildly acidic (pI ~ 5). 
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In the cadherin domain structure (1NCJ) three Ca2+ atoms are bound in the cavity 
between two domains by the negatively charged residues contributed by the linker 
region and the loops from the adjacent domains. It is possible that CSPGs bind calcium 
by the same mechanism. However, CSPG tertiary structure models built on the basis of 
the N-cadherin domain structure (following the alignment reported by Staub et al. or an 
alternative alignment created by me (not shown)), do not explain the absolute 
conservation of phenylalanine and the QXD motif. In the models based on both 
alignments, the phenylalanine is hidden inside the hydrophobic core and located on a E-
strand in the position corresponding to the N-cadherin domain positions F74/Y1861 in 
my alignment or F51/F162 in the alignment published by Staub. This arrangement,
however, brings the conserved Gln and Glu, which are at positions +2 and +4 from the 
Phe and, therefore, on the same side of the strand, inside the domain core. If the model
is correct, such an arrangement may suggest the presence of another cation-binding site 
inside the domain, as there is no sufficiently conserved partner to form a polar 
interaction with the conserved negatively charged sidechains. 
1 The 1ncj structure contains two different N-cadherin domains, each of which can be used as a 
template.
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6.3.3  NG2 family genomics
I have performed a whole-genome search in the current human and mouse genome
sequence assemblies using a method similar to that I used to identify CTLD-encoding 
genes in the Fugu genome: this revealed a set of undescribed loci encoding putative 
NG2 family members. As in the case of CBCP, the loci encoding the novel NG2 family
members that I found are not covered by reasonable gene predictions either in the 
EnsEMBL or NCBI annotations. This can be explained by the large size of the 
predicted transcripts, lack of cDNA or EST sequences extending far enough from the 
end into the coding sequence and only moderate similarity with the closest known 
homologue.
Mouse
I found two ECM3 gene paralogues in mouse, ECM3-M1 and ECM3-M2 located on 
chromosomes 3 and 8, respectively. ECM3-M1 is very well conserved; the identity 
between the sea urchin and the predicted mouse sequences is 52%. The predicted 
ECM3-M2 is also highly similar to the sea urchin protein (43% ID), but in the current 
assembly only the 5’ fragment can be predicted. The region containing EMC3-M2 is 
assembled from very small contigs, so it is most likely that the 3’ end is missing
because of the incomplete sequence. ECM3-M1 is expressed, and its cytoplasmic
domain has been characterized functionally (discussed on p. 134). The gene encoding 
the published mouse NG2/AN2 protein has two paralogues, NG2-M1 and NG2-M2 on 
chromosomes 13 and 2, respectively, which are also well conserved (30-50% identity
with the known mouse NG2 sequence). At least one of them is expressed (NG2-M1, 
partial cDNA BC067074.1). Both Fras1 and CBCP genes are present in the mouse
genome in a single copy. 
Human
The human genome also has two ECM3 paralogues, ECM3-H1 and ECM3-H2, 
located on chromosomes 4 and 13, respectively. ECM3-H2 is covered by a curated 
prediction from the Vega project. As in mouse, a single copy of both Fras1 and CBCP 
genes was detected. However, the number of NG2 paralogues is much higher in human 
138
Chapter 6 CBCP  cloning 
than in mouse. The gene encoding the characterized NG2/MCSP transcript is located on
chromosome 15. Adjacent to it are its 7 copies (NG2-H2 – NG2-H8), which would 
seem to have arisen as a result of recent segmental duplications. Some of the copied 
genes are annotated as, and probably are, pseudogenes, and for some of them only a part 
of the original NG2 sequence can be predicted. But there is evidence that several of
these paralogues are expressed. For example, the C-terminus of the predicted NG2-H6 
corresponds to the putative protein KIAA1920 from GenBank, and I have found ESTs 
confirming the expression of hNG2-H5. It seems that the same region that was 
duplicated on chromosome 15 was copied to the Y chromosome, as two other NG2 
paralogues (hNG2-H9 and hNG2-H10), which are found there are adjacent to the 
paralogues of the same gene that is found on Ch15 next to NG2/MCSP and its copies 
(Golgi autoantigen golgin subfamily a member 2, GM130). The Y chromosome NG2 
copies are pseudogenes. Finally, another putative NG2 locus (hNG2-H1) is found on Ch 
8, in the region syntenous to the region on mouse Ch 13 where NG2-M1 is located. 
However, unlike its mouse orthologue, the human gene is most likely silent, as it was 
not possible to build a gene model encompassing all the domains found in NG2 and the 
coding sequence is not very well conserved. There is a possibility that the NG2-H1 
locus is misassembled, as it is located in a pericentromeric region of the Ch 5, and the 
region was assembled from short fragments.
Multiplication of the human and mouse NG2/MCSP/AN2 genes may have 
interesting functional implications. As more than one of the paralogues is expressed and 
the similarity between them is high, a possibility exists that the NG2/MCSP function 
described in the literature is in fact composite.
6.4 Conclusions 
Both CBCP and the family it belongs to are extremely interesting taking into 
account the high conservation levels of the sequences from distantly related species and 
the roles the characterized members play. At the moment we can say very little about 
the function of CBCP. The domain architecture of CBCP leaves little doubt that it is a
secreted extracellular protein. An endoplasmic reticulum membrane translocation signal
peptide (residues 1-29) is predicted with a 1.0 probability by the SignalP programs
(Bendtsen et al. 2004), and both the NG2 and CTLD domains are only found
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extracellularly. Because CBCP is so conserved between fish and mammals (Appendix 
F), it is likely to play an important role in development or tissue integrity maintenance.
To my knowledge, CBCP is the first NG2-containing protein expressed at high levels in 
lung. Its organ-level expression profile resembles more that of NG2 than of Fras1. The 
fact that CBCP is found in multiple organs does not necessarily mean that it is 
ubiquitous, as just like NG2 it may be expressed by, or interact with, a limited
population of cells. It is not clear whether CBCP is a proteoglycan. Of the known 
family members only NG2 glycosylation has been studied. Judging from the ECM3 
Western blot pictures, it is not heavily glycosylated and doesn’t contain a GAG chain. 
The CBCP sequence does have 18 potential N- and several O-glycosylation motifs, but 
there is no region matching the experimentally established rat NG2 CS attachment site. 
Further computational studies of CBCP may provide more clues about its function. 
Two regions of CBCP are currently “unknown domains”. The first one is between the 
signal peptide and the first CSPG repeat and is homologous to the N-terminal domain of 
ECM3. This region is one of the most conserved parts of CBCP from fish and mammal.
Application of fold recognition, pattern finding and profile-based searches may shed 
some light on the function of this domain. The second region is between the Calx-E and 
CBCP domains. It is less conserved and not found in other NG2 members.
The cloned full-length cDNA of murine CBCP provides a foundation for 
characterizing the biology of this interesting protein. Experimental studies aimed to 
characterize its expression and interactions with other proteins are currently underway 
or planned in the near future. The immediate plans include determination of the precise 
localization of the CBCP expression by in situ RNA hybridization and 
immunohistochemistry, testing of the hypothesis that CBCP is connected to the blebbed 
phenotype in mouse by screening the CBCP exons in the heb mouse genomic DNA for 
possible mutations, and analysis of the CBCP alternative splicing by Northern blotting
and real time PCR to identify the relative abundance of the different splice forms.
This further work, however, is beyond the scope of my PhD project. 
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Summary and conclusions 
The overall goal of the project was to analyze the structure, function and evolution 
of the CTLD fold in silico. Several studies using very different approaches and methods
to achieve this goal have been performed.
Stability and adaptability of the CTLD fold has been studied by comparing 37 
distinct CTLD structures. This study resulted in the assignment of structural roles to a 
set of positions that were previously described as conserved based on sequence analysis, 
and to identification of several new positions and interactions that were not described
before. The goal of another study was to expand the set of known CTLD structures with
CTLDs from C. elegans by suggesting them as targets for a high-throughput structure 
determination project carried out by RIKEN Genomic Sciences Center; 70 CTLDs have
been considered so far in the structural genomics pipeline, and one structure has been 
completely solved already by RIKEN. 
The evolution of the vertebrate CTLD groups has been studied by identifying the 
family members encoded by the Fugu rubripes genome and comparing them with their 
mammalian orthologues. The study revealed that most of the groups appeared early in 
vertebrate evolution, and did not undergo major changes in domain architecture or 
number of members during the 450 million years of independent evolution of fish and 
mammals. But the study also showed that several groups are much more evolutionarily 
flexible than others. Importantly, several novel members of the family were identified - 
some with the aid of systematic analysis of the information from the expressed 
sequence databases, others only as a result of comparison of fish and mammalian
genomic DNA sequences. This study demonstrated the power of comparative genomics,
and shed light on the early history of vertebrate CTLD evolution.
One of the novel sequences predicted using the comparative genomics approach was 
CBCP, a putative large extracellular protein from the NG2 family. Cloning of the 
mouse CBCP cDNA confirmed the prediction and showed that a combination of 
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genomic sequence comparison, ab initio gene-structure prediction and comparison with 
distant homologues can produce very precise gene predictions, which not only capture 
the overall structure of the gene but also correctly predict most of the exon/intron
boundaries. Analysis of the literature on the known NG2 family members suggests that 
CBCP is linked to important physiological processes and may be responsible for 
inherited developmental disorders in mammals. Cloning of mCBCP cDNA, which is 
among the largest mammalian transcripts, was an important initial step in CBCP 
research; functional studies of the protein have already been started and will continue in 
my supervisors’ laboratories. 
The studies, which I carried out, would not be possible without an appropriate
bioinformatics infrastructure. The annotated collection of the CTLD sequences stored in 
a relational database and accessed both programmatically and interactively through the 
interfaces that I have developed, helped to consolidate and analyze the information on 
the family and was very useful in virtually every study that I performed.
I hope that the results presented in this thesis have demonstrated the advantages of 
the applied bioinformatics approach. In silico analysis of CTLD sequences and 
structures not only extended the descriptive framework of the domain, but also 
generated some experimentally testable hypotheses. One of the predictions has been 
confirmed by me in the final stage of my project, and I hope that the description of 
systematic studies that we published will lead others to confirm the other findings.
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Appendix B CTLDs in Fugu 
B.CTLD-encoding genes identified in the Fugu
rubripes genome
All Fugu CTLDcps identified in the Fugu genome analysis are listed. Columns 3 
and 4 contain stable identifiers for gene models in the v.2 and v.3 assembly databases, 
respectively. Identifiers starting with ANUFRU and ANUFR2 belong to my predictions 
on the v.2 and v.3 assemblies, respectively, and are underlined. EnsEMBL gene stable 
identifiers are given if the original predictions were used. Bolded members denote Fugu
proteins matched with novel human orthologues. 
Name Description v.2 gene ID v.3 gene ID 
I  Hyalectans 
AGGRECAN AGGRECAN ANUFRUG00000000095 ANUFR2G00000000089
AGGRECAN-F1 Fugu aggrecan paralogue ANUFRUG00000000081 ANUFR2G00000000077
BREVICAN BREVICAN SINFRUG00000078610 SINFRUG00000151617
BREVICAN-F1 Fugu brevican paralogue SINFRUG00000074933 SINFRUG00000128229,
SINFRUG00000128230,
SINFRUG00000128231
NEUROCAN NEUROCAN SINFRUG00000054833 SINFRUG00000150572,
SINFRUG00000150573,
SINFRUG00000150574,
SINFRUG00000150576
NEUROCAN-F1 Fugu Neurocan paralogue ANUFRUG00000000142 ANUFR2G00000000154
VERSICAN VERSICAN ANUFRUG00000000144 ANUFR2G00000000164
VERSICAN-F1 Fugu versican paralogue (fragment
containing EGF, CTLD and CCP 
domains)
ANUFRUG00000000061 ANUFR2G00000000059
VERSICAN-F2 Fugu versican paralogue (fragment
containing link and Ig domains)
ANUFRUG00000000043 ANUFR2G00000000041
II  Dendritic cell receptors, mono-ctld macrophage receptors, ASGR 
DC-SIGN-F1 Fugu DC-SIGN paralogue ANUFRUG00000000029 ANUFR2G00000000027
DC-SIGN-F2 Fugu DC-SIGN paralogue ANUFRUG00000000067 ANUFR2G00000000063
DC-SIGN-F3 Fugu DC-SIGN paralogue ANUFRUG00000000069 ANUFR2G00000000065
DC-SIGN-F4 Fugu DC-SIGN paralogue ANUFRUG00000000071 ANUFR2G00000000067
DC-SIGN-F5 Fugu DC-SIGN paralogue ANUFRUG00000000073 ANUFR2G00000000069
DC-SIGN-F6 Fugu DC-SIGN paralogue ANUFRUG00000000109 ANUFR2G00000000105
DC-SIGN-F7 Fugu DC-SIGN paralogue ANUFRUG00000000085 ANUFR2G00000000123
DC-SIGN-F8 Fugu DC-SIGN paralogue ANUFRUG00000000087 ANUFR2G00000000081
DC-SIGNR DCSIGN receptor ANUFRUG00000000027 ANUFR2G00000000025
HML2 Similar to human macrophage lectin SINFRUG00000060881 SINFRUG00000120587
SRCL Scavenger receptor with C-type lectin SINFRUG00000071148 SINFRUG00000134389
199
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SRCL-F1 Putative Fugu paralogue of SRCL SINFRUG00000064389 SINFRUG00000152316
XLCMCL eXtra Large Coiled coil region 
containing Membrane C-type Lectin
ANUFRUG00000000053 ANUFR2G00000000051
III  Collectins 
COLEC10 COLEC10 SINFRUG00000077039 SINFRUG00000125405
MGC3279 Uncharacterized collectin family
member
SINFRUG00000064196 SINFRUG00000147955
IV  Selectins
SELECTIN-E E-Selectin ANUFRUG00000000001 ANUFR2G00000000001
SELECTIN-L L-SELECTIN ANUFRUG00000000003 ANUFR2G00000000003
SELECTIN-P P-SELECTIN ANUFRUG00000000005 ANUFR2G00000000005
VI  Multi-CTLD molecules. Macrophage Mannose Receptor (MMR) family 
DEC205 DEC205 ANUFRUG00000000011 ANUFR2G00000000011
Endo180 Endo180 SINFRUG00000058766 SINFRUG00000152106
MManR Macrophage mannose receptor SINFRUG00000071196 SINFRUG00000126868,
SINFRUG00000134363
MManR-F1 Fugu mannose receptor paralogue
(fragment)
SINFRUG00000064600 SINFRUG00000152797
MManR-F2 Fugu macrophage mannose receptor 
paralogue.
ANUFRUG00000000039 ANUFR2G00000000035
ANUFR2G00000000037
MManR-F3 Fugu paralogue of MMR-family gene SINFRUG00000066378 SINFRUG00000152288
MManR-F4 Fugu paralogue of MMR-family gene 
(fragment)
SINFRUG00000078047 SINFRUG00000152861
MManR-F5 Fugu MMR-family member (fragment) ANUFRUG00000000091 ANUFR2G00000000085
PLA2R Phosopholipase A2 receptor ANUFRUG00000000009 ANUFR2G00000000009
VIII  MT-75, layilin 
LAYILIN Layilin ANUFRUG00000000089 ANUFR2G00000000083
LAYILIN-F1 Fugu layilin paralogue ANUFRUG00000000075 ANUFR2G00000000071
MT-75 MT-75 SINFRUG00000084745 SINFRUG00000145404
IX  Tetranectin family
CLECSF1 CLECSF1 SINFRUG00000050048 SINFRUG00000136890
SCGF SCGF ANUFRUG00000000125 ANUFR2G00000000121
TETRANECTIN Tetranectin SINFRUG00000084961 SINFRUG00000144710
TETRANECTIN-F1 Fugu tetranectin paralogue SINFRUG00000083037 SINFRUG00000149544
X  PKD 
PKD1 Polycystic kidney disease protein 1 SINFRUG00000033997
PKD1L2 PKD-1 homologue 2 ANUFRUG00000000121 ANUFR2G00000000117
XI  Attractin family 
ATTRACTIN Attractin SINFRUG00000071911 SINFRUG00000136030
ATTRACTIN-F1 Fugu paralogue of Attractin SINFRUG00000060472 SINFRUG00000147061
KIAA0534 KIAA0534 SINFRUG00000056251 SINFRUG00000121439
XII  Eosinophil major basic protein family 
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EMBPL Putative Fugu EMBP-like protein ANUFRUG00000000023 ANUFR2G00000000021
XIII  DGCR family 
DGCR2 DGCR2 SINFRUG00000082125 SINFRUG00000155593
XIV  Thrombomodulin family 
C1qRP C1qRP ANUFRUG00000000049 ANUFR2G00000000047
C1qRP-F1 Putative Fugu C1qRP paralogue
(fragment)
ANUFRUG00000000013 disappeared
CETM Protein containing CTLD, EGF and
transmembrane domains
ANUFRUG00000000057 ANUFR2G00000000055
ENDOSIALIN ENDOSIALIN ANUFRUG00000000117 ANUFR2G00000000113
THROMBOMOD Thrombomodulin SINFRUG00000077807 SINFRUG00000153798
XV Bimlec 
BIMLEC Novel C-type lectin from BCG cell
wall induced monocyte
ANUFRUG00000000007 ANUFR2G00000000007
XVI SEEC
SEEC Novel SCP-EGF-EFG-CTLD
containing protein.
ANUFRUG00000000041 ANUFR2G00000000039
XVII CBCP
CBCP Calx-Beta and CTLD containing 
protein
ANUFRUG00000000047 ANUFR2G00000000045
AFP  Antifreeze protein 
AFPL-F1 Antifreeze protein-like ANUFRUG00000000045 ANUFR2G00000000043
AFPL-F2 Antifreeze protein-like ANUFRUG00000000139 disappeared
F1  Fugu dual-CTLD molecules
FDC-F1 Putative Fugu dual-CTLD protein 1 ANUFRUG00000000025 ANUFR2G00000000023
FDC-F2 Putative Fugu dual-CTLD protein 2 ANUFRUG00000000037 ANUFR2G00000000033
FDC-F3 Putative Fugu dual-CTLD protein 3 ANUFRUG00000000099 ANUFR2G00000000093
FDC-F4 Putative Fugu dual-CTLD protein 4 ANUFRUG00000000103 ANUFR2G00000000097,
ANUFR2G00000000099
FDC-F5 Putative Fugu dual-CTLD protein 5 ANUFRUG00000000107 ANUFR2G00000000103
FDC-F6 Putative Fugu dual-CTLD protein 6 ANUFRUG00000000123 ANUFR2G00000000119
FDC-F7 Putative Fugu dual-CTLD protein 7 ANUFRUG00000000101 ANUFR2G00000000095
FTCP Putative Fugu triple-CTLD protein ANUFRUG00000000015 ANUFR2G00000000013
L  Link domain 
BRAL1 Brain link protein-1 SINFRUG00000078615 SINFRUG00000151615
CD44 CD44 ANUFRUG00000000113 ANUFR2G00000000109
CRTL1 Cartilage linking protein 1 SINFRUG00000078961 SINFRUG00000137046
CRTL1-F1 Putative fugu cartilage linking protein
paralogue
ANUFRUG00000000059 ANUFR2G00000000057
CRTL1-F2 Putative fugu cartilage linking protein
paralogue
SINFRUG00000074643 SINFRUG00000142167,
SINFRUG00000142169,
SINFRUG00000142171
HAPLN3 Hyaluronan and proteoglycan link SINFRUG00000052853 SINFRUG00000155413
201
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protein 3 
HAPLN3-F1 Putative Fugu paralogue of HAPLN3 SINFRUG00000079552 SINFRUG00000129575
Lyve-1 Lymphatic vessel endothelial HA 
receptor-1
ANUFRUG00000000077 ANUFR2G00000000073
STABILIN-1 Stabilin-1 ANUFRUG00000000079 ANUFR2G00000000075
STABILIN-2 Stabilin-2 SINFRUG00000074867 SINFRUG00000146665
TSG-6 TSG-6 SINFRUG00000075173 SINFRUG00000148136
NLSLH
NLSLH Novel L-SeLectin Homologue ANUFRUG00000000055 ANUFR2G00000000053
NLSLH-F1 Fugu CTLD containing gene fragment,
NLSLH paralogue
ANUFRUG00000000097 ANUFR2G00000000091
U  Unclassified 
AGGRECOL Putative Fugu CTLD-containing protein 
equally similar to aggrecan and placenta
collectin.
ANUFRUG00000000083 ANUFR2G00000000079
ANZG001 Putative Fugu CTLD-containing protein
(fragment)
ANUFRUG00000000019 ANUFR2G00000000017
ANZG002 Putative Fugu CTLD-containing protein
(fragment)
ANUFRUG00000000021 ANUFR2G00000000019
ANZG004 Putative Fugu protein with CTLD and
FTP domains
ANUFRUG00000000093 ANUFR2G00000000087
ANZG005 Putative Fugu CTLD-containing protein
(fragment)
ANUFRUG00000000065 disappeared
ANZG006 Putative Fugu CTLD-containing protein
(fragment)
ANUFRUG00000000111 ANUFR2G00000000107
ANZG007 Putative Fugu CTLD-containing protein
(fragment)
ANUFRUG00000000063 ANUFR2G00000000061
ANZG008 Putative Fugu CTLD-containing protein
(fragment)
ANUFRUG00000000017 ANUFR2G00000000015
ANZG010 Putative Fugu CTLD-containing protein ANUFRUG00000000051 ANUFR2G00000000049
ANZG011 Putative Fugu CTLD-containing protein ANUFRUG00000000115 ANUFR2G00000000111
CFN3 Protein with CTLD and FN3 domains. ANUFRUG00000000105 ANUFR2G00000000101
DEC205-FUSE Large Fugu protein which looks like a 
DEC205 fused to another CTLD-
containing gene 
ANUFRUG00000000119 ANUFR2G00000000115
FG75645 Fugu CTLD-containing protein
fragment
SINFRUG00000075645 SINFRUG00000139863
PTP-GMC1 Protein-tyrosine phosphatase expressed
by glomerular mesangial cells 
ANUFRUG00000000130 ANUFR2G00000000137
.
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Appendix C mCBCP CDS1-6 
C.The nucleotide sequence of the mCBCP-CDS1-6 
clone.
>mCBCP-CDS1-6
GGCATTGGAGGAGACCTGCAAACAGTGTGTTTGGGAACTCCAATTCTCTACCTATTTGTTTGTGCGGGTT
AAAGGATTTTTGGCACAAACAAAGCCTAAACTCAGCTGACTAGAACGACTGGAATTTCAGCTCTCCTCCT
TGGATGGGATGTTTTAGCTTCCTCTTCCTCTGACAACTCTTTAAGGCTGTTACCAGGTTAGCATCCAGCC
CTCTACTTCCAAGGGTGGCCAGCCCTTGGCTCGGAAAGAAAACCAGGAACTGATTAGGAAGGCACTTGGG
AGGCACATTAATCTTGCCAGCGTTGTCAGGAATGATCAGCGAGTTTTATTAAAAAGCCCCGATTGCCTGA
AAGGCCTCCTTGTCTGAATCTGAATGGAAGGAGCATGTTAAGGTCTTGGGGCACGCTGTCGGGACCCCTA
GTATTACCCCCTGGACCTCAAGCTGACACTTGGGGAAGAAGTGCAGGAAGCTTGCTTTGTTGAACAGACT
GTGCCTGTGGACAGAGCTGGCCCTGGCATCATGCACTCTCCAGGCTGCACTGGGCCCAAGGCTCAGTGGT
TCTTGCTGCTCCAGCTGCTTCTGCTGCACCTGGACCGGGTCAGTGCCACCTTCATCAGCATCAACCGGGG
CCTGAGGGTGATGAAGGGTAGTTCTGCCTTCCTGTCTGGAGATCACCTGAGGGTTGCAGTCCCTAAAGAA
AAGGACGCCTGCAGACTGGAGGTGGTGATGAACGAGCCCGTAACCCAGAGGGTTGGGAAACTCTCTCCAC
AGGTCTTTGATTGCCATTTTCTTCCCAACGAAGTGAAGTATGTTCACAATGGATGCCCAATTCTGGATGA
AGACTCTGTGAAGCTTAGACTTTACAGGTTTACTGAAACAGACACCTTCATGGAAACCTTTCTCTTGCGG
GTTTATCTTGTGGAACCAGACTGTAACATCATCCGTATGAGCAGTAATGTGTTGGAAGTGACTGAATTCT
ATGGCTTATCGCAAGCCATTGATAAGAACCTGCTCCAGTTTGATTATGATAGGACTGCCAGCCTGGATTG
CACCATCAGACTAGACCCACTGAGGACTCAGCTGCCAGCTCACGGCAAGCTGGTCGTGGTGAATCGTAAG
TCAGAGGGGCCTCGTGGAGATCAGCCACACAGCTTCTTCTCTGAGACAGAGCTAGGGGCTGGACTGAAGT
GTCCAGATGGAAGCTGTGCCCTGGAATTGAAGCAAGTGGCAAGTCTGAAAGTGAGCTGTGAGGAGTTTCT
GCTGACGGGGTTTCACTACCAACACATGCAGCCCCCTTCACCCAACATTGATTACATCCCCATTCAGTTG
GATCTCACCGACAGAAGGAGCAAAACCGTATACAAGTCAGAGAGTGCGTGGTTGCCTGTCTATCAGAGTT
GGCATTCCTAACCAGGTCCCAAGGGCTGCATTTATGGCCATGTTTGTTCTGGAGGTGGACCAGTTCATAC
TGACCCCTCTGACAACCTCCGTTCTGGACTGTGAGGAGGATGAGACTCCGAAACCCTTGTTGGTGTTCAA
CATCACTAAAGCCCCACTCCAGGGCTATGTGACCCACCTGCTGGATCATACCAGACCCATCTCTTCATTC
ACCTGGAAGGATCTCAGTGACATGCAAGTTGCCTACCAGCCACCAAACAGCAGCCACCCTGAGAGGAGAC
ATTACACGATGGAGCTGGAGGTGTACGACTTCTTCTTTGAGAGGAGTGCCCCCATCACTGTCCACATCTC
CATCAGAACAGCAGACACGAATGCACCACGGGTGTCTTGGAATACAGGTTTGAATCTCCTAGAGGGGCAG
TCTCGGGCCATCACTTGGGAACAATTTCAGATCGTTGACAATGATGACATTGGTGCTGTGCAGTTGGTCA
CCATTGGTGGCCTGCAGCATGGACGGCTTACAGTACGAGAGGGGAAAGGATTTCTCTTCACCGTGACTGA
CCTTCAAGCTGGAGTTGTCCGCTATCATCACGATGACAGTGATACCACCAAAGACTTTGTGGCTTTCAGG
ATATTCGATGGCCACCACAGCAGCCACCACAAGTTTCCTATCAACATCTTGCCTAAAGATGACAGCCCCC
CATTCCTCATCACCAATGTCGTGATTGAACTAGAAGAGGGGAAGACCATCTTGATCCAAGGGTCTATGTT
GAGAGCTTCAGATATGGACTCCAGTGATGACTACATCTTCTTTAATATCACAAAGTTTCCACAGGCTGGG
GAGATCATGAAGAAGCCAGGGCCAAGACTGATAGGGTATCCTGTCCCTGGCTTCCTGCAGAGAGACCTGT
TCAGTGGAATCATTTACTATCGTCACTTTGGTGGAGAAATCTTTGAAGATTCCTTTGAATTCGTACTGTG
GGACAGCCATGAGCCTCCAAATCTCTCAGTGCCACAGGTGGTGACAATTCATATCACTCCAGTAGATGAC
CAGCTTCCTAAAGAAGCTCCTGGCATTTCCCGGCATTTGGTTGTCAAGGAAACAGAGGTGGCCTACATCA
CTAAAAAGCACCTACATTTCCTAGACATGGAATCCCGTGATGGGGAACTCATCTACACAGTAACACGCCC
TCCATGTTTCTCCTTCAGCCACAGACACTTGGATGCTGGGAAGCTATTCATGGTGGACAGCATACCAAAG
CTAACCAAAAATCCGACAGCCCCAGGGCTAAGTTCATTTACTCAGCATGCCGTGAACCATATGAAAGTGG
CCTACATGCCACCCATGCAAGATATAGGCCCCTCCCCTCGACATGTGCAGTTCACAGTGTCTGTCAGTAA
CCAGCATGGAGGTGCTTTGCATGGAATCTGCTTCAACATCACAGTTCTCCCAGTGGACAACCAGGTTCCC
GAGGTATTCACCAACACCCTGAGAGTGGTCGAGGGCGGTCAGTGCACCATCAGCACAGAGCACATTTTGG
TTTCTGATGTGGACACCCCGCTAGACAGCATCAGCCTCTCTCTTAAGGAGAGGCCTCTGCATGGCGGGGT
AGAGCTGGACGGATTTCCTCTAAACCCAAGAGGCACATTTTCTTGGCGAGACCTCAATACCTTAAAAGTT
TGGTATCAACATGATGGATCTGAGGTTCTTCAGGATGAGATATTTTTGGAGGTCACAGATGGCACAAATT
CAGCAGCATTTGTTCTCCACATTGAGGTGTTCCCTGTGAATGATGAGCCACCCATTCTGAAGGCTGACCT
CATCCCCATGATGCACTGCTCTGAGGGTGGAGAGGTGACCATCACCCCTGAATACATTTCCGCTACTGAT
GCAGACAGCGATGACTTAGAACTGCTGTTTCTGATTGCCCGAGAGCCTCAGCATGGAGTGGTGAGAAAGG
CTGGACTTCACGTGGACAGGTTCTCTCAGGGAGATGTCATCTCAGGGGCTGTGACATACAAACATACAGG
TGGCGAGATTGGCCTTGAACCTTGTTCTGACACTGTTGTATTGGTGGTTTCGGATGGTGAAGCTGACCCT
TTGATGAACGGCTGTTGCTACGATGGACCTGATTCATCTGTTCCTCTTCATAAGTCCTTCCCCACATACC
AGCTCAACATCACAGTACATCCAGTCGACAACCAGCCACCTTCAATTATAATAGGTAGGATGCTCACAGT
GGATGAAGGCTTCTCAGCAGCCCTTACTACTCATCACTTGACTGTTGTTGATTGGGACACTGCCCCGGAT
GACTTAAAATTCATGTTGGCTTCTCAGCCCCAGTTTGGCTACTTAGAAAACGCACTGCCTTCTGCAGGCT
TTGAGAAAAGTAACATCGGCATAAGGATAGCCTCATTCCAGTGGACAGACATGAAGGCTTCACACATTAA
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CTATGTGCAGTCCAGGCACCTGAGAGTGGAACCAACTGCTGACCAGTTCACAGTATATGCCACAGACGGG
AAGCATCGCTCCTTGGAGACAACATTTCACGTTATCATCAACCCCACAAACGATGAAGCTCCTGACCTTG
CAGTACAGAACATCACTGTGTATGAGGGGCACATGGTAGAACTGGATTCTTCCATCATCAGTGCTACTGA
CAGGGATATTCCCAAGGACCCCTTGCTCTTCAGCATCGCTCTCAAGCCCCAGCACGGCCTGCTCGTCGAT
GCTGCCATCAGCAAGGACTCCCATCAGATCAAGCAGCTGCAACACGAAATCCACAGCTTCTCCGTGGACC
TTCTCAAGAATGGAATGAAGCTGGTCTATGCCCACGACGACTCAGAGAGCTCTGCTGATAACTTCGTGAT
CCAGTTGTCAGACGGGAAACATAAAATCCTTAAAACCATCTCAGTAAACATTACCCCAGTGAATGACGAG
ACACCAACGCTAAGCAAGAAGGCTGAAATCTCAATGGCTGTGGGCGATACTCGCGTCCTGTCTAGTGCTG
TTCTTTCAGCCACAGATAAAGACTCGCCCAGAGAGAAGATTCACTATGTATTTGAAAGACTTCCCCAAAA
TGGACAACTTCAACTTAAGATAGGGAGGGACTGGGTCCCTCTCTCCACTGGCATGCAGTGCACCCAGGAG
GATGTGGACCTGAACTTGCTAAGATACACGCATGCTGGTAAAACGGACTCCCAGGATGGAGACAGCTTCA
CCTTCTACCTCTGGGATGAGGACAACAGGTCACCTGCATTTGACTGTCACATCATCATTGAAGACATGGG
CAAAGGTGATATTGTCATTCATGCAAAACCACTCGTGGTAGTCAAAGGTGACAGAGGTCTCTTGACGACT
GCCACCCTTCTGGCTGTGGATGGAGCAGACAAGCCTGAGGAACTGCTCTACCTCATCACCTCCCCACCAC
GGCATGGCCAAGTGGAGTACGTCCACTCTCCTGGAGTCCCCATTGCCAGCTTCAGCCAAATGGACATAGC
AGGACAGACAGTGTGCTACATACACAAGAGCAGGACAGCTGTCCCCACTGACAGCTCCAGATTTACCATC
AGCAATGGACTGCAGACCCAGCGTGGGGTGTTTGAAATCACACTGCAGACTGTGGACAGCGCCTTGCCTG
TGCTGACCAAGAACAAAAGGCTGAGGCTAGCCGAAGGGGCCATGGGCCTCCTGTCCGCTGATCACCTTCA
GCTGACTGACCCCGACACACCTCCAGAGAACCTGACCTTCTTTCTGGCTCAGCTCCCACGCCACGGGTAC
CTCTTCCTGAGAGGGAAAGCACTCCAACACAACTTCACCCAGCGAGATGTGGACAGCGGGGGCGTGGCCT
ACCAGCACTCAGGAGGCGGCGCCCGGGAGGACTATTTTACTTTTCTAGCCACAGACAGGAAGAACCAAGG
CTTTGTTGTGGATGGGAAAGTTCAGAAAGAGCCTGTTCGCTTCACAATCCAGGTGGATCAGCTGGACAAG
GCAGCGCCCCGTATCACACACTTGCACTCCCCTACTCAAGTGGGGCTCTTGAAAAATGGCTGCTATGGGA
TTTACATCACTTCCCGTGTGCTGAAGGCATCAGACCCTGACACAGAGGATGACCAGATCATCTTTAAGAT
TTTACGAGGCCCATTGTACGGACGTCTGGAGAACACAACAACAGGTGAATTCATCCACGAGCGATTTAGC
CAGAAGGACTTAAGCCATAAGACCATCCTTTACATCATAAACCCTTCTTTGCAAGTGACTTCCGATATCC
TGGAATTTCAGGCCATGGACCCCACAGGGAACACTGCCACTCCCCAGAGCTTGGACTTGAGATGGTCGTA
TATTGAATGGGCCCAGACTGCATATGAGGTTTGTGAGAATGTGGGCTTATTGCCCTTGGAAGTTACCAGA
AGGGGATATCCCATGGACTCAGCCTTTGTGGGTGTAGAGGTTAACCAAGTGTCAGCTACAGTTGGAAAAG
ATTTTACTGTCACTCCATCCAAACTGCTTCAATTTGACCCAGGAATGTCAACTAAGATGTGGAATATAGC
AATTACCTATGACGGATTAGAGGAAGATGATGAGGTCTTTGAAGTAATTCTGAACTCCCCTGTGAATGCG
GTTCTTGGCACGCAGACAAAAGCGGCGGTGAAAATTTTGGACTCAAAAGGAGGACGGTGCCATCCTTCAA
ATTCCTTCAACCAAAGCAAGCACAGCACGTGGGGGAAGGGCCCTTGGCATCCGCTGCCCTCAGGCTCATC
CTCGCTCACCACTTCAGGTTCTCCTCTTCTGGAAAGGCCTCCTCCATCTTTCACCAGTGGAGATGCTCTT
CAGGGTTTTGGTCTCACCGACCTCACTCAAAGGAAGACAATGACCCAGGGGAATGGCAAATCAGTTCTCC
CATCCTCTGTTTGTAGAAATGGGACAGACACCATCTACAATTACCATGGTATAGTTTCCTTGAAACTAGA
GGGCGACAGATTCTCAGCTCACAAACGGAAGGCCAAAATATCCATTGTTAGTCAGCCACAGAGGACAATC
AAGGTGGCAGAGCTGCCTCTAGCTGATAAGGTGGAATCCACAACTGATTTGCACTTTCTCAGACAGGGTC
TGCGGCCCTTGTTTCCAAAGAATTGTTCTGTGGACTTAAAGGGACTCTTTCATTTTGAAGAAAGCACCCA
CAGATTGTATCAATGTGATGGGATCTCCTGGAAAGCCTGGAGCCCCCAAACCAAGGGGCTGGAGGACAGA
TCCTGCCCAGGTGGATGGCTCCTTCATTCTGGCTACTGTCACATCTTGGTCACAAGACAGAAAGGCACCT
GGACCACAGCTACCCGAGCTTGCAGAGAACAGCACCAGGGCGACCTTGTGACCGTACTCTCCAGAAGGCA
TATGCAGTGGCTATGGGCGATGAGTGGAAGAAAACCCTTCTGGATAGGCTTGAAGAACCAACCGAGGACT
GGCCACTGGGAGTGGATCGGAGGTGAACCTGTTGCTTTTACCAACTGGAGGAGAGGGGCCCCTCTGCACC
CAAAACCTGGAAAGAACTGTGCTTTGGTTCAGAAAAGAGGACAATGGCGGACAAAGAACTGTAGCAAAGG
CAAGGCTCACAATTTTGTGTGCTCAAGGAAACTCTGAACACAACCTAGCCTTTCTCATTCATCTATTTAC
AAGATCTATGTGTATTGCCCAGTGAAGATGCGTTGTTGTGGCTGG
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D.Comparison between the predicted and the 
assembled mCBCP-CDS1-6 sequences 
Alignment between the mCBCP-CDS1-6 sequence predicted from the genomic
DNA (query) and assembled from sequencing reads (subject). 
Query: 1    ggcattggaggagacctgcaaacagtgtgtttgggaactccaattctctacctatttgtt 60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1    ggcattggaggagacctgcaaacagtgtgtttgggaactccaattctctacctatttgtt 60 
                              Silent substitution in the 5’ UTR 
Query: 61   tgtgcgggttaaaggatttttagcacaaacaaagcctaaactcagctgactagaacgact 120 
            ||||||||||||||||||||| |||||||||||||||||||||||||||||||||||||| 
Sbjct: 61   tgtgcgggttaaaggatttttggcacaaacaaagcctaaactcagctgactagaacgact 120 
Query: 121  ggaatttcagctctcctccttggatgggatgttttagcttcctcttcctctgacaactct 180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 121  ggaatttcagctctcctccttggatgggatgttttagcttcctcttcctctgacaactct 180 
Query: 181  ttaaggctgttaccaggttagcatccagccctctacttccaagggtggccagcccttggc 240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 181  ttaaggctgttaccaggttagcatccagccctctacttccaagggtggccagcccttggc 240 
Query: 241  tcggaaagaaaaccaggaactgattaggaaggcacttgggaggcacattaatcttgccag 300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 241  tcggaaagaaaaccaggaactgattaggaaggcacttgggaggcacattaatcttgccag 300 
Query: 301  cgttgtcaggaatgatcagcgagttttattaaaaagccccgattgcctgaaaggcctcct 360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 301  cgttgtcaggaatgatcagcgagttttattaaaaagccccgattgcctgaaaggcctcct 360 
Query: 361  tgtctgaatctgaatggaaggagcatgttaaggtcttggggcacgctgtcgggaccccta 420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 361  tgtctgaatctgaatggaaggagcatgttaaggtcttggggcacgctgtcgggaccccta 420 
Silent substitution in the 5’ UTR
Query: 421  gtattgccccctggacctcaagctgacacttggggaagaagtgcaggaagcttgctttgt 480 
            ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 421  gtattaccccctggacctcaagctgacacttggggaagaagtgcaggaagcttgctttgt 480 
Query: 481  tgaacagactgtgcctgtggacagagctggccctggcatcatgcactctccaggctgcac 540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 481  tgaacagactgtgcctgtggacagagctggccctggcatcatgcactctccaggctgcac 540 
Query: 541  tgggcccaaggctcagtggttcttgctgctccagctgcttctgctgcacctggaccgggt 600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 541  tgggcccaaggctcagtggttcttgctgctccagctgcttctgctgcacctggaccgggt 600 
Query: 601  cagtgccaccttcatcagcatcaaccggggcctgagggtgatgaagggtagttctgcctt 660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 601  cagtgccaccttcatcagcatcaaccggggcctgagggtgatgaagggtagttctgcctt 660 
Query: 661  cctgtctggagatcacctgagggttgcagtccctaaagaaaaggacgcctgcagactgga 720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 661  cctgtctggagatcacctgagggttgcagtccctaaagaaaaggacgcctgcagactgga 720 
Query: 721  ggtggtgatgaacgagcccgtaacccagagggttgggaaactctctccacaggtctttga 780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 721  ggtggtgatgaacgagcccgtaacccagagggttgggaaactctctccacaggtctttga 780 
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Query: 781  ttgccattttcttcccaacgaagtgaagtatgttcacaatggatgcccaattctggatga 840 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 781  ttgccattttcttcccaacgaagtgaagtatgttcacaatggatgcccaattctggatga 840 
Query: 841  agactctgtgaagcttagactttacaggtttactgaaacagacaccttcatggaaacctt 900 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 841  agactctgtgaagcttagactttacaggtttactgaaacagacaccttcatggaaacctt 900 
Query: 901  tctcttgcgggtttatcttgtggaaccagactgtaacatcatccgtatgagcagtaatgt 960 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 901  tctcttgcgggtttatcttgtggaaccagactgtaacatcatccgtatgagcagtaatgt 960 
Query: 961  gttggaagtgactgaattctatggcttatcgcaagccattgataagaacctgctccagtt 1020 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 961  gttggaagtgactgaattctatggcttatcgcaagccattgataagaacctgctccagtt 1020 
Query: 1021 tgattatgataggactgccagcctggattgcaccatcagactagacccactgaggactca 1080 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1021 tgattatgataggactgccagcctggattgcaccatcagactagacccactgaggactca 1080 
Query: 1081 gctgccagctcacggcaagctggtcgtggtgaatcgtaagtcagaggggcctcgtggaga 1140 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1081 gctgccagctcacggcaagctggtcgtggtgaatcgtaagtcagaggggcctcgtggaga 1140 
Query: 1141 tcagccacacagcttcttctctgagacagagctaggggctggactgaagtgtccagatgg 1200 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1141 tcagccacacagcttcttctctgagacagagctaggggctggactgaagtgtccagatgg 1200 
Query: 1201 aagctgtgccctggaattgaagcaagtggcaagtctgaaagtgagctgtgaggagtttct 1260 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1201 aagctgtgccctggaattgaagcaagtggcaagtctgaaagtgagctgtgaggagtttct 1260 
Query: 1261 gctgacggggtttcactaccaacacatgcagcccccttcacccaacattgattacatccc 1320 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1261 gctgacggggtttcactaccaacacatgcagcccccttcacccaacattgattacatccc 1320 
Query: 1321 cattcagttggatctcaccgacagaaggagcaaaaccgtatacaagtcagagagtgcgtg 1380 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1321 cattcagttggatctcaccgacagaaggagcaaaaccgtatacaagtcagagagtgcgtg 1380 
                              Dinucleotide deletion
Query: 1381 gttgcctgtctatatcagagttggcattcctaaccaggtcccaagggctgcatttatggc 1440 
            |||||||||||||  ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1381 gttgcctgtctat--cagagttggcattcctaaccaggtcccaagggctgcatttatggc 1438 
Query: 1441 catgtttgttctggaggtggaccagttcatactgacccctctgacaacctccgttctgga 1500 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1439 catgtttgttctggaggtggaccagttcatactgacccctctgacaacctccgttctgga 1498 
Query: 1501 ctgtgaggaggatgagactccgaaacccttgttggtgttcaacatcactaaagccccact 1560 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1499 ctgtgaggaggatgagactccgaaacccttgttggtgttcaacatcactaaagccccact 1558 
Query: 1561 ccagggctatgtgacccacctgctggatcataccagacccatctcttcattcacctggaa 1620 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1559 ccagggctatgtgacccacctgctggatcataccagacccatctcttcattcacctggaa 1618 
Query: 1621 ggatctcagtgacatgcaagttgcctaccagccaccaaacagcagccaccctgagaggag 1680 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1619 ggatctcagtgacatgcaagttgcctaccagccaccaaacagcagccaccctgagaggag 1678 
Query: 1681 acattacacgatggagctggaggtgtacgacttcttctttgagaggagtgcccccatcac 1740 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1679 acattacacgatggagctggaggtgtacgacttcttctttgagaggagtgcccccatcac 1738 
Query: 1741 tgtccacatctccatcagaacagcagacacgaatgcaccacgggtgtcttggaatacagg 1800 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1739 tgtccacatctccatcagaacagcagacacgaatgcaccacgggtgtcttggaatacagg 1798 
Query: 1801 tttgaatctcctagaggggcagtctcgggccatcacttgggaacaatttcagatcgttga 1860 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1799 tttgaatctcctagaggggcagtctcgggccatcacttgggaacaatttcagatcgttga 1858 
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Query: 1861 caatgatgacattggtgctgtgcagttggtcaccattggtggcctgcagcatggacggct 1920 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1859 caatgatgacattggtgctgtgcagttggtcaccattggtggcctgcagcatggacggct 1918 
Query: 1921 tacagtacgagaggggaaaggatttctcttcaccgtgactgaccttcaagctggagttgt 1980 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1919 tacagtacgagaggggaaaggatttctcttcaccgtgactgaccttcaagctggagttgt 1978 
Query: 1981 ccgctatcatcacgatgacagtgataccaccaaagactttgtggctttcaggatattcga 2040 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1979 ccgctatcatcacgatgacagtgataccaccaaagactttgtggctttcaggatattcga 2038 
Query: 2041 tggccaccacagcagccaccacaagtttcctatcaacatcttgcctaaagatgacagccc 2100 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2039 tggccaccacagcagccaccacaagtttcctatcaacatcttgcctaaagatgacagccc 2098 
Query: 2101 cccattcctcatcaccaatgtcgtgattgaactagaagaggggaagaccatcttgatcca 2160 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2099 cccattcctcatcaccaatgtcgtgattgaactagaagaggggaagaccatcttgatcca 2158 
Query: 2161 agggtctatgttgagagcttcagatatggactccagtgatgactacatcttctttaatat 2220 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2159 agggtctatgttgagagcttcagatatggactccagtgatgactacatcttctttaatat 2218 
Query: 2221 cacaaagtttccacaggctggggagatcatgaagaagccagggccaagactgatagggta 2280 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2219 cacaaagtttccacaggctggggagatcatgaagaagccagggccaagactgatagggta 2278 
Query: 2281 tcctgtccctggcttcctgcagagagacctgttcagtggaatcatttactatcgtcactt 2340 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2279 tcctgtccctggcttcctgcagagagacctgttcagtggaatcatttactatcgtcactt 2338 
Query: 2341 tggtggagaaatctttgaagattcctttgaattcgtactgtgggacagccatgagcctcc 2400 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2339 tggtggagaaatctttgaagattcctttgaattcgtactgtgggacagccatgagcctcc 2398 
Query: 2401 aaatctctcagtgccacaggtggtgacaattcatatcactccagtagatgaccagcttcc 2460 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2399 aaatctctcagtgccacaggtggtgacaattcatatcactccagtagatgaccagcttcc 2458 
Query: 2461 taaagaagctcctggcatttcccggcatttggttgtcaaggaaacagaggtggcctacat 2520 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2459 taaagaagctcctggcatttcccggcatttggttgtcaaggaaacagaggtggcctacat 2518 
Query: 2521 cactaaaaagcacctacatttcctagacatggaatcccgtgatggggaactcatctacac 2580 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2519 cactaaaaagcacctacatttcctagacatggaatcccgtgatggggaactcatctacac 2578 
Query: 2581 agtaacacgccctccatgtttctccttcagccacagacacttggatgctgggaagctatt 2640 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2579 agtaacacgccctccatgtttctccttcagccacagacacttggatgctgggaagctatt 2638 
Query: 2641 catggtggacagcataccaaagctaaccaaaaatccgacagccccagggctaagttcatt 2700 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2639 catggtggacagcataccaaagctaaccaaaaatccgacagccccagggctaagttcatt 2698 
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Query: 2701 tactcagcatgccgtgaaccatatgaaagtggcctacatgccacccatgcaagatatagg 2760 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2699 tactcagcatgccgtgaaccatatgaaagtggcctacatgccacccatgcaagatatagg 2758 
Query: 2761 cccctcccctcgacatgtgcagttcacagtgtctgtcagtaaccagcatggaggtgcttt 2820 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2759 cccctcccctcgacatgtgcagttcacagtgtctgtcagtaaccagcatggaggtgcttt 2818 
Query: 2821 gcatggaatctgcttcaacatcacagttctcccagtggacaaccaggttcccgaggtatt 2880 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2819 gcatggaatctgcttcaacatcacagttctcccagtggacaaccaggttcccgaggtatt 2878 
Query: 2881 caccaacaccctgagagtggtcgagggcggtcagtgcaccatcagcacagagcacatttt 2940 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2879 caccaacaccctgagagtggtcgagggcggtcagtgcaccatcagcacagagcacatttt 2938 
Query: 2941 ggtttctgatgtggacaccccgctagacagcatcagcctctctcttaaggagaggcctct 3000 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2939 ggtttctgatgtggacaccccgctagacagcatcagcctctctcttaaggagaggcctct 2998 
Query: 3001 gcatggcggggtagagctggacggatttcctctaaacccaagaggcacattttcttggcg 3060 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2999 gcatggcggggtagagctggacggatttcctctaaacccaagaggcacattttcttggcg 3058 
Query: 3061 agacctcaataccttaaaagtttggtatcaacatgatggatctgaggttcttcaggatga 3120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3059 agacctcaataccttaaaagtttggtatcaacatgatggatctgaggttcttcaggatga 3118 
Query: 3121 gatatttttggaggtcacagatggcacaaattcagcagcatttgttctccacattgaggt 3180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3119 gatatttttggaggtcacagatggcacaaattcagcagcatttgttctccacattgaggt 3178 
Query: 3181 gttccctgtgaatgatgagccacccattctgaaggctgacctcatccccatgatgcactg 3240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3179 gttccctgtgaatgatgagccacccattctgaaggctgacctcatccccatgatgcactg 3238 
Query: 3241 ctctgagggtggagaggtgaccatcacccctgaatacatttccgctactgatgcagacag 3300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3239 ctctgagggtggagaggtgaccatcacccctgaatacatttccgctactgatgcagacag 3298 
Query: 3301 cgatgacttagaactgctgtttctgattgcccgagagcctcagcatggagtggtgagaaa 3360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3299 cgatgacttagaactgctgtttctgattgcccgagagcctcagcatggagtggtgagaaa 3358 
Query: 3361 ggctggacttcacgtggacaggttctctcagggagatgtcatctcaggggctgtgacata 3420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3359 ggctggacttcacgtggacaggttctctcagggagatgtcatctcaggggctgtgacata 3418 
Query: 3421 caaacatacaggtggcgagattggccttgaaccttgttctgacactgttgtattggtggt 3480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3419 caaacatacaggtggcgagattggccttgaaccttgttctgacactgttgtattggtggt 3478 
Query: 3481 ttcggatggtgaagctgaccctttgatgaacggctgttgctacgatggacctgattcatc 3540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3479 ttcggatggtgaagctgaccctttgatgaacggctgttgctacgatggacctgattcatc 3538 
Query: 3541 tgttcctcttcataagtccttccccacataccagctcaacatcacagtacatccagtcga 3600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3539 tgttcctcttcataagtccttccccacataccagctcaacatcacagtacatccagtcga 3598 
Query: 3601 caaccagccaccttcaattataataggtaggatgctcacagtggatgaaggcttctcagc 3660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3599 caaccagccaccttcaattataataggtaggatgctcacagtggatgaaggcttctcagc 3658 
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Query: 3661 agcccttactactcatcacttgactgttgttgattgggacactgccccggatgacttaaa 3720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3659 agcccttactactcatcacttgactgttgttgattgggacactgccccggatgacttaaa 3718 
Query: 3721 attcatgttggcttctcagccccagtttggctacttagaaaacgcactgccttctgcagg 3780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3719 attcatgttggcttctcagccccagtttggctacttagaaaacgcactgccttctgcagg 3778 
Query: 3781 ctttgagaaaagtaacatcggcataaggatagcctcattccagtggacagacatgaaggc 3840 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3779 ctttgagaaaagtaacatcggcataaggatagcctcattccagtggacagacatgaaggc 3838 
Query: 3841 ttcacacattaactatgtgcagtccaggcacctgagagtggaaccaactgctgaccagtt 3900 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3839 ttcacacattaactatgtgcagtccaggcacctgagagtggaaccaactgctgaccagtt 3898 
Query: 3901 cacagtatatgccacagacgggaagcatcgctccttggagacaacatttcacgttatcat 3960 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3899 cacagtatatgccacagacgggaagcatcgctccttggagacaacatttcacgttatcat 3958 
Query: 3961 caaccccacaaacgatgaagctcctgaccttgcagtacagaacatcactgtgtatgaggg 4020 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 3959 caaccccacaaacgatgaagctcctgaccttgcagtacagaacatcactgtgtatgaggg 4018 
Query: 4021 gcacatggtagaactggattcttccatcatcagtgctactgacagggatattcccaagga 4080 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4019 gcacatggtagaactggattcttccatcatcagtgctactgacagggatattcccaagga 4078 
Query: 4081 ccccttgctcttcagcatcgctctcaagccccagcacggcctgctcgtcgatgctgccat 4140 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4079 ccccttgctcttcagcatcgctctcaagccccagcacggcctgctcgtcgatgctgccat 4138 
Query: 4141 cagcaaggactcccatcagatcaagcagctgcaacacgaaatccacagcttctccgtgga 4200 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4139 cagcaaggactcccatcagatcaagcagctgcaacacgaaatccacagcttctccgtgga 4198 
Query: 4201 ccttctcaagaatggaatgaagctggtctatgcccacgacgactcagagagctctgctga 4260 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4199 ccttctcaagaatggaatgaagctggtctatgcccacgacgactcagagagctctgctga 4258 
Query: 4261 taacttcgtgatccagttgtcagacgggaaacataaaatccttaaaaccatctcagtaaa 4320 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4259 taacttcgtgatccagttgtcagacgggaaacataaaatccttaaaaccatctcagtaaa 4318 
Query: 4321 cattaccccagtgaatgacgagacaccaacgctaagcaagaaggctgaaatctcaatggc 4380 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4319 cattaccccagtgaatgacgagacaccaacgctaagcaagaaggctgaaatctcaatggc 4378 
Query: 4381 tgtgggcgatactcgcgtcctgtctagtgctgttctttcagccacagataaagactcgcc 4440 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4379 tgtgggcgatactcgcgtcctgtctagtgctgttctttcagccacagataaagactcgcc 4438 
Query: 4441 cagagagaagattcactatgtatttgaaagacttccccaaaatggacaacttcaacttaa 4500 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4439 cagagagaagattcactatgtatttgaaagacttccccaaaatggacaacttcaacttaa 4498 
Query: 4501 gatagggagggactgggtccctctctccactggcatgcagtgcacccaggaggatgtgga 4560 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4499 gatagggagggactgggtccctctctccactggcatgcagtgcacccaggaggatgtgga 4558 
Query: 4561 cctgaacttgctaagatacacgcatgctggtaaaacggactcccaggatggagacagctt 4620 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4559 cctgaacttgctaagatacacgcatgctggtaaaacggactcccaggatggagacagctt 4618 
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Query: 4621 caccttctacctctgggatgaggacaacaggtcacctgcatttgactgtcacatcatcat 4680 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4619 caccttctacctctgggatgaggacaacaggtcacctgcatttgactgtcacatcatcat 4678 
Query: 4681 tgaagacatgggcaaaggtgatattgtcattcatgcaaaaccactcgtggtagtcaaagg 4740 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4679 tgaagacatgggcaaaggtgatattgtcattcatgcaaaaccactcgtggtagtcaaagg 4738 
Query: 4741 tgacagaggtctcttgacgactgccacccttctggctgtggatggagcagacaagcctga 4800 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4739 tgacagaggtctcttgacgactgccacccttctggctgtggatggagcagacaagcctga 4798 
Query: 4801 ggaactgctctacctcatcacctccccaccacggcatggccaagtggagtacgtccactc 4860 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4799 ggaactgctctacctcatcacctccccaccacggcatggccaagtggagtacgtccactc 4858 
Query: 4861 tcctggagtccccattgccagcttcagccaaatggacatagcaggacagacagtgtgcta 4920 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4859 tcctggagtccccattgccagcttcagccaaatggacatagcaggacagacagtgtgcta 4918 
Phe->Ser (TTC->TCC)
Query: 4921 catacacaagagcaggacagctgtccccactgacagcttcagatttaccatcagcaatgg 4980 
            |||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||| 
Sbjct: 4919 catacacaagagcaggacagctgtccccactgacagctccagatttaccatcagcaatgg 4978 
Query: 4981 actgcagacccagcgtggggtgtttgaaatcacactgcagactgtggacagcgccttgcc 5040 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 4979 actgcagacccagcgtggggtgtttgaaatcacactgcagactgtggacagcgccttgcc 5038 
Query: 5041 tgtgctgaccaagaacaaaaggctgaggctagccgaaggggccatgggcctcctgtccgc 5100 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5039 tgtgctgaccaagaacaaaaggctgaggctagccgaaggggccatgggcctcctgtccgc 5098 
Query: 5101 tgatcaccttcagctgactgaccccgacacacctccagagaacctgaccttctttctggc 5160 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5099 tgatcaccttcagctgactgaccccgacacacctccagagaacctgaccttctttctggc 5158 
Query: 5161 tcagctcccacgccacgggtacctcttcctgagagggaaagcactccaacacaacttcac 5220 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5159 tcagctcccacgccacgggtacctcttcctgagagggaaagcactccaacacaacttcac 5218 
Query: 5221 ccagcgagatgtggacagcgggggcgtggcctaccagcactcaggaggcggcgcccggga 5280 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5219 ccagcgagatgtggacagcgggggcgtggcctaccagcactcaggaggcggcgcccggga 5278 
Query: 5281 ggactattttacttttctagccacagacaggaagaaccaaggctttgttgtggatgggaa 5340 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5279 ggactattttacttttctagccacagacaggaagaaccaaggctttgttgtggatgggaa 5338 
Query: 5341 agttcagaaagagcctgttcgcttcacaatccaggtggatcagctggacaaggcagcgcc 5400 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5339 agttcagaaagagcctgttcgcttcacaatccaggtggatcagctggacaaggcagcgcc 5398 
Query: 5401 ccgtatcacacacttgcactcccctactcaagtggggctcttgaaaaatggctgctatgg 5460 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5399 ccgtatcacacacttgcactcccctactcaagtggggctcttgaaaaatggctgctatgg 5458 
Query: 5461 gatttacatcacttcccgtgtgctgaaggcatcagaccctgacacagaggatgaccagat 5520 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5459 gatttacatcacttcccgtgtgctgaaggcatcagaccctgacacagaggatgaccagat 5518 
Query: 5521 catctttaagattttacgaggcccattgtacggacgtctggagaacacaacaacaggtga 5580 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5519 catctttaagattttacgaggcccattgtacggacgtctggagaacacaacaacaggtga 5578 
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Query: 5581 attcatccacgagcgatttagccagaaggacttaagccataagaccatcctttacatcat 5640 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5579 attcatccacgagcgatttagccagaaggacttaagccataagaccatcctttacatcat 5638 
Query: 5641 aaacccttctttgcaagtgacttccgatatcctggaatttcaggccatggaccccacagg 5700 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5639 aaacccttctttgcaagtgacttccgatatcctggaatttcaggccatggaccccacagg 5698 
Query: 5701 gaacactgccactccccagagcttggacttgagatggtcgtatattgaatgggcccagac 5760 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5699 gaacactgccactccccagagcttggacttgagatggtcgtatattgaatgggcccagac 5758 
Query: 5761 tgcatatgaggtttgtgagaatgtgggcttattgcccttggaagttaccagaaggggata 5820 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5759 tgcatatgaggtttgtgagaatgtgggcttattgcccttggaagttaccagaaggggata 5818 
Query: 5821 tcccatggactcagcctttgtgggtgtagaggttaaccaagtgtcagctacagttggaaa 5880 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5819 tcccatggactcagcctttgtgggtgtagaggttaaccaagtgtcagctacagttggaaa 5878 
Query: 5881 agattttactgtcactccatccaaactgcttcaatttgacccaggaatgtcaactaagat 5940 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5879 agattttactgtcactccatccaaactgcttcaatttgacccaggaatgtcaactaagat 5938 
Query: 5941 gtggaatatagcaattacctatgacggattagaggaagatgatgaggtctttgaagtaat 6000 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5939 gtggaatatagcaattacctatgacggattagaggaagatgatgaggtctttgaagtaat 5998 
Query: 6001 tctgaactcccctgtgaatgcggttcttggcacgcagacaaaagcggcggtgaaaatttt 6060 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 5999 tctgaactcccctgtgaatgcggttcttggcacgcagacaaaagcggcggtgaaaatttt 6058 
Query: 6061 ggactcaaaaggaggacggtgccatccttcaaattccttcaaccaaagcaagcacagcac 6120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6059 ggactcaaaaggaggacggtgccatccttcaaattccttcaaccaaagcaagcacagcac 6118 
Query: 6121 gtgggggaagggcccttggcatccgctgccctcaggctcatcctcgctcaccacttcagg 6180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6119 gtgggggaagggcccttggcatccgctgccctcaggctcatcctcgctcaccacttcagg 6178 
Query: 6181 ttctcctcttctggaaaggcctcctccatctttcaccagtggagatgctcttcagggttt 6240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6179 ttctcctcttctggaaaggcctcctccatctttcaccagtggagatgctcttcagggttt 6238 
Query: 6241 tggtctcaccgacctcactcaaaggaagacaatgacccaggggaatggcaaatcagttct 6300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6239 tggtctcaccgacctcactcaaaggaagacaatgacccaggggaatggcaaatcagttct 6298 
Query: 6301 cccatcctctgtttgtagaaatgggacagacaccatctacaattaccatggtatagtttc 6360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6299 cccatcctctgtttgtagaaatgggacagacaccatctacaattaccatggtatagtttc 6358 
Query: 6361 cttgaaactagagggcgacagattctcagctcacaaacggaaggccaaaatatccattgt 6420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6359 cttgaaactagagggcgacagattctcagctcacaaacggaaggccaaaatatccattgt 6418 
Query: 6421 tagtcagccacagaggacaatcaaggtggcagagctgcctctagctgataaggtggaatc 6480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6419 tagtcagccacagaggacaatcaaggtggcagagctgcctctagctgataaggtggaatc 6478 
Query: 6481 cacaactgatttgcactttctcagacagggtctgcggcccttgtttccaaagaattgttc 6540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6479 cacaactgatttgcactttctcagacagggtctgcggcccttgtttccaaagaattgttc 6538 
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Query: 6541 tgtggacttaaagggactctttcattttgaagaaagcacccacagattgtatcaatgtga 6600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6539 tgtggacttaaagggactctttcattttgaagaaagcacccacagattgtatcaatgtga 6598 
Query: 6601 tgggatctcctggaaagcctggagcccccaaaccaaggggctggaggacagatcctgccc 6660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6599 tgggatctcctggaaagcctggagcccccaaaccaaggggctggaggacagatcctgccc 6658 
Query: 6661 aggtggatggctccttcattctggctactgtcacatcttggtcacaagacagaaaggcac 6720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6659 aggtggatggctccttcattctggctactgtcacatcttggtcacaagacagaaaggcac 6718 
Query: 6721 ctggaccacagctacccgagcttgcagagaacagcaccagggcgaccttgtgaccgtact 6780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6719 ctggaccacagctacccgagcttgcagagaacagcaccagggcgaccttgtgaccgtact 6778 
Query: 6781 ctccagaaggcatatgcagtggctatgggcgatgagtggaagaaaacccttctggatagg 6840 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6779 ctccagaaggcatatgcagtggctatgggcgatgagtggaagaaaacccttctggatagg 6838 
Query: 6841 cttgaagaaccaaccgaggactggccactgggagtggatcggaggtgaacctgttgcttt 6900 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6839 cttgaagaaccaaccgaggactggccactgggagtggatcggaggtgaacctgttgcttt 6898 
Query: 6901 taccaactggaggagaggggcccctctgcacccaaaacctggaaagaactgtgctttggt 6960 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6899 taccaactggaggagaggggcccctctgcacccaaaacctggaaagaactgtgctttggt 6958 
Gln->Arg
Query: 6961 tcagaaaagaggacaatggcagacaaagaactgtagcaaaggcaaggctcacaattttgt 7020 
            |||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||| 
Sbjct: 6959 tcagaaaagaggacaatggcggacaaagaactgtagcaaaggcaaggctcacaattttgt 7018 
Query: 7021 gtgctcaaggaaactctgaacacaacctagcctttctcattcatctatttacaagatcta 7080 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 7019 gtgctcaaggaaactctgaacacaacctagcctttctcattcatctatttacaagatcta 7078 
Query: 7081 tgtgtattgcccagtgaagatgcgttgttgtggctgg 7117 
            ||||||||||||||||||||||||||||||||||||| 
Sbjct: 7079 tgtgtattgcccagtgaagatgcgttgttgtggctgg 7115 
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E. Sequence of the mCBCP-CDS1-6L 
     1 ---------+---------+---------+---------+---------+---------+ 60
       GGCATTGGAGGAGACCTGCAAACAGTGTGTTTGGGAACTCCAATTCTCTACCTATTTGTT
    61 ---------+---------+---------+---------+---------+---------+ 120
       TGTGCGGGTTAAAGGATTTTTGGCACAAACAAAGCCTAAACTCAGCTGACTAGAACGACT
   121 ---------+---------+---------+---------+---------+---------+ 180
       GGAATTTCAGCTCTCCTCCTTGGATGGGATGTTTTAGCTTCCTCTTCCTCTGACAACTCT
   181 ---------+---------+---------+---------+---------+---------+ 240
       TTAAGGCTGTTACCAGGTTAGCATCCAGCCCTCTACTTCCAAGGGTGGCCAGCCCTTGGC
   241 ---------+---------+---------+---------+---------+---------+ 300
       TCGGAAAGAAAACCAGGAACTGATTAGGAAGGCACTTGGGAGGCACATTAATCTTGCCAG
   301 ---------+---------+---------+---------+---------+---------+ 360
       CGTTGTCAGGAATGATCAGCGAGTTTTATTAAAAAGCCCCGATTGCCTGAAAGGCCTCCT
   361 ---------+---------+---------+---------+---------+---------+ 420
       TGTCTGAATCTGAATGGAAGGAGCATGTTAAGGTCTTGGGGCACGCTGTCGGGACCCCTA
   421 ---------+---------+---------+---------+---------+---------+ 480
       GTATTACCCCCTGGACCTCAAGCTGACACTTGGGGAAGAAGTGCAGGAAGCTTGCTTTGT
   481 ---------+---------+---------+---------+---------+---------+ 540
       TGAACAGACTGTGCCTGTGGACAGAGCTGGCCCTGGCATCATGCACTCTCCAGGCTGCAC
                                               M  H  S  P  G  C  T
   541 ---------+---------+---------+---------+---------+---------+ 600
       TGGGCCCAAGGCTCAGTGGTTCTTGCTGCTCCAGCTGCTTCTGCTGCACCTGGACCGGGT
        G  P  K  A  Q  W  F  L  L  L  Q  L  L  L  L  H  L  D  R  V
   601 ---------+---------+---------+---------+---------+---------+ 660
       CAGTGCCACCTTCATCAGCATCAACCGGGGCCTGAGGGTGATGAAGGGTAGTTCTGCCTT
        S  A  T  F  I  S  I  N  R  G  L  R  V  M  K  G  S  S  A  F
   661 ---------+---------+---------+---------+---------+---------+ 720
       CCTGTCTGGAGATCACCTGAGGGTTGCAGTCCCTAAAGAAAAGGACGCCTGCAGACTGGA
        L  S  G  D  H  L  R  V  A  V  P  K  E  K  D  A  C  R  L  E
   721 ---------+---------+---------+---------+---------+---------+ 780
       GGTGGTGATGAACGAGCCCGTAACCCAGAGGGTTGGGAAACTCTCTCCACAGGTCTTTGA
        V  V  M  N  E  P  V  T  Q  R  V  G  K  L  S  P  Q  V  F  D
   781 ---------+---------+---------+---------+---------+---------+ 840
       TTGCCATTTTCTTCCCAACGAAGTGAAGTATGTTCACAATGGATGCCCAATTCTGGATGA
        C  H  F  L  P  N  E  V  K  Y  V  H  N  G  C  P  I  L  D  E
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   841 ---------+---------+---------+---------+---------+---------+ 900
       AGACTCTGTGAAGCTTAGACTTTACAGGTTTACTGAAACAGACACCTTCATGGAAACCTT
        D  S  V  K  L  R  L  Y  R  F  T  E  T  D  T  F  M  E  T  F
   901 ---------+---------+---------+---------+---------+---------+ 960
       TCTCTTGCGGGTTTATCTTGTGGAACCAGACTGTAACATCATCCGTATGAGCAGTAATGT
        L  L  R  V  Y  L  V  E  P  D  C  N  I  I  R  M  S  S  N  V
   961 ---------+---------+---------+---------+---------+---------+ 1020
       GTTGGAAGTGACTGAATTCTATGGCTTATCGCAAGCCATTGATAAGAACCTGCTCCAGTT
        L  E  V  T  E  F  Y  G  L  S  Q  A  I  D  K  N  L  L  Q  F
  1021 ---------+---------+---------+---------+---------+---------+ 1080
       TGATTATGATAGGACTGCCAGCCTGGATTGCACCATCAGACTAGACCCACTGAGGACTCA
        D  Y  D  R  T  A  S  L  D  C  T  I  R  L  D  P  L  R  T  Q
  1081 ---------+---------+---------+---------+---------+---------+ 1140
       GCTGCCAGCTCACGGCAAGCTGGTCGTGGTGAATCGTAAGTCAGAGGGGCCTCGTGGAGA
        L  P  A  H  G  K  L  V  V  V  N  R  K  S  E  G  P  R  G  D
  1141 ---------+---------+---------+---------+---------+---------+ 1200
       TCAGCCACACAGCTTCTTCTCTGAGACAGAGCTAGGGGCTGGACTGAAGTGTCCAGATGG
        Q  P  H  S  F  F  S  E  T  E  L  G  A  G  L  K  C  P  D  G
  1201 ---------+---------+---------+---------+---------+---------+ 1260
       AAGCTGTGCCCTGGAATTGAAGCAAGTGGCAAGTCTGAAAGTGAGCTGTGAGGAGTTTCT
        S  C  A  L  E  L  K  Q  V  A  S  L  K  V  S  C  E  E  F  L
  1261 ---------+---------+---------+---------+---------+---------+ 1320
       GCTGACGGGGTTTCACTACCAACACATGCAGCCCCCTTCACCCAACATTGATTACATCCC
        L  T  G  F  H  Y  Q  H  M  Q  P  P  S  P  N  I  D  Y  I  P
  1321 ---------+---------+---------+---------+---------+---------+ 1380
       CATTCAGTTGGATCTCACCGACAGAAGGAGCAAAACCGTATACAAGTCAGAGAGTGCGTG
        I  Q  L  D  L  T  D  R  R  S  K  T  V  Y  K  S  E  S  A  W
  1381 ---------+---------+---------+---------+---------+---------+ 1440
       GTTGCCTGTCTATATCAGAGTTGGCATTCCTAACCAGGTCCCAAGGGCTGCATTTATGGC
        L  P  V  Y  I  R  V  G  I  P  N  Q  V  P  R  A  A  F  M  A
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  1441 ---------+---------+---------+---------+---------+---------+ 1500
       CATGTTTGTTCTGGAGGTGGACCAGTTCATACTGACCCCTCTGACAACCTCCGTTCTGGA
        M  F  V  L  E  V  D  Q  F  I  L  T  P  L  T  T  S  V  L  D
  1501 ---------+---------+---------+---------+---------+---------+ 1560
       CTGTGAGGAGGATGAGACTCCGAAACCCTTGTTGGTGTTCAACATCACTAAAGCCCCACT
        C  E  E  D  E  T  P  K  P  L  L  V  F  N  I  T  K  A  P  L
  1561 ---------+---------+---------+---------+---------+---------+ 1620
       CCAGGGCTATGTGACCCACCTGCTGGATCATACCAGACCCATCTCTTCATTCACCTGGAA
        Q  G  Y  V  T  H  L  L  D  H  T  R  P  I  S  S  F  T  W  K
  1621 ---------+---------+---------+---------+---------+---------+ 1680
       GGATCTCAGTGACATGCAAGTTGCCTACCAGCCACCAAACAGCAGCCACCCTGAGAGGAG
        D  L  S  D  M  Q  V  A  Y  Q  P  P  N  S  S  H  P  E  R  R
  1681 ---------+---------+---------+---------+---------+---------+ 1740
       ACATTACACGATGGAGCTGGAGGTGTACGACTTCTTCTTTGAGAGGAGTGCCCCCATCAC
        H  Y  T  M  E  L  E  V  Y  D  F  F  F  E  R  S  A  P  I  T
  1741 ---------+---------+---------+---------+---------+---------+ 1800
       TGTCCACATCTCCATCAGAACAGCAGACACGAATGCACCACGGGTGTCTTGGAATACAGG
        V  H  I  S  I  R  T  A  D  T  N  A  P  R  V  S  W  N  T  G
  1801 ---------+---------+---------+---------+---------+---------+ 1860
       TTTGAATCTCCTAGAGGGGCAGTCTCGGGCCATCACTTGGGAACAATTTCAGATCGTTGA
        L  N  L  L  E  G  Q  S  R  A  I  T  W  E  Q  F  Q  I  V  D
  1861 ---------+---------+---------+---------+---------+---------+ 1920
       CAATGATGACATTGGTGCTGTGCAGTTGGTCACCATTGGTGGCCTGCAGCATGGACGGCT
        N  D  D  I  G  A  V  Q  L  V  T  I  G  G  L  Q  H  G  R  L
  1921 ---------+---------+---------+---------+---------+---------+ 1980
       TACAGTACGAGAGGGGAAAGGATTTCTCTTCACCGTGACTGACCTTCAAGCTGGAGTTGT
        T  V  R  E  G  K  G  F  L  F  T  V  T  D  L  Q  A  G  V  V
  1981 ---------+---------+---------+---------+---------+---------+ 2040
       CCGCTATCATCACGATGACAGTGATACCACCAAAGACTTTGTGGCTTTCAGGATATTCGA
        R  Y  H  H  D  D  S  D  T  T  K  D  F  V  A  F  R  I  F  D
  2041 ---------+---------+---------+---------+---------+---------+ 2100
       TGGCCACCACAGCAGCCACCACAAGTTTCCTATCAACATCTTGCCTAAAGATGACAGCCC
        G  H  H  S  S  H  H  K  F  P  I  N  I  L  P  K  D  D  S  P
  2101 ---------+---------+---------+---------+---------+---------+ 2160
       CCCATTCCTCATCACCAATGTCGTGATTGAACTAGAAGAGGGGAAGACCATCTTGATCCA
        P  F  L  I  T  N  V  V  I  E  L  E  E  G  K  T  I  L  I  Q
  2161 ---------+---------+---------+---------+---------+---------+ 2220
       AGGGTCTATGTTGAGAGCTTCAGATATGGACTCCAGTGATGACTACATCTTCTTTAATAT
        G  S  M  L  R  A  S  D  M  D  S  S  D  D  Y  I  F  F  N  I
  2221 ---------+---------+---------+---------+---------+---------+ 2280
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       CACAAAGTTTCCACAGGCTGGGGAGATCATGAAGAAGCCAGGGCCAAGACTGATAGGGTA
        T  K  F  P  Q  A  G  E  I  M  K  K  P  G  P  R  L  I  G  Y
  2281 ---------+---------+---------+---------+---------+---------+ 2340
       TCCTGTCCCTGGCTTCCTGCAGAGAGACCTGTTCAGTGGAATCATTTACTATCGTCACTT
        P  V  P  G  F  L  Q  R  D  L  F  S  G  I  I  Y  Y  R  H  F
  2341 ---------+---------+---------+---------+---------+---------+ 2400
       TGGTGGAGAAATCTTTGAAGATTCCTTTGAATTCGTACTGTGGGACAGCCATGAGCCTCC
        G  G  E  I  F  E  D  S  F  E  F  V  L  W  D  S  H  E  P  P
  2401 ---------+---------+---------+---------+---------+---------+ 2460
       AAATCTCTCAGTGCCACAGGTGGTGACAATTCATATCACTCCAGTAGATGACCAGCTTCC
        N  L  S  V  P  Q  V  V  T  I  H  I  T  P  V  D  D  Q  L  P
  2461 ---------+---------+---------+---------+---------+---------+ 2520
       TAAAGAAGCTCCTGGCATTTCCCGGCATTTGGTTGTCAAGGAAACAGAGGTGGCCTACAT
        K  E  A  P  G  I  S  R  H  L  V  V  K  E  T  E  V  A  Y  I
  2521 ---------+---------+---------+---------+---------+---------+ 2580
       CACTAAAAAGCACCTACATTTCCTAGACATGGAATCCCGTGATGGGGAACTCATCTACAC
        T  K  K  H  L  H  F  L  D  M  E  S  R  D  G  E  L  I  Y  T
  2581 ---------+---------+---------+---------+---------+---------+ 2640
       AGTAACACGCCCTCCATGTTTCTCCTTCAGCCACAGACACTTGGATGCTGGGAAGCTATT
        V  T  R  P  P  C  F  S  F  S  H  R  H  L  D  A  G  K  L  F
  2641 ---------+---------+---------+---------+---------+---------+ 2700
       CATGGTGGACAGCATACCAAAGCTAACCAAAAATCCGACAGCCCCAGGGCTAAGTTCATT
        M  V  D  S  I  P  K  L  T  K  N  P  T  A  P  G  L  S  S  F
  2701 ---------+---------+---------+---------+---------+---------+ 2760
       TACTCAGCATGCCGTGAACCATATGAAAGTGGCCTACATGCCACCCATGCAAGATATAGG
        T  Q  H  A  V  N  H  M  K  V  A  Y  M  P  P  M  Q  D  I  G
  2761 ---------+---------+---------+---------+---------+---------+ 2820
       CCCCTCCCCTCGACATGTGCAGTTCACAGTGTCTGTCAGTAACCAGCATGGAGGTGCTTT
        P  S  P  R  H  V  Q  F  T  V  S  V  S  N  Q  H  G  G  A  L
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  2821 ---------+---------+---------+---------+---------+---------+ 2880
       GCATGGAATCTGCTTCAACATCACAGTTCTCCCAGTGGACAACCAGGTTCCCGAGGTATT
        H  G  I  C  F  N  I  T  V  L  P  V  D  N  Q  V  P  E  V  F
  2881 ---------+---------+---------+---------+---------+---------+ 2940
       CACCAACACCCTGAGAGTGGTCGAGGGCGGTCAGTGCACCATCAGCACAGAGCACATTTT
        T  N  T  L  R  V  V  E  G  G  Q  C  T  I  S  T  E  H  I  L
  2941 ---------+---------+---------+---------+---------+---------+ 3000
       GGTTTCTGATGTGGACACCCCGCTAGACAGCATCAGCCTCTCTCTTAAGGAGAGGCCTCT
        V  S  D  V  D  T  P  L  D  S  I  S  L  S  L  K  E  R  P  L
  3001 ---------+---------+---------+---------+---------+---------+ 3060
       GCATGGCGGGGTAGAGCTGGACGGATTTCCTCTAAACCCAAGAGGCACATTTTCTTGGCG
        H  G  G  V  E  L  D  G  F  P  L  N  P  R  G  T  F  S  W  R
  3061 ---------+---------+---------+---------+---------+---------+ 3120
       AGACCTCAATACCTTAAAAGTTTGGTATCAACATGATGGATCTGAGGTTCTTCAGGATGA
        D  L  N  T  L  K  V  W  Y  Q  H  D  G  S  E  V  L  Q  D  E
  3121 ---------+---------+---------+---------+---------+---------+ 3180
       GATATTTTTGGAGGTCACAGATGGCACAAATTCAGCAGCATTTGTTCTCCACATTGAGGT
        I  F  L  E  V  T  D  G  T  N  S  A  A  F  V  L  H  I  E  V
  3181 ---------+---------+---------+---------+---------+---------+ 3240
       GTTCCCTGTGAATGATGAGCCACCCATTCTGAAGGCTGACCTCATCCCCATGATGCACTG
        F  P  V  N  D  E  P  P  I  L  K  A  D  L  I  P  M  M  H  C
  3241 ---------+---------+---------+---------+---------+---------+ 3300
       CTCTGAGGGTGGAGAGGTGACCATCACCCCTGAATACATTTCCGCTACTGATGCAGACAG
        S  E  G  G  E  V  T  I  T  P  E  Y  I  S  A  T  D  A  D  S
  3301 ---------+---------+---------+---------+---------+---------+ 3360
       CGATGACTTAGAACTGCTGTTTCTGATTGCCCGAGAGCCTCAGCATGGAGTGGTGAGAAA
        D  D  L  E  L  L  F  L  I  A  R  E  P  Q  H  G  V  V  R  K
  3361 ---------+---------+---------+---------+---------+---------+ 3420
       GGCTGGACTTCACGTGGACAGGTTCTCTCAGGGAGATGTCATCTCAGGGGCTGTGACATA
        A  G  L  H  V  D  R  F  S  Q  G  D  V  I  S  G  A  V  T  Y
  3421 ---------+---------+---------+---------+---------+---------+ 3480
       CAAACATACAGGTGGCGAGATTGGCCTTGAACCTTGTTCTGACACTGTTGTATTGGTGGT
        K  H  T  G  G  E  I  G  L  E  P  C  S  D  T  V  V  L  V  V
  3481 ---------+---------+---------+---------+---------+---------+ 3540
       TTCGGATGGTGAAGCTGACCCTTTGATGAACGGCTGTTGCTACGATGGACCTGATTCATC
        S  D  G  E  A  D  P  L  M  N  G  C  C  Y  D  G  P  D  S  S
  3541 ---------+---------+---------+---------+---------+---------+ 3600
       TGTTCCTCTTCATAAGTCCTTCCCCACATACCAGCTCAACATCACAGTACATCCAGTCGA
        V  P  L  H  K  S  F  P  T  Y  Q  L  N  I  T  V  H  P  V  D
  3601 ---------+---------+---------+---------+---------+---------+ 3660
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       CAACCAGCCACCTTCAATTATAATAGGTAGGATGCTCACAGTGGATGAAGGCTTCTCAGC
        N  Q  P  P  S  I  I  I  G  R  M  L  T  V  D  E  G  F  S  A
  3661 ---------+---------+---------+---------+---------+---------+ 3720
       AGCCCTTACTACTCATCACTTGACTGTTGTTGATTGGGACACTGCCCCGGATGACTTAAA
        A  L  T  T  H  H  L  T  V  V  D  W  D  T  A  P  D  D  L  K
  3721 ---------+---------+---------+---------+---------+---------+ 3780
       ATTCATGTTGGCTTCTCAGCCCCAGTTTGGCTACTTAGAAAACGCACTGCCTTCTGCAGG
        F  M  L  A  S  Q  P  Q  F  G  Y  L  E  N  A  L  P  S  A  G
  3781 ---------+---------+---------+---------+---------+---------+ 3840
       CTTTGAGAAAAGTAACATCGGCATAAGGATAGCCTCATTCCAGTGGACAGACATGAAGGC
        F  E  K  S  N  I  G  I  R  I  A  S  F  Q  W  T  D  M  K  A
  3841 ---------+---------+---------+---------+---------+---------+ 3900
       TTCACACATTAACTATGTGCAGTCCAGGCACCTGAGAGTGGAACCAACTGCTGACCAGTT
        S  H  I  N  Y  V  Q  S  R  H  L  R  V  E  P  T  A  D  Q  F
  3901 ---------+---------+---------+---------+---------+---------+ 3960
       CACAGTATATGCCACAGACGGGAAGCATCGCTCCTTGGAGACAACATTTCACGTTATCAT
        T  V  Y  A  T  D  G  K  H  R  S  L  E  T  T  F  H  V  I  I
  3961 ---------+---------+---------+---------+---------+---------+ 4020
       CAACCCCACAAACGATGAAGCTCCTGACCTTGCAGTACAGAACATCACTGTGTATGAGGG
        N  P  T  N  D  E  A  P  D  L  A  V  Q  N  I  T  V  Y  E  G
  4021 ---------+---------+---------+---------+---------+---------+ 4080
       GCACATGGTAGAACTGGATTCTTCCATCATCAGTGCTACTGACAGGGATATTCCCAAGGA
        H  M  V  E  L  D  S  S  I  I  S  A  T  D  R  D  I  P  K  D
  4081 ---------+---------+---------+---------+---------+---------+ 4140
       CCCCTTGCTCTTCAGCATCGCTCTCAAGCCCCAGCACGGCCTGCTCGTCGATGCTGCCAT
        P  L  L  F  S  I  A  L  K  P  Q  H  G  L  L  V  D  A  A  I
  4141 ---------+---------+---------+---------+---------+---------+ 4200
       CAGCAAGGACTCCCATCAGATCAAGCAGCTGCAACACGAAATCCACAGCTTCTCCGTGGA
        S  K  D  S  H  Q  I  K  Q  L  Q  H  E  I  H  S  F  S  V  D
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  4201 ---------+---------+---------+---------+---------+---------+ 4260
       CCTTCTCAAGAATGGAATGAAGCTGGTCTATGCCCACGACGACTCAGAGAGCTCTGCTGA
        L  L  K  N  G  M  K  L  V  Y  A  H  D  D  S  E  S  S  A  D
  4261 ---------+---------+---------+---------+---------+---------+ 4320
       TAACTTCGTGATCCAGTTGTCAGACGGGAAACATAAAATCCTTAAAACCATCTCAGTAAA
        N  F  V  I  Q  L  S  D  G  K  H  K  I  L  K  T  I  S  V  N
  4321 ---------+---------+---------+---------+---------+---------+ 4380
       CATTACCCCAGTGAATGACGAGACACCAACGCTAAGCAAGAAGGCTGAAATCTCAATGGC
        I  T  P  V  N  D  E  T  P  T  L  S  K  K  A  E  I  S  M  A
  4381 ---------+---------+---------+---------+---------+---------+ 4440
       TGTGGGCGATACTCGCGTCCTGTCTAGTGCTGTTCTTTCAGCCACAGATAAAGACTCGCC
        V  G  D  T  R  V  L  S  S  A  V  L  S  A  T  D  K  D  S  P
  4441 ---------+---------+---------+---------+---------+---------+ 4500
       CAGAGAGAAGATTCACTATGTATTTGAAAGACTTCCCCAAAATGGACAACTTCAACTTAA
        R  E  K  I  H  Y  V  F  E  R  L  P  Q  N  G  Q  L  Q  L  K
  4501 ---------+---------+---------+---------+---------+---------+ 4560
       GATAGGGAGGGACTGGGTCCCTCTCTCCACTGGCATGCAGTGCACCCAGGAGGATGTGGA
        I  G  R  D  W  V  P  L  S  T  G  M  Q  C  T  Q  E  D  V  D
  4561 ---------+---------+---------+---------+---------+---------+ 4620
       CCTGAACTTGCTAAGATACACGCATGCTGGTAAAACGGACTCCCAGGATGGAGACAGCTT
        L  N  L  L  R  Y  T  H  A  G  K  T  D  S  Q  D  G  D  S  F
  4621 ---------+---------+---------+---------+---------+---------+ 4680
       CACCTTCTACCTCTGGGATGAGGACAACAGGTCACCTGCATTTGACTGTCACATCATCAT
        T  F  Y  L  W  D  E  D  N  R  S  P  A  F  D  C  H  I  I  I
  4681 ---------+---------+---------+---------+---------+---------+ 4740
       TGAAGACATGGGCAAAGGTGATATTGTCATTCATGCAAAACCACTCGTGGTAGTCAAAGG
        E  D  M  G  K  G  D  I  V  I  H  A  K  P  L  V  V  V  K  G
  4741 ---------+---------+---------+---------+---------+---------+ 4800
       TGACAGAGGTCTCTTGACGACTGCCACCCTTCTGGCTGTGGATGGAGCAGACAAGCCTGA
        D  R  G  L  L  T  T  A  T  L  L  A  V  D  G  A  D  K  P  E
  4801 ---------+---------+---------+---------+---------+---------+ 4860
       GGAACTGCTCTACCTCATCACCTCCCCACCACGGCATGGCCAAGTGGAGTACGTCCACTC
        E  L  L  Y  L  I  T  S  P  P  R  H  G  Q  V  E  Y  V  H  S
  4861 ---------+---------+---------+---------+---------+---------+ 4920
       TCCTGGAGTCCCCATTGCCAGCTTCAGCCAAATGGACATAGCAGGACAGACAGTGTGCTA
        P  G  V  P  I  A  S  F  S  Q  M  D  I  A  G  Q  T  V  C  Y
  4921 ---------+---------+---------+---------+---------+---------+ 4980
       CATACACAAGAGCAGGACAGCTGTCCCCACTGACAGCTCCAGATTTACCATCAGCAATGG
        I  H  K  S  R  T  A  V  P  T  D  S  S  R  F  T  I  S  N  G
  4981 ---------+---------+---------+---------+---------+---------+ 5040
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       ACTGCAGACCCAGCGTGGGGTGTTTGAAATCACACTGCAGACTGTGGACAGCGCCTTGCC
        L  Q  T  Q  R  G  V  F  E  I  T  L  Q  T  V  D  S  A  L  P
  5041 ---------+---------+---------+---------+---------+---------+ 5100
       TGTGCTGACCAAGAACAAAAGGCTGAGGCTAGCCGAAGGGGCCATGGGCCTCCTGTCCGC
        V  L  T  K  N  K  R  L  R  L  A  E  G  A  M  G  L  L  S  A
  5101 ---------+---------+---------+---------+---------+---------+ 5160
       TGATCACCTTCAGCTGACTGACCCCGACACACCTCCAGAGAACCTGACCTTCTTTCTGGC
        D  H  L  Q  L  T  D  P  D  T  P  P  E  N  L  T  F  F  L  A
  5161 ---------+---------+---------+---------+---------+---------+ 5220
       TCAGCTCCCACGCCACGGGTACCTCTTCCTGAGAGGGAAAGCACTCCAACACAACTTCAC
        Q  L  P  R  H  G  Y  L  F  L  R  G  K  A  L  Q  H  N  F  T
  5221 ---------+---------+---------+---------+---------+---------+ 5280
       CCAGCGAGATGTGGACAGCGGGGGCGTGGCCTACCAGCACTCAGGAGGCGGCGCCCGGGA
        Q  R  D  V  D  S  G  G  V  A  Y  Q  H  S  G  G  G  A  R  E
  5281 ---------+---------+---------+---------+---------+---------+ 5340
       GGACTATTTTACTTTTCTAGCCACAGACAGGAAGAACCAAGGCTTTGTTGTGGATGGGAA
        D  Y  F  T  F  L  A  T  D  R  K  N  Q  G  F  V  V  D  G  K
  5341 ---------+---------+---------+---------+---------+---------+ 5400
       AGTTCAGAAAGAGCCTGTTCGCTTCACAATCCAGGTGGATCAGCTGGACAAGGCAGCGCC
        V  Q  K  E  P  V  R  F  T  I  Q  V  D  Q  L  D  K  A  A  P
  5401 ---------+---------+---------+---------+---------+---------+ 5460
       CCGTATCACACACTTGCACTCCCCTACTCAAGTGGGGCTCTTGAAAAATGGCTGCTATGG
        R  I  T  H  L  H  S  P  T  Q  V  G  L  L  K  N  G  C  Y  G
  5461 ---------+---------+---------+---------+---------+---------+ 5520
       GATTTACATCACTTCCCGTGTGCTGAAGGCATCAGACCCTGACACAGAGGATGACCAGAT
        I  Y  I  T  S  R  V  L  K  A  S  D  P  D  T  E  D  D  Q  I
  5521 ---------+---------+---------+---------+---------+---------+ 5580
       CATCTTTAAGATTTTACGAGGCCCATTGTACGGACGTCTGGAGAACACAACAACAGGTGA
        I  F  K  I  L  R  G  P  L  Y  G  R  L  E  N  T  T  T  G  E
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  5581 ---------+---------+---------+---------+---------+---------+ 5640
       ATTCATCCACGAGCGATTTAGCCAGAAGGACTTAAGCCATAAGACCATCCTTTACATCAT
        F  I  H  E  R  F  S  Q  K  D  L  S  H  K  T  I  L  Y  I  I
  5641 ---------+---------+---------+---------+---------+---------+ 5700
       AAACCCTTCTTTGCAAGTGACTTCCGATATCCTGGAATTTCAGGCCATGGACCCCACAGG
        N  P  S  L  Q  V  T  S  D  I  L  E  F  Q  A  M  D  P  T  G
  5701 ---------+---------+---------+---------+---------+---------+ 5760
       GAACACTGCCACTCCCCAGAGCTTGGACTTGAGATGGTCGTATATTGAATGGGCCCAGAC
        N  T  A  T  P  Q  S  L  D  L  R  W  S  Y  I  E  W  A  Q  T
  5761 ---------+---------+---------+---------+---------+---------+ 5820
       TGCATATGAGGTTTGTGAGAATGTGGGCTTATTGCCCTTGGAAGTTACCAGAAGGGGATA
        A  Y  E  V  C  E  N  V  G  L  L  P  L  E  V  T  R  R  G  Y
  5821 ---------+---------+---------+---------+---------+---------+ 5880
       TCCCATGGACTCAGCCTTTGTGGGTGTAGAGGTTAACCAAGTGTCAGCTACAGTTGGAAA
        P  M  D  S  A  F  V  G  V  E  V  N  Q  V  S  A  T  V  G  K
  5881 ---------+---------+---------+---------+---------+---------+ 5940
       AGATTTTACTGTCACTCCATCCAAACTGCTTCAATTTGACCCAGGAATGTCAACTAAGAT
        D  F  T  V  T  P  S  K  L  L  Q  F  D  P  G  M  S  T  K  M
  5941 ---------+---------+---------+---------+---------+---------+ 6000
       GTGGAATATAGCAATTACCTATGACGGATTAGAGGAAGATGATGAGGTCTTTGAAGTAAT
        W  N  I  A  I  T  Y  D  G  L  E  E  D  D  E  V  F  E  V  I
  6001 ---------+---------+---------+---------+---------+---------+ 6060
       TCTGAACTCCCCTGTGAATGCGGTTCTTGGCACGCAGACAAAAGCGGCGGTGAAAATTTT
        L  N  S  P  V  N  A  V  L  G  T  Q  T  K  A  A  V  K  I  L
  6061 ---------+---------+---------+---------+---------+---------+ 6120
       GGACTCAAAAGGAGGACGGTGCCATCCTTCAAATTCCTTCAACCAAAGCAAGCACAGCAC
        D  S  K  G  G  R  C  H  P  S  N  S  F  N  Q  S  K  H  S  T
  6121 ---------+---------+---------+---------+---------+---------+ 6180
       GTGGGGGAAGGGCCCTTGGCATCCGCTGCCCTCAGGCTCATCCTCGCTCACCACTTCAGG
        W  G  K  G  P  W  H  P  L  P  S  G  S  S  S  L  T  T  S  G
  6181 ---------+---------+---------+---------+---------+---------+ 6240
       TTCTCCTCTTCTGGAAAGGCCTCCTCCATCTTTCACCAGTGGAGATGCTCTTCAGGGTTT
        S  P  L  L  E  R  P  P  P  S  F  T  S  G  D  A  L  Q  G  F
  6241 ---------+---------+---------+---------+---------+---------+ 6300
       TGGTCTCACCGACCTCACTCAAAGGAAGACAATGACCCAGGGGAATGGCAAATCAGTTCT
        G  L  T  D  L  T  Q  R  K  T  M  T  Q  G  N  G  K  S  V  L
  6301 ---------+---------+---------+---------+---------+---------+ 6360
       CCCATCCTCTGTTTGTAGAAATGGGACAGACACCATCTACAATTACCATGGTATAGTTTC
        P  S  S  V  C  R  N  G  T  D  T  I  Y  N  Y  H  G  I  V  S
  6361 ---------+---------+---------+---------+---------+---------+ 6420
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       CTTGAAACTAGAGGGCGACAGATTCTCAGCTCACAAACGGAAGGCCAAAATATCCATTGT
        L  K  L  E  G  D  R  F  S  A  H  K  R  K  A  K  I  S  I  V
  6421 ---------+---------+---------+---------+---------+---------+ 6480
       TAGTCAGCCACAGAGGACAATCAAGGTGGCAGAGCTGCCTCTAGCTGATAAGGTGGAATC
        S  Q  P  Q  R  T  I  K  V  A  E  L  P  L  A  D  K  V  E  S
  6481 ---------+---------+---------+---------+---------+---------+ 6540
       CACAACTGATTTGCACTTTCTCAGACAGGGTCTGCGGCCCTTGTTTCCAAAGAATTGTTC
        T  T  D  L  H  F  L  R  Q  G  L  R  P  L  F  P  K  N  C  S
  6541 ---------+---------+---------+---------+---------+---------+ 6600
       TGTGGACTTAAAGGGACTCTTTCATTTTGAAGAAAGCACCCACAGATTGTATCAATGTGA
        V  D  L  K  G  L  F  H  F  E  E  S  T  H  R  L  Y  Q  C  D
  6601 ---------+---------+---------+---------+---------+---------+ 6660
       TGGGATCTCCTGGAAAGCCTGGAGCCCCCAAACCAAGGGGCTGGAGGACAGATCCTGCCC
        G  I  S  W  K  A  W  S  P  Q  T  K  G  L  E  D  R  S  C  P
  6661 ---------+---------+---------+---------+---------+---------+ 6720
       AGGTGGATGGCTCCTTCATTCTGGCTACTGTCACATCTTGGTCACAAGACAGAAAGGCAC
        G  G  W  L  L  H  S  G  Y  C  H  I  L  V  T  R  Q  K  G  T
  6721 ---------+---------+---------+---------+---------+---------+ 6780
       CTGGACCACAGCTACCCGAGCTTGCAGAGAACAGCACCAGGGCGACCTTGTGACCGTACT
        W  T  T  A  T  R  A  C  R  E  Q  H  Q  G  D  L  V  T  V  L
  6781 ---------+---------+---------+---------+---------+---------+ 6840
       CTCCAGAAGGCATATGCAGTGGCTATGGGCGATGAGTGGAAGAAAACCCTTCTGGATAGG
        S  R  R  H  M  Q  W  L  W  A  M  S  G  R  K  P  F  W  I  G
  6841 ---------+---------+---------+---------+---------+---------+ 6900
       CTTGAAGAACCAACCGAGGACTGGCCACTGGGAGTGGATCGGAGGTGAACCTGTTGCTTT
        L  K  N  Q  P  R  T  G  H  W  E  W  I  G  G  E  P  V  A  F
  6901 ---------+---------+---------+---------+---------+---------+ 6960
       TACCAACTGGAGGAGAGGGGCCCCTCTGCACCCAAAACCTGGAAAGAACTGTGCTTTGGT
        T  N  W  R  R  G  A  P  L  H  P  K  P  G  K  N  C  A  L  V
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  6961 ---------+---------+---------+---------+---------+---------+ 7020
       TCAGAAAAGAGGACAATGGCGGACAAAGAACTGTAGCAAAGGCAAGGCTCACAATTTTGT
        Q  K  R  G  Q  W  R  T  K  N  C  S  K  G  K  A  H  N  F  V
  7021 ---------+---------+---------+---------+---------+---------+ 7080
       GTGCTCAAGGAAACTCTGAACACAACCTAGCCTTTCTCATTCATCTATTTACAAGATCTA
        C  S  R  K  L  *
  7081 ---------+---------+---------+------- 7117
       TGTGTATTGCCCAGTGAAGATGCGTTGTTGTGGCTGG
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F.  Alignment of Fugu, human and mouse CBCPs 
                        10        20        30        40        50        60
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   1    MHSPGCTGPKAQWFLLLQLLLLHLDRVSATFISINRGLRVMKGSSAFLSGDHLRVAVPKE 60
human   1    MNSLSWGAANA------VLLLLLLAWASPTFISINRGVRVMKGHSAFLSGDDLKFAIPKE 54
fugu   1    -------PQRLIWTLFPVVLLGLGSSSHTSLLKVNKGLKVKRGQTAFLQEGDLQFNIPRQ 53
                        70        80        90       100       110       120
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   61 KDACRLEVVMNEPVTQRVGKLSPQVFDCHFLPNEVKYVHNGCPILDEDSVKLRLYRFTET 120
human   55 KDACKVEVVMNEPITQRVGKLTPQVFDCHFLPNEVKYVHNGCPILDEDTVKLRLYRFTER 114
fugu   54 KDACKLEVVLNEPITQRVGKLLPQVFDCHYLSDEVKYVHNGCPLLQEDTVQLRLYRFTET 113
                       130       140       150       160       170       180
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   121 DTFMETFLLRVYLVEPDCNIIRMSSNVLEVTEFYGLSQAIDKNLLQFDYDRTASLDCTIR 180
human   115 DTFIETFILWVYLLEPDCNIIHMSNNVLEVPEFNGLSQAIDKNLLRFDYDRMASLECTVS 174
fugu   114 ETHMEVFSIHVDIVQPDCSIIKLGPKSLKVPEFYSLSDAVDGNVVSFHYEKRSSLQCSIL 173
                       190       200       210       220       230       240
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   181 LDPLRTQLPAHGKLVVVNRKSEGPRGDQPHSFFSE-TELG--AGLKCPDGSCALELKQVA 237
human   175 LDTARTRLPAHGQMVLGEPRPEEPRGDQPHSFFPE-SQLR--AKLKCPGGSCTPGLKKIG 231
fugu   174 LSSQDTHFPAHGQLVTGEPEEATKRGDEPESFVPLRQQLDNKARAMCRSEDCLKGLKLVK 233
                       250       260       270       280       290       300
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   238  SLKVSCEEFLLTGFHYQHMQPPSPNIDYIPIQLDLTDRRSKTVYKSESAWLPVYIRVGIP 297
human   232  SLKVSCEEFLLMGLRYQHLDPPSPNIDYISIQLDLTDTRSKIVYKSESAWLPVYIRAGIP 291
fugu   234  FTKIPCDQFLMMGLRYQHTDPPSPDKDYITIKLELKDVRSGSIYRSEQVWIPVQIVSAMP 293
                       310       320       330       340       350       360
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   298 NQVPRAAFMAMFVLEVDQFILTPLTTSVLDCEEDETPKPLLVFNITKAPLQGYVTHLLDH 357
human   292 NQIPKAAFMAVFILEVDQFILTSLTTSVLDCEEDETPKPLLVFNITKAPLQGYVTHLLDH 351
fugu   294 NQPPKPSFMSMFILEVDQFILTPLSTATVDAEDEETPQQLLVFNITKPPTHGFITHLSDH 353
                       370       380       390       400       410       420
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   358 TRPISSFTWKDLSDMQVAYQPPNSSHPERRHYTMELEVYDFFFERSAPITVHISIRTADT 417
human   352 TRPISSFTWKDLSDMQIAYQPPNSSHSERRHDEVELEVYDFFFERSAPMTVHISIRTADT 411
fugu   354 TRPVSSFTWLDLNDMLIGYQPPNSSHSQRQNYEVEFEVHDLFFERSPSITVHMSVRNADT 413
                       430       440       450       460       470       480
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   418 NAPRVSWNTGLNLLEGQSRAITWEQFQIVDNDDIGAVQLVTIGGLQHGRLTVREGKGFLF 477
human   412 NAPRVSWNTGLSLLEGQSRAITWEQFQVVDNDDIGAVRLVTVGGLQHGWLTLRGGKGFLF 471
fugu   414 NAPRVSWNMGLSLLEGQSRPITWEQLQIVDNDNLNAVRLITLDGLQHGRLTVRGGKGFMF 473
                       490       500       510       520       530       540
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   478 TVTDLQAGVVRYHHDDSDTTKDFVAFRIFDGHHSSHHKFPINILPKDDSPPFLITNVVIE 537
human   472 TVADLQAGVVRYHHDDSDSTKDFVVFRIFDGHHSIRHKFPINVLPKDDSPPFLITNVVIE 531
fugu   474 TVSDIKAGVVRYHHDDSDTTKDFIIFRISDGQHQTRHKFPIKVLPKDDSPPFLITNMLLE 533
                       550       560       570       580       590       600
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   538 LEEGKTILIQGSMLRASDMDSSDDYIFFNITKFPQAGEIMKKPGPRLIGYPVPGFLQRDL 597
human   532 LEEGQTILIQGSMLRASDVDASDDYIFFNITKPPQAGEIMKKPGPGLIGYPVHGFLQRDL 591
fugu   534 VSEGQTVLLRGSTLQASDMDSSDDYILFNITRPPQAGEIMKVPGPGLTGYPVSQFLQKDL 593
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                       610       620       630       640       650       660
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   598 FSGIIYYRHFGGEIFEDSFEFVLWDSHEPPNLSVPQVVTIHITPVDDQLPKEAPGISRHL 657
human   592 FNGIIYYRHFGGEIFEDSFQFVLWDSHEPPNLSVPQVATIHITPVDDQLPKEAPGVSRHL 651
fugu   594 FQSIIYYRHLGNEVFDDSFEVVLSDFHDPPNFSESQVVMVYIEPVPDQPPKEAPGSSRCL 653
                       670       680       690       700       710       720
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   658 VVKETEVAYITKKHLHFLDMESRDGELIYTVTRPPCFSFSHRH-LDAGKLFMVDSIPKLT 716
human   652 VVKETEVAYITKKQLHFIDSESYDRELVYTITTPPFFSFSHRH-LDAGKLFMVDSIPKVV 710
fugu   654 VIRETDVVHITRQELQFVDEESPDSELTYTVTSPPFYSSSHSHSSDAGRLFLVDSIPKFH 713
                       730       740       750       760       770       780
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   717 KNPTAPGLSSFTQHAVNHMKVAYMPPMQDIGPSPRHVQFTVSVSNQHGGALHGICFNITV 776
human   711 KNPTALELRSFTQHAVNYMKVAYMPPMQDIGPHCRDVQFTFSVSNQHGGTLHGICFNITI 770
fugu   714 KDPTAPVLRLFTQHAVNFMKVAYMPPILDIGPNPQHIQMILSVTNHLGRTVTGICFNITV 773
                       790       800       810       820       830       840
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   777 LPVDNQVPEVFTNTLRVVEGGQCTISTEHILVSDVDTPLDSISLSLKERPLHGGVELDGF 836
human   771 LPVDNQVPEAFTNPLKVTEGGQSIISTEHILISDADTKLDNIDLSLRELPLHGRVELNGF 830
fugu   774 MPVDNQPPQVVTHALIVDEGRESPLSSQNLLLSDMDSREEVLQVQLKTGPQHGSLRIGPL 833
                       850       860       870       880       890       900
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   837  PLNPRGTFSWRDLNTLKVWYQHDGSEVLQDEIFLEVTDGTNSAAFVLHIEVFPVNDEPPI 896
human   831  PLNSGGTFSWGDLHTLKVRYQHDGTEVLQDDLLLEVTDGTNSAEFVLHVEVFPVNDEPPV 890
fugu   834  PLENGGFFTVKDLKSLKMRYSHDGSETLEDNIEFMATDGTNSITFILKVKVNPINDEVPV 893
                       910       920       930       940       950       960
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   897 LKADLIPMMHCSEGGEVTITPEYISATDADSDDLELLFLIAREPQHGVVRKAGLHVDRFS 956
human   891 LKADLMPVMNCSEGGEVVITSEYIFATDVDSDNLKLMFVIAREPQHGVVRRAGVTVDQFS 950
fugu   894 VAPGLKPVLSCPEGQEILITTEFLYATDADTINSSLLFLIARQPHHGVVLRKDSIVDRFI 953
                       970       980       990       1000      1010      1020
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   957 QGDVISGAVTYKHTGGEIGLEPCSDTVVLVVSDGEADPLMNGCCYDGPDSSVPLHKSFPT 1016
human   951 QRDVISEAVTYKHTGGEIGLMPCFDTITLVVSDGEAGPFVNGCCYNGPNPSVPLHASFPV 1010
fugu   954 QADVAAGIISYKHMGQEIGLTPRHDTITFVISDEESG---SGGVTAESRKRAELRNSLPV 1010
                       1030      1040      1050      1060      1070      1080
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   1017 YQLNITVHPVDNQPPSIIIG----RMLTVDEGFSAALTTHHLTVVDWDTAPDDLKFMLAS 1072
human   1011 YDLNITVYPVDNQPPSIAIG----PVFVVDEGCSTALTVNHLSATDPDTAADDLEFVLVS 1066
fugu   1011 YDLHVTVFPVDSQPPSLTAGEFLREVFSVEEGGVATITASHLRASDVDTALDKLVVSLTY 1070
                       1090      1100      1110      1120      1130      1140
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   1073 QPQFGYLENALPSAGFEKSNIGIRIASFQWTDMKASHINYVQSRHLRVEPTADQFTVYAT 1132
human   1067 PPQFGYLENILPSVGFEKSNIGISIDSFQWKDMNAFHINYVQSRHLRIEPTADQFTVYVT 1126
fugu   1071 PPQFGYIENVLPSPGFEKSNTGISIASFSYRDIINGHVNYVQSRHQRVEPTADQFKLYVS 1130
                       1150      1160      1170      1180      1190      1200
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   1133 DGKHRSLETTFHVIINPTNDEAPDLAVQNITVYEGHMVELDSSIISATDRDIPKDPLLFS 1192
human   1127 DGKHHSLEIPFSIIINPTNDEAPDFVVQNITVCEGQMKELDSSIISAVDLDIPQDALLFS 1186
fugu   1131 DGQRTSAHVPFYIIIKPTNDEIPEFVAHNITVEEGEKKQLDLSILQVMDLDVPENKLQFS 1190
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                       1210      1220      1230      1240      1250      1260
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   1193 IALKPQHGLLVDAAISKDSHQIK------QLQHEIHSFSVDLLKNGMKLVYAHDDSESSA 1246
human   1187 ITQKPRHGLLIDRGFSKDFSENKQPANPHQKHAPVHSFSMELLKTGMRLTYMHDDSESLA 1246
fugu   1191 VLKAPKHGSIVS--YSADRLNTK------RREAPIADFTLQDLQNGMDVMYVHDDSENME 1242
                       1270      1280      1290      1300      1310      1320
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   1247 DNFVIQLSDGKHKILKTISVNITPVNDETPTLSKKAEISMAVGDTRVLSSAVLSATDKDS 1306
human   1247 DDFTIQLSDGKHKILKTISVEVIPVNDEKPMLSKKAEIAMNMGETRIISSAILSAIDEDS 1306
fugu   1243 DSFILQLTDGRHQLDREVMVRVEPVNDEKPQLVRNNGLEVEPGETRLISSVVLLAQDADT 1302
                       1330      1340      1350      1360      1370      1380
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   1307 PREKIHYVFERLPQNGQLQLKIGRDWVPLSTGMQCTQEDVDLNLLRYTHAGKTDSQDGDS 1366
human   1307 PREKIYYVFERLPQNGQLQLKIGRDWVPLSPGMKCTQEEVDLNLLRYTHTGAMDSQNQDS 1366
fugu   1303 LSTDVIYMIQSVPKQGVLQLKEAQDWVTLRVGSNCSQEGVNMNLLRYVHTGADDTKALDF 1362
                       1390      1400      1410      1420      1430      1440
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   1367 FTFYLWDEDNRSPAFDCHIIIEDMGKGDIVIHAKPLVVVKGDRGLLTTATLLAVDGADKP 1426
human   1367 FTFYLWDGNNRSPALDCQITIKDMEKGDIVILTKPLVVSKGDRGFLTTTTLLAVDGTDKP 1426
fugu   1363 FVFCLFDGKNQSPPQHFYISIKELEKGIISIFVKPVKVSRGDRVVLTTDVLLATDGSDKP 1422
                       1450      1460      1470      1480      1490      1500
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   1427 EELLYLITSPPRHGQVEYVHSPGVPIASFSQMDIAGQTVCYIHKSRTAVPTDSFRFTISN 1486
human   1427 EELLYVITSPPRYGQIEYVHYPGVPITNFSQMDVVGQTVCYVHKSKVTVSSDRFRFIISN 1486
fugu   1423 EELLYVVTTPPSHGHIEYITHPGVAISTFSQLDVAANHVAYTHDNRXAAPREHFQFVVSN 1482
                       1510      1520      1530      1540      1550      1560
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   1487 GLQTQRGVFEITLQTVDSALPVLTKNKRLRLAEGAMGLLSADHLQLTDPDTPPENLTFFL 1546
human   1487 GLRTEHGVFEITLETVDRALPVVTRNKGLRLAQGAVGLLSPDLLQLTDPDTPAENLTFLL 1546
fugu   1483 GQMSRNGSFEISVEMVDRILPSLTANRGLSVPQGTTVILGPECLALSDPDTPPEALTFAL 1542
                       1570      1580      1590      1600      1610      1620
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   1547 AQLPRHGYLFLRGK-ALQHN-FTQRDVDSGGVAYQHSGGGAREDYFTFLATDRKNQGFVV 1604
human   1547 VQLPQHGQLYLWGTGLLQHN-FTQQDVDSKNVAYRHSGGDSQTDCFTFMATDGTNQGFIV 1605
fugu   1543 IQPPQYGKLLLNGVALTSGSNFTQKNIQGMEVTYKHDGGPSQIDRFGFTASDSSARGFLL 1602
                       1630      1640      1650      1660      1670      1680
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   1605 DGKVQKEPVRFTIQVDQLDKAAPRITHLHSPTQVGLLKNGCYGIYITSRVLKASDPDTED 1664
human   1606 NGRVWEEPVLFTIQANQLDKTAPRITLLHSPSQVGLLKNGCYGIYITSRVLKASDPDTED 1665
fugu   1603 DGRLQTAAVFFTIQIQPLDTRAPDVVKLLPLWKAEPLGDGRHGIFLSAHELKAQDSGSRD 1662
                       1690      1700      1710      1720      1730      1740
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   1665 DQIIFKILRGPLYGRLENTTTGEFIHERFSQKDLSHKTILYIINPSLQVTSDILEFQAMD 1724
human   1666 DQIIFKILQGPKHGHLENTTTGEFIHEKFSQKDLNSKTILYIINPSLEVNSDTVEFQIMD 1725
fugu   1663 EQLMFCITRQPYFGYLENITTGGFVPQRFSQLELSKRTIVYVINPDKQSLSDSLEFQVSD 1722
                       1750      1760      1770      1780      1790      1800
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   1725 PTGNTATPQSLDLRWSYIEWAQTAYEVCENVGLLPLEVTRRGYPMDSAFVGVEVNQVSAT 1784
human   1726 PTGNSATPQILELKWSHIEWSQTEYEVCENVGLLPLEIIRRGYSMDSAFVGIKVNQVSAA 1785
fugu   1723 TLGNTGPSHLLEFSWSSVELSLQTYFVCEEQGSVSLDIVRKGNLAESSYITVKVEEVTAT 1782
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                       1810      1820      1830      1840      1850      1860
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   1785 VGKDFTVTPSKLLQFDPGMSTKMWNIAITYDGLEEDDEVFEVILNSPVNAVLGTQTKAAV 1844
human   1786 VGKDFTVIPSKLIQFDPGMSTKMWNIAITYDGLEEDDEVFEVILNSPVNAVLGTKTKAAV 1845
fugu   1783 AGRDYLPNPSSLIQFDPGVSQRSWQIQIIQDNLEEAEEIFEVLLTSPEGTVVGSNSKAQV 1842
                       1870      1880      1890      1900      1910      1920
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   1845 KILDSKGGR-CHPSNSFNQSKHSTWGKGPWHPLPSGSSSLTTSGSPLLER-PPPS----- 1897
human   1846 KILDSKGGQ-CHPSYSSNQSKHSTWEKGIWHLLPPGSSSSTTSGSFHLERRPLPSSMQLA 1904
fugu   1843 TIRRSGSRTGVLGGKEIPSNFYPQHGSIQLEKLPLGTDSVIWSRGDRISR---PS----- 1894
                       1930      1940      1950      1960      1970      1980
....|....|....|....|....|....|....|....|....|....|....|....|
mouse   1898 FTSGDALQGFGLTDLTQRKTMTQGNGKSVLPSSVCRNGTDTIYNYHGIVSLKLEGDRFSA 1957
human   1905 VIRGDTLRGFDSTDLSQRKLRTRGNGKTVRPSSVYRNGTDIIYNYHGIVSLKLEDDSFPT 1964
fugu   1894 ------------GDVTGNKVRVIGNPKVVAPSSVFHNGTDVVFTYHGIMQLQVEDDTSPS 1942
                       1990      2000      2010      2020      2030      2040
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   1958 HK-RKAKISIVSQPQRTIKVAELPLADKVESTTDLHFLRQGLRPLFPKNCSVDLKGLFHF 2016
human   1965 HK-RKAKVSIISQPQKTIKVAELPQADKVESTTDSHFPRQDQLPSFPKNCTLELKGLFHF 2023
fugu   1943 RKGRKANIHVVSRG--VEQQAPAPKSKNREKTLKPEG--RGTERSIPKPCTPELMGLLHL 1998
                       2050      2060      2070      2080      2090      2100
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   2017 EESTHRLYQCDGISWKAWSPQTKGLEDRSCPGGWLLHSGYCHILVTRQKGTWTTATRACR 2076
human   2024 EEGIQKLYQCNGIAWKAWSPQTKDVEDKSCPAGWHQHSGYCHILITEQKGTWNAAAQACR 2083
fugu   1999 NQSTNQLLHCNGVSWKPWTPTDQMVSAQTCPRDWTFHGGRCYILIAENKVTWSEANRSCR 2058
                       2110      2120      2130      2140      2150      2160
               ....|....|....|....|....|....|....|....|....|....|....|....| 
mouse   2077 EQHQGDLVTVLSRRHMQWLWAMSGRKPFWIGLKNQPRTGHWEWIGGEPVAFTNWRRGAPL 2136
human   2084 EQYLGNLVTVFSRQHMRWLWDIGGRKSFWIGLNDQVHAGHWEWIGGEPVAFTNGRRGPSQ 2143
fugu   2059 ERYKGTLSSVLSKVDMDWLWDFSGRKPFWIGLNDREGRGRWEWVGGEPLVYTNWRKTPPR 2118
                       2170      2180      2190
....|....|....|....|....|....|....|..
mouse   2137 HPKPG-KNCALVQKRGQWQTKNCSKGKAHNFVCSRKL 2172
human   2144 RSKLG-KSCVLVQRQGKWQTKDCRRAKPHNYVCSRKL 2179
fugu   2119 RRTKGRKKCVLVWRRAKWQSRDCKSAQGRGFMC---- 2151
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